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Perspectives on. Parkinson's disease •••• 
It is now twenty-one years since my patients' awakenings ... and yet, it seems to me, the 
subject is inexhaustible ~ medically, humanly, theoretically, dramatically. It is this which 
keeps the subject for me - and,· I trust, my readers - evergreen and alive. 
OtiverW. Sacks, 1990. 
the real adventure is putting on your socks 
the real adventure is putting on your socks, 
it's difficult to do in the morning. 
your eyes, (hey don'tfocus, 
your fingers, they don't pinch, 
your toes, they don't wiggle. 
i sometimes sleep in my socks, 
i'm not always in the mood for adventure. 
Jeffery R. Romanyshyn, 1994. 
ill 
PIIARMA€0KINETIC AND 1PHARMACODYNAMIC STUDIES 0F'Al>oMORPIDNE 
IN Tm: TREATMENT OF IDIOPATIDC PARKINSON'S DISEAsE, 
WENnv·MEREWYN:INGRAM 
There were two aspects to the study of apomorphine in the treatmentofParkinson' s 
disease: (i) a·clinicalpbarmacokinetic,-pharmacodynamic (PK~P9)istudy was designed and 
implemented·linespo~ to the,challenges,ofapomorphine dose-titration in Parkinson's 
disease, and in view of the scarcity of available literature on .the PK~PD relationships:of 
apomorphine in ParkinSon's disease, (ii) the PK(and.tolerability)of apomorphine dosing 
using noveJ:delivery/formulationcombinationswere explored in view of the inherent 
limitations associated with the ronventionall(ie. sulx:utaneous) route of administration of 
apomorphine (e.g. cutaneous nodule formation,.needle-phobia). 
An HPLC assay was developed for the quantification of apomorphine in plasma, and 
stability issues relating to sample storage and assay were investigated. 
With regards to the first aspect of the research, simultaneOus PK-PD modelling was 
performed, using an effect compartment model to account for counterclockwise hysteresis 
in a sub-group of patients. According. to the traditional two-stage approach to data · 
analysis, qrean (standard deviation) clearance following sulx:utaneous bolus was 2.2 (0.5) 
L/kg/h, (apparent) volume of distribution was 1.9 (0.8) Ukg, absorption half-life was 4.1 
(2.1) minutes and elimination half-life was 69.5 (2l.l)minutes (n=7). Equilibration half-
life was estimated for two patients at 8.3 and 16.5 minutes. 
Focus was:given to investigating the relevance of a potential correlation (which had 
previously been identified using in-house pilot data) between post-distributional 
apomorphine PK and apomorphine-induced anti-parkinsonian response in patients with 
Parkinson's disease. It was hypothesised that this,particular correlation may be of use in a 
dose-optimisation scheme. However it was demonstrated that, in the patients studied, the 
concept could not be applied to apomorphine dose~ptimisation. 
The novel delivery systems under scrutiny were: (i) Britaject® (Britannia Pharmaceuticals 
Ltd.) apomorphine formulation administered sulx:utaneously using a needle-free (jet) 
injector (J-TIP®~ National Medical Products Inc.), (ii) an intranasal apomorphine powder 
formulation delivered using a turbospin insufflator (CDFS), and (iii) an apomorphine 
hydrogel co-polymer produced as a dosage-form for buccal delivery (Controlled 
Therapeutics (Scotland) Ltd.). As a result of this work, a rationale for subsequent 
development of the novel systems was provided. Indeed, the needle-free and buccal 
systems were, in their existing format,. shown not to convey a net advantage over the 
existing system. However the intranasal formulation, with a mean (standard deviation) 
relative bioavailability of 41 (18)% (n=16) compared to subcutaneous bolus 
administration (and·with a favourable outcome as regards to tolerability), was considered 
to be potentially suitable for further development. 
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SECTIONl: 
LITERATURE REVIEW 
1. Literature Review. 
1.1. Pharmacokinetic-Pharmacodynamlc Modelling TechniqueS. 
Pharmacokinetics can be defined as the quantitative relationship between (observed) dfug 
concentration (in plasma and/or tissue) and time. Pharmacodynamics describes the 
qUfllltitative relationship between (observed) plasma and/or tissue concentration of the drug 
and (observed) pharmacological effect, the latter being defined as a drug induced change in 
a physiological parameter when compared to respective pre-dose (baseline) value[ I] 
(Figure 1-1 }. 
The combination of these two disciplines leads to a therapeutically relevant description of 
pharmacological effects and time. This description takes the form of a pbarmacokinetic-
pbarmacpdynam.ic model, whereby model parameter estimates provide information about 
intrinsic drug properties and hence enable predictions of concentration versus time and 
effect versus time profiles for different dosing schemes[l, 2]. 
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Figure 1-1 Schematic representation of the relationship between pharmacokinetics 
and phann-cokinetics (modified from [3-5)). 
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There are a number of distinct approaches to the estimation of pharmaco.kinetic and 
pharmacodynamic parameters for a population. The standard two-stage approach .[6-11 ). 
is appropriate when rich datasets are available, ie. when the number of drug concentration 
observations per patient far outnumbers the number of parameters being estimated, and 
when measurements are associated with only a small degree of error. Under these 
conditions, the standard t\w-stage approach is considered to be the "gold-standard" by 
which to compare other (more direct) approaches to population modelling, e.g. mixed 
effect modelling. Practically-speaking the standard two-stage approach involves the 
sampling of plasma (for plasma drug concentration) and response from each individual at a 
series of pre-speci.tied times, and the subsequent generation of model parameter estimates 
for each individual within the study population (first stage). Thereafter the parameter mean 
and variance for the population are calculated from the individual estimates (second stage). 
Finally, the association between certain pharmaco.kinetic parameters and detmgraphic 
characteristics are evaluated. A major disadvantage of this approach is that the residual 
inter-individual variability cannot be resolved from the other random effects, e.g. the 
(considerable) intra-individual error or measurement error 
This constraint is avoided in the mixed effects modelling approach whereby both intra .. and 
inter-individual variation are derived using built-in statistical protocols within the 
modelling process£6-11]. In contrast to the standard two-stage approach, the mixed effects 
modelling approach functions with sparse and/or observational data from individuals, and 
hence requires neither a stringently controlled study design nor intensive sampling from 
each individual. The observed data are pooled into a single dataset, although critically the 
individuals are still identifiable (allowing an uneven amount of data from different 
individuals to be input into the modelling process), and the population parameters are 
determined in a single stage of analysis. 
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1.1.1. Phannacodynamic Models. 
Pharmacodynamic models predict drug effect .from (effect site) drug concentrations at 
steady state. There are four commonly encountered pharmacodynamic models. 
The Emu model derives from drug-receptor interaction theory. Concentration (C) and 
effect (E) are related as follows: E = Eo+ [(Emax. C') I (C1 + ECso1)], where Emax denotes 
the maximum theoretical effect, ECso is the concentration required to induce 500/o of 
maximal effect (and hence represents drug potency), and y is the Hill co-efficient. The Hill 
co-efficient accounts for the sigmoidicity of the relationship, allowing a better fit to 
observed data, and as such dose not have a direct biological interpretation. 
In the simple (or hyperbolic) Emax model, y = 1 (Figure 1-2). 
ti 
.: 
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E. 0~~~~~~--~+-~~~ 
0 
Conotntr.tloll 
Figure 1-2 Simple E_.. model with baseline effect parameter. 
Ify > 1 then the concentration-effect relationship is sigmoid, and the larger the value of the 
exponent, the steeper the slope (Figure 1-3). The sigmoid Emu model is considered the 
most versatile of the basic pharmacodynamic models, however since the number of model 
parameters is relatively great (compared to other common pharmacodynamic models) the 
precision with which these parameters are estimated is decreased[2, 5, 11]. In order to 
obtain accurate and precise model parameter estimates, the observations throughout the 
entire range of the concentration-effect profile must be obtained. Generally this is 
achieved by the administration of ascending doses of drug to each individual[2]. 
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Figure 1-3 Sigmoid EIIIH model with baseHne effect parameter. 
The relationship between concentration (C) and effect (E) can be descnl>ed more simply in 
terms of a linear function: E = S.C +Eo, where S denotes the proportionality factor (and 
hence is a measure of the sensitivity of the pharmacodynamic effect to changes in C) and 
Eo is the intercept of the relationship (and the baseline value of E). The linear model 
I 
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parameters are easily obtained by linear regression (a f~ which perhaps may be 
considere<1 an advantage), however this model is limited in that maximum pharmacological 
effect cannot be described[5, 1 1]. 
Concentration-effect relationships may also be described using the log-linear function, i.e. 
E = S. log (C) + b, where b is they-axis intercept (an arbitrary constant). The derivation of 
the log-linear model came from the observation that for a hyperbolic concentration-f!ffect 
relationship, log-transformed concentration versus effect is approximately linear in the 
tange of20 to 800/o of maximum effect. In common with the limitation of the linear 
model, maximum effect cannot be predicted using the log-linear model. In additjon, the 
latter model (always) predicts the existence of a threshold concentration below which there 
is no effect, indeed the effect at C = 0 cannot be estimated using this model [2, 5, 11]. 
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1.1.2. Combin~ Pharmacokinetic-Phannacodynamic Models. 
Pbarmaookinetic and pharmacodynamic data are linked directly or indirectly, depending on 
the·nature of the relationship between concentration an effect. An exploration of a plot of 
observed drug concentration (usually the concentration in plasma) and observed effect, in 
which data points are connected in chronological order allows an insight into the 
relationship. 
A direct link is implicated when the relationship between observed drug concentration and 
oPset'ved effect is independent of time, i.e. the times courses of observed plasma 
concentration and effect are in phase with each other. In this situation there is rapid 
equilibration of drug between the systemic and effect compartments. Under such 
conditions the observed drug concentration and (unobservable) effect site drug 
concentration are proportional, hence the observed plasma concentration is a good 
predictor ofthe concentration at the effect site and thus effect[1, 2, 12, 13]. 
In other circum.Sta.nces the time courses of observed drug concentration and effect are not 
superimposed. Here the relationship between observed drug concentration and effect is 
time-dependent, and hysteresis is displayed in the plot of observed drug concentration 
versus observed effect. An indirect link between pharmacokinetics and pharmacodynamics 
is required in this situation. 
Hysteresis in a clockwise direction (or proteresis) is indicative. of: (i) the development of 
(pharmacodynamic) tolerance, e.g. by receptor desemitisation, (ii) the action of inhibitory 
metabolite(s), (ill) having sampled venous blood for pharmacokinetic-pharmacodynamic 
study when the equilibration of drug between the effect site and venous blood is relatively 
slow compared to that between effect site and arterial blood [11-15]. 
Counterclockwise hysteresis is displayed when the kinetics of effect are delayed with 
respect to the kinetics of observed drug concentrations. Mechanisms which explain this 
phenomenon include: (i) the time taken for distribution of drug from plasma to the effect 
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site, (it) the action of active (synergistic) metabolite(s), (iit) delays due to post-receptor 
transduction processes, iv) receptor up-regulation[1, 2, 11-13]. 
Temporal disequilibrium between observed concentration and observed effect can be 
accounted forby the use of an effect compartment (or link) model (Figure 1-4) (2, 5, 11-
14, 16]. This approach, which was first proposed by Segre[l7] and Hul1(18], was 
formalised by Sheiner et al in the context of the simultaneous characterisation of 
pharmacokinetics and pharmacodynamics of d-tubocurarine[19J: 
' .. 
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Figure 1-4 Schematic representation of effed compartment model described by 
Sheiner et al[19], whereby the hypothetical effed compartment receives 
input from the central compartment (modified from (12, 13, 16]). 
The central compartment of the pharmacokinetic model (usually plasma) is linked to a 
hypothetical effect (or biophase) compartment by a first-order rate constant, klE; thus drug 
concentration in the effect compartment (i.e. Ce) depends on the kinetics of the central 
compartment. The observed effect is related to the drug concentriJ,tion in the effect 
compartment by means of a pharmacodynamic modeL e.g. Emax. 
It is assumed that km is very small relative to any other rate constant in the 
pharmacokinetic mode~ consequently the amount of drug which reaches the biopbase is 
insignificant compared to the total amount of drug in other body compartments. In this 
respect the effect compartment cannot be distinguished pharmacokinetically from the 
plasma concentration-time profile as a peripheral compartment. 
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The first-order ~e oonstant:keo describes tbe:dis..;ipation of drug from the hypothetical 
. effect site. This parameter isused'to cbaracterise:tbe degree ofhysteresis, in>that the·half- · 
life of equilibration of drug between plasma and effect site (Teq) is given by In (2)1 keo. Teq 
can also be interpreted as the half-life of: the time require(ho "collapse" ·the two limbs of 
the hysteresis loop fu the concentration-effect relationship. 
Other approaches applicable to the indirect linking ofpharrnacokinetics·and 
phannacodymlmics include linking the effect compartment to a peripheral compartment as 
opposed to the central compartment[ 16, 20, 21 ]. 
1.1.3. Assessing Goodness of Fit of Pharmacokinetic/Pharmacokinetic Models. 
The characteristics of an well-defmed model according to Gabrielsson and Weiner[S] are 
as folloWs:-
• the model has: biological relevance, 
• the fitted curve mimics trends in the observed data e.g. T max. 
• the residuals display a random scatter and are free from systematic deviation. 
• the parameter estimates have good precision. 
• the parameters have low correlation. 
• the condition number of the fit is (relatively) low and the rank is full. 
These features, along with associated statistical tools, are used when comparing corripeting 
models for the best fit. No single statistic is more important than another, thUs a set of 
diagnostic features (given·below) should be. considered when attempting to discriminate 
between models. 
Weighted Sum of Squared Residuals (WSSR). 
The process of producing a set of model parameter estimates (e.g. volume of distribution 
and elimination rate) is based on the minimisation of the difference between observed and 
predicted data, ie. the minimisation of residuals. Thus nonlinear regression programs are 
l-7 
employecho dctermine parameter estimates ,by adjusting pala.meter values iteratively: using . 
WRSS:as an objective function. Convergence·is achieved when the relative change 
between WRSSo1d and WSSR..ew is less than the·(user-defined}convergence criteria, the 
. defuuh (for WmNonlin®)1being,O.OOOl. At convergence the iteration process.ceases and 
· the .final.parameter estimates are;given. 
Residual Analysis. 
Residual plots should be inspected for·evidence of systematic deviation. random scatter 
and the presence of outliers. Systematic deviation·is evidenced by sequences of 
consecutive positive or negative residuals, or "runs". A model that possesses a lack of 
systematic deviation ie. one that rusplays a relatively high number of changes in sign of 
consecutive residuals, is considered to be superior to one displaying systematic deviation. 
When plptted against the independent Variable or the predicted dependent variable, 
residuals should be randomly distributed about the mean (i.e. i.ero)and full within a narrow 
horizontal band (tramlines). 
Visual inspection of residual plots also allows the detection of outliers ie. isolated data 
values which were not fit well by the model Such data values will possess unusually high 
residuals. An outlying data value may deviate in the colicentration- or time-dimension, or 
both. Depending upon the point at which the deviation occurs within the data set, outliers 
may exert leverage on.parameter estimation, compromising accuracy and/or affecting 
precision. 
· Parameter.ConelatiOn. 
The parameter correlation matrix provides a means.ofassessing the eo-dependence of 
parameters. Ideally model parameters should be totally uncorrelated with each other, . 
i.e. R = 0. Furthermore where high correlations, say R > j0.95j, exist between a given pair 
of parameters, the associated parameter estimates should be interpreted with caution. This 
is because such correlations relate to there being insufficient information in the 
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concentratio&.time data to generate the,parameter estimates with sufficient accuracy and 
precision. 
Condition Number (of the matrix of; partial derivatives). 
The condition number is a marker of the stability, of the model fitting.process. The 
condition number is defined as the square root9fthe ratio of the largest to·the smallest 
eigenvalue. A low condition number is desired (less than lONpar, as a general rule, where 
Npar is.the number of parameters); large condition numbers are indicative of instability in 
the minimisation process. 
Rank of the matrix of partial derivatives of the model parameters. · 
If rank is l~.than Npar then the model is ill-conditioned ie. there is notenough 
information contained in the data to precisely estimate all of the parameters in the model 
When·rapk is equal to Npar. the matrix is said to possess full rank, this being an indication 
of a robust fit. 
Akaike Information Criteria (AJC) and Schwarz Criteria (SC). 
AIC and se are measures of goodness of fit based on maximum likelihood. The use of 
AIC and SC is appropriate only when comparing competing inodels ofthe same weighting 
scheme. The model associated with the smallest AIC (or SC) is regarded as·giVing the best 
fit ofthose·models under consideration. The distribution of these values is unknown, 
therefore no statistical significance can be associated with the AIC or SC values o~tained 
for competing models. Computational formulae are given below:-
Akaike Information Criteria. 
AIC =Nobs • LOG(WSSR) + 2 • Npar 
Schwartz Criteria 
SC =Nobs • LOG(WSSR) + LOG(Nobs)*Npar 
where WSSR = L wt (yi-yl)2 
and jii denotes the predicted value ofyi. 
Nobs = number of observations 
Npar = number of parameters 
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1.2. 'Parkinson's Disease. 
·1.2.1. Parkirisanism (The Parkinsonian Syndrome). 
The Parkinsoniim Syndrome was first described by James Parkinson in 18l7 as paralysis 
agitans,.or the "shaking palsy". He documentetl a state of.-
" ..• involrmtary tremulous motion with lessened muscle power inpatie1ils not in 
action with a propensity to bend the trunk forward and to pass from a walking 
. . 
io a runiling pace" [22]. 
Parkinson had described a clinical syndrome which was dominated by a disorder of muscle 
movement (dyskinesia}and muscle tone (dystonia). The characteristic clinical features of 
parkinsonism, each of which reflect the. altered activity of the basal ganglia (see Section 
1.1.1.1, page I-13}are: akinesia, rigidity, andtremor. 
Akines~ ie. loss of movement, is described as a symptom complex consisting of 
" 
bradykin~ (slowness ofmovement)and hypokinesia (decreased amplitude of 
movement)[23], Akinesia is considered to be the impairment which causes the most 
prominent disability to the parkinsonian individual[24, 25]. the broad consequence of 
akinesia is that difficulty in initiating movement aitd performing simultaneous, sequential 
and repetitive alteinating motor tasks is experienced[24]. 
More specifically, fine motor tasks involving the hands and fingers, such as writing 
become inordinately difficult to accomplish. A slow, shuffling gait with impaired arm 
swing occurs. ·Difficulty may be experienced when the affected individual·attempts to 
cease walking (festination). Facial amimia develops, which, coupled with reduced rate of 
blinking and swallowing, results in·a "masked" facial appearance. The voice becomes quiet 
and monotonous[26]. 
The uh4nate expression• of akinesia is "freezing", where the individual suddenly becomes 
completely immobile. A parkinsonian individual will suddenly become "rooted to the 
spot" whilst walking, especially when attempting to change direction [27, 28]. 
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Rigidity,thatis,.an increased resistance ofmuscle·to:passive·movement, can occur 
. . 
throughout the full range of movetnent of the limbs, trunk and neck[26, 29]. · Rigidity may 
be of a "lead:pipe" or "cogwheel" quality,-the fonner being likenedito the sensation of 
bending a lead pipe, the latter, Which is due to:the combination: of existing treinor and -
rigidity, being likened to turirlng a sticking cogwheel[23, 28]. The-increase jn,oiuscle tone 
in flexor muscles is slightly more pronounced than in extensors. Thus when all four lili1bs 
are affected, a "stooped" or "simian" posture:is produced[24] .. 
Tremor has been described as the symptom which is publicly identified with:parkinsonism. 
It is the most common-symptom, although not universal, being absent in about 300/o of-
individuals with parkinsonism due to idiopathic Parkinson's disease[24]. Where tremor is 
present it can affect the facial, jaw, tongue or leg muscles but it principally affects the 
hands at a frequency of 4-6Hz[23, i6, 28]. In the upper limb(s) tremor produces rhythmical 
pronation/supination and "pill-rolling" movement of the thumb and fingers[23]. 
Parkinsonian tremor is typically described as occurrin,g at rest, being worsened by anxiety 
and being greatly reduced by voluntary movement, although it is documented that tremor 
may persist during activity in those individuals who nonnally experience a particularly 
well-developed tremor[23, 28]. 
1.2.2. Idiopathic Parkinson's Disease. 
Idiopathic ParkinsOn's disease accounts for the majority of cases of true parkinsonism[24]. 
In this thesis, the term Parkinson's disease is used in reference to the idiopathic form. 
The "gold standard" for diagnosis of Parkinson's disease is the pathological finding of 
specific degeneration of nigrostriatal and other pigmented nuclei, with a characteristic 
inclusion, the Lewy body, in remaining nerve cells[30]. 
The following features are predictive of idiopathic Parkinson's disease: unilateral onset,_ 
classic rest tremor, and pronounced reduction of parkinsonian symptoms with L-dopa 
therapy[3l]. Autonomic disturbance may occur as a late feat.ure of the disease, as does 
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freezing and postumlinstability[24). Parkinson's disease doesnot cause cerebellar or . 
pyramidal signs[24]. 
Many individualS with Parkinson's disease exhibit a' range of non-motor Symptoms in 
·addition to the characteristic motor deficits. lthas been'estimaied that dementia occurs in 
over 15% of patients and that depreSsion is commori(32]. Depression is generally of a mild 
' 
to moderate intensity and can be difficult to diagnose ifhypomimia and hypokinesia are 
present. The presence of neuropsychiatric conditions can compromise the use of standard 
anti-parkinsonian pharmacotherapy. 
Olfactory dysfunction has been demonstrated in Parkinson's disease. Typically, the 
olfactory deficit is bilateral, occurs for a wide range of odours and is not influcmcecf by 
anti-parkinsonian dtugs[32, 33]. 
SensoryiS)'rnptoms such as'pain and parasthesias,bave been reported[32). In general the 
manifestations are mild, but distressing. Although these symptorm may be variable, they 
predominantly ilffecttbe side of the body with most severe motor symptoms. 
Constipation is common in individuals with Parkinson's disease[32]. It is thought that 
physical inactivity, impaired forcefulness ofabdominal.musculature and dysfunction ofthe 
enteric nervous system and anal'sphincter oontribute to this condition[34). 
Bladder dysfuitction involving detrusor hyperactivity has been reported in some 
patients[32]. Abnormal heat regulation can be observed to different degrees. Sensations 
of cold and.acute attacks noctumal attacks of sweating have been documenled[32]. Mild 
dysphagia and sialorrhoea is considered to be coounon in advanced Parkinson's disease 
[32]. Sleep disturbances, which include insomnia, parasonmias and excessive daytime 
somnolence have also been descn'bed[35]. 
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1.2.3. Epidemiology of Idiopathic~ Parkinson's' Disease.· 
The.incidence,ofParkinson's:disease is rare befordifty years of age, but increases With 
age tliereafter[36]. The prevalence of. Patkinson's disease in North America and Europe is 
estimated' to be between lOO and 200 cases pet: 100,000 population[36]. By the eighth 
decade of life, the estimated1prevalence in North America and Europe rises to between 
1,000 and 3,000 cases per 100;000 persons. In•the UK, there is an annual incidence of 12" 
new cases per 100,000 of the populati0n[37]. Parkinson's disease is known to be a world· 
wide disease, but is,possibly less,prevalent in China, Japan and Africa as compared to 
. Western countries[38], and is slightly niore common in men than in women[36, 38] 
1.2.4. Pathogenesis of Idiopathic Parkinson~s Disease. 
1.1.1.1. The Nigrostriatai.Pathway. 
The nigrostriatal pathway is one of three dopaminergic systems in the human CNS. 'Fhis 
pathway accowits for 75% of dopaminergic activity in the brain. Cell bodies lie in the 
substantia nigra. The axons project, via the medial forebrain bundle, to·the corpus striatum 
and terminate at the neostriatmn. 
The corpus striatum is the principle input structure of the basal ganglia and receives 
excitatory glutaminergic input from many areas of the cortex. The majority of neurones 
within the striatum are projection neurones that innervate other basal ganglia structures. A 
small subgroup of striatal neurones are interneurones which do not project beyond the 
borders of the corpus striatum. 
The outflow of the striatum proceeds along two routes, identified as the direct and indirect 
pathways. The direct pathway is formed by neurones in the striatum that project directly to 
the output stages of the basa1 ganglia, the substantia niwa pars compacta and the medial 
globus pallidus, using the inhibitory neurotransmitter GABA: these in turn relay to the 
thalamus, which provides excitatory input to the cortex. The striatal neurones giving rise 
to the direct pathway express primarily the excitatory D 1 dopamine receptors. 
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The indirect.pathway is composed of striatal neurones that project to the lateral globus; _ 
This structure in turn innervates the subthalamic-nucleus, which provides outflow to the 
substantia nigra pars reticulata and medial globus,pallidus output. This pathway involves 
two inhibitory GABA-mediated projections and one excitatory glutamiriergic,projection. 
The striatal neurones giving rise to the indirect pathway express primarily the inhibitory 
D2 dopamine receptors. 
The-substantia nigra pars compacta provides dopaminergic funervation to the striatal 
neurones giving rise to both the direct and indirect pathways, and regulates the relative 
activity of these two routes[23, 28, 39]. 
1.1.1.2. Dopamine Receptors 
Dopamine exerts its physiological effects at the nigrostriatal pathway throUgh receptors of 
" the G-protein-coupled receptor superfamily, Two major classes of dopamine receptor, D l 
and D2, are distinguishable by both pharmacological and biochemical criteria. 
ln terminals of dopamine neurones-projecting from the midbrain to forebrain, levo-tyrosine 
is oxidised to levodopa by tyrosine hydroxylase. This is the rate-limiting step in 
catecholamine biosynthesis. Dopa is then decarboxylated to dopamine by aromatic L-
amino acid decarboxylase and stored in vesicles. Following exocytotic release by 
depolarisation in the presence ofCi+, dopamine interacts with post-synaptic Dl and D2 
receptors, as well as pre-synaptic D2 autoreceptors. Inactivation oftrans-synaptic 
communication occurs primarily by active transport of dopamine into pre-synaptic 
terminals, with secondary deamination by mitochondrial monoamine oxidase-B to 3,4-
dihydroxyphenylacetic acid and ultimately to noradrenaline. Postsynaptic Dl receptors, 
through Gs type G-proteins, activate adenylyl cyclase and the conversion of ATP to cAMP, 
while D2 receptors inhibit adenylyl cyclase through·G; proteins. D2 receptors also activate 
receptor-operated IC channels and stimulate phospholipase C, perhaps via the By subunits · 
liberated from activated G;, to convert phosphatidylinositol to inositol triphosphate and 
diacylglycero~ with secondary modulation ofCa2+ and protein kinases[39]. 
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D2 autoreceptors suppress ,the synthesis of dopamine by diminishing phosphorylation of 
rate-limiting tyrosine hydroxylase, as "Well as limiting dopamine release (possibly through 
modulation,ofCa2+ or r currents[39D. 
1.1.1.3. Consequences of,Nigroatriatal Palflway Degeneration. 
'1iKl primary deficit in Parkinson's disease-~ the degeneration of the dopaminergic 
neurones of the nigrostriatalpath~y. Progressive loss of such neurones is a normal 
feature of ageing, however a loss ofS0-900/o ofdopaminergic neurones occms,in 
symptomatic Parkinson's disease[39]. lt'IJBS beeli.:ell1cidated, by post mortum and by 
positron emission tomography studies, that afthls degree of neurone destruction up to 
50% of brain dopamine may be lost[ ]. 
In Parkinson' disease the loss of the dopaminergic input to the corjms striatum has a 
' >. 
differential effect on the two output pathwa,Ys; the direct pathway to the substantia nigra 
pars reticulata and medial·globus pallidus is less active, while the activity in the indirect 
pathway is increased .. The net effect is ,that neurones in the substantia nigra pars reticulata 
and medial globus pallidus are more active. This leads to increased inhibition of the 
tha1amus and reduced excitatory input to the motor cortex. This ultimately results in 
akinesia, rigidity and tremor. 
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1.2.5. Management of Idiopathic Parkinson's;Djsease. 
1.1.1A~ R;ltionale for Anti-Parldnsonian Phannacotherapy. 
Currently pharn'Iacother&py is"symptomatic,only sitice there is insufficient evidence of the-
effeet of any available drug on disease progressi0n[l7]. The,preparations which are 
currently available.aim to.correct the Iieurohormonalimbalance atthe:basal'ganglia. 
Levodopa is the treatment of choice for ParkinSon's disease, being the most effective and 
reliable treatment available at the time ofwriting[37, 40, 41]. Levodopa is the.natural _ 
intermediary in the enzymatic synthesis of dopamine from L~tyrosine,.and has no 
pharmacological action of its own, but acts to repleniSh depleted• Striiltal dopamine by 
crossing the blood-brain-barrier where it is decarboxy)ated to dopainine by L-amino acid 
decarbox}'Jase. Levodopa is combined with a dopa~decarboxylase inhibitor (benserazide 
or carbidopa) which inhibits of breakdown oflevodopa to dopamine in the periphery. 
Improvement in parkinsonian symptoms. especially bradykinesia and rigidity, occurs in 
approximately 80% of patients on levodopa pharmaootherapy[41], however treatment is 
limited by the development of neuro-psychiatric complications and the emergence of 
motor fluctuations; Such motor fluctuations take the form of end-of-dose deterioration (or 
wearing-off effect), inter-dose (or peak dose)abnornial involuntary movements, and 
unpredictable "on-ofr' fluctuations. In the latter case, periods of severe parkinsonian 
motor deficit alternate unpredictably with-periods of relative mobility. It remains unclear _ 
whether duration of disease or duration oflevodopa therapy causes such complications. 
It has been postulated that disease progression is accelerated as a consequence of 
potentially neurotoxic radicals produced by metabolism oflevodopa, however this has not 
been conf1rmed in human studies[37] 
The development of dopamine agonists has sought to produce a more predictable and 
sustained dopaminergic action than that oflevodopa. Dopamine agonists currently 
available for use in the UK are: apomorphine, bromocriptine, cabergoline, lisuride, 
pergolide, pramipexole and ropinerole. 
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1.2;6. Apomorphine. in the Treatment of Parkinson's Disease. 
The discovery of apomorphine is·credited to Mattbiessen and Wright who, inJ869, 
publisheditheir work on the chemistry of opium bases[43]. Since:then apomorphine bas 
been used as emetic, expectorant and in various;motor disturbances, however it Was not 
untill951 that Schwab showed that apomorphine coukl reduce rigidity in:decerebrate 
animals[44]. Based on his pre-clinical work, Schwab attempted to alleviate parkinsonism 
in humans using subcutaneously .administered apomorphine; an improvement in tremor and · 
rigidity wa8 seen in the patients. A dec8de would pass before it .was reali!!OO that · 
apomorphine acted at dopamine receptors, or that nigrostriatal dopamine deficiency 
occurred in Parkinson's disease. 
Conformation of the therapeutic effects of apomorphine in Parkinson's disease followed, 
but introduction into clinical practice was limited by the need for parenteral administration, 
" the occurrence of adverse reactions (such as vomiting, drowsiness, arterial hypotension, 
yawning), and also by the success of oral levodopa. An advance was made in 1979, when 
Agid found that domperidone (an extra-cerebral dopamine antagonist) could prevent the 
typical adverse effects of apomorphine (as given above), with the exception of yawning. 
Domperidone Was subsequently recommended for the improvement oftoierance to orally 
active dopamine agonists. Key clinical studies were performed in .patients in the 1980s 
[45-47]. Apomorphine was administered subcutaneously, either intermittently with the 
Penject® (Britannia Pharmaceuticals) to effect a "rescue" from "off' phases, or by 
continuous infusion using a Grasby MS 16A pump, the latter being applicable to patients 
who require multiple injections daily or who are W1Bble to anticipate an "off' period with 
adequate time to self-administer a bolus. Administration of apomorphine by continuous 
infusion usually allows a reduction in oral dopaminergic medication. 
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Currently apomorphine is licensed in·the UK 1 to manage motor fluctuations that are 
inadequately controUed by 1:.-dopa and!othet agonists; · Patients with Parkinson~s diSease · 
who can expect to have a significant therapeutic benefit ftom apomorphine:are those With 
severe off periods and with a;good qwility of on periods- particularly if not associated ·With 
troublesome'interdose dyskinesias. Daily "off' time is reduced by more than 500/o in 
patients with "on-off' motorfluctuations, with extended benefits seen up to; eight years of 
foUow-up[ ]. 
Adverse Effects. 
1qe side effects are as those observed with other dopamirie agonists, with the addition of 
yawning 8nd drowsiness. The most frequent side effect is a local skin reaction at needle 
insertion points, consisting of itchy fibrotic nodules ~hich may scab and occasionally . 
h 
. become infected and bleed. It is possible to minimise these by diluting the apomorphine 
solution with saline and rotating injection sites[48-50). 
Coombs-positive haemolytic anaemia which is drug-dependant and reversible has occurred 
in a few patients on apomorphine and L-dopa[46, 51]. This condition haS been descnDed in 
patients on L-dopa alone. 
1 Apomorphine was licmced as BRITAJECf® (Britannia Pharmaceuticals).fur the duration o~the clinical 
and analytical work contained in this thesis, however the formulation is now licensed as APO-GO® 
(Britannia Pharmaceuticals) 
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1.1.1.5. Chemistry of Apomorphine. 
The molecqlar weight of apomorphine as a base is 267.3 and as aHCL-salt is 312.8 
(Figure 1-5). Apomorphine readily undergoes oxidative changes, especially in solution 
under alkali.ne. conditions, and in the presence pf oxygen and light. On oxidation 
apomorphine turns green[52, 53]. 
;. H~ 
Figure 1-5 Structure of apomorphine. 
The dopaminergic properties of aporphines results frQm the binding to both hydroxyl 
groups and the nitrogen atom. The hydroxyl group at the CII position contributes most to 
the receptor binding and biological activity[ ]. 
The preferred conformation for central dopaminergic receptor agonist activity is the a-
conformation, where both hydroxyl groups are located at the Cl 0 and C11 atoms[ 52]. 
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1.1.1.$. :Metabolism of Apomorph~ne. 
Data.rehlting.to!apomorphirie metabolism in hw:Dans is·scarce. Bioavailability after an oral· 
dose isilow (17%), indicating an extensive first-pass effect[ 56]. Enantiomeric 
· interconvmiion, methylation, sulphation and glucuronidation of RH-apomorphine have 
. . 
each been proposed'aS potential metabolic .pathways[52] .(Figure 1- ). Apocodeine, 
iso~eine, and apomorphine-gluci.Jronide 90njugate(s) potentially exhibit 
dopaminergic stimulation, whem.s S-apomorphine is a potential dopamine antagonist[ 54]. 
'fhC contributions of the aforementioned pathways'were examined in ten patients with 
Parkinson's disease by van der Geest et a/[54]. The total·excretion ofunchanged 
apomorphine was only 0.3% of the administered·subcutaneous dose, and as such accounted 
for only"- minor proportion ofthe,administered dose. The authors conchuled that neither 
enantiomeric interconversion nor methylation occurred in vivo (based on the absence of 
detectable concentrations ofS-apomorphine fu the plasma, and apocodeine and 
isoapocodeine fu the plasma or urine). The conjugation of apomorphine via 
glucuronidation and sulphation pathways was identified as havfug a minor role in vivo; the 
total excretion of sulphated and glucuronidated apomorphine was 3.8 and 6.0% of the 
administered dose, respectively. The authors suggested• that N-deniethylation of 
apomorphine to norapomorphine, by the cytochrome P-450 system, may contribute to 
apomorphine metabolism; norapomorphine possesses dopaminergic activity, but is 
significantly less:potent than apomorphine in'terms of stereotyped behaviour in 
animals[52]. Additionally (auto )oxidation to quinone derivatives may prove to be a 
quantitatively important process with regard to apomorphine metabolism[ 54] however the 
contribution of such derivatives to the pharmacological response to apomorphine fu 
Parkinson's disease remains to be established. 
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Figure 1-
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1.1.1.7. Phannacoklnetics.:Pharmacodynamlcs of. Subcutaneous Apomorphine. 
The peripheraJ:pbannacokinetics of apomorphine were first described, by Gimcher.etal, in 
1989[56). These data, along witMbose :from, more recent studies'are summarised in Tables 
6-2 and>6-3 (pages 6-4 to 6-6). 
Apomorphine pharmacokinetics have been modelled'using either a one-or~ 
compartmeilt modeL The bioavailability of the subcutaneous route· (compared to 
intravenous administration) is 100% [56; 58]. Following subcutaneous injection, there is a 
short absorption half-live (approximately 6 minutes) and a briefT mu: (approximately 14 
minutes) which is dose-independent[ 56-58, 85]. Both Cmax and AUC are linearly-related to 
. . 
dose, the latter ranging :from approximatelY 10 to.90)J.glkg[56-58, 61, 85]. A large inter-
patieilt variation in absorption has been reported, but with lower intra-patient 
variation[ 56, 58]. Explanations for the variation in pbarmacokinetic parameters·bave 
centred on d~nces in choice of injection site, local skin temperature, and local nodule 
fonnation. ·The distribution and elimination half-lives are short; i.e. approximately 10 and 
50 minutes, respectively[ 54, 56, 58]. 
Clearance.(at approximately 3Liblkg) exceeds hepatic blood flow, indicating that 
metabolism must occur to a significant degree in extra-hepatic tissues[54]. The (appareirt) 
volume of distribution is given as approximately 1.5Likg, indicating extensive distribution 
outside the.plasma compartment[ 54, 56-58, 61]. 
'The onset of anti-parkinsonian effect following a subcutaneous bolus dose occurs shortly 
after dose administration (approximately 5 to 20 minutes), but.the effect is short-lived 
(approximately 45 to 90 minutes). 
The rapid distribution of apomorphine :from the subcutaneous 8dministration site into 
plasma, and the rapid clearance from plasma, are attributed to the high lipophilicity of 
apomorphine[ 54, 56-58, 61]. The short latency of onset to anti-parkinsonian effect, and 
the briefduration of effect, reflect a rapid·passage across the blood-brain-barrier and a fust 
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equili~on:witMhe site ofactioa These processes are similarly associated with the . 
lipophilic properties of apomorphine, 
Van·I..aar eta/ employed:a muhiple pseudo steady-state protocol in the characterisation of 
apamorphine:concentration-effect relationship in ten patients with Parkinson's disease[62J 
The d~se:ranged from 10 to lOo Jlg/kg/h, comprising ofal0J1glkglh increase every io 
minutes. It was thus demonstrated that a nan'owtherapeutic window.exists, and 
furtbermore t1iat there is a high inter-patient variation in the minimum plasma 
concentration for onset of beneficial effect (lA to 10.7 ng/mL), onset of dyskinesia, (2.7 to 
20.0 nglmL) and for onset of adverse effects, e.g. nausea. hypotension,(8.5 to 24.5 
ng/mL). 
Harder et a/ performed a pharmacokinetic-pharmacodynamic study in which four 
ascending bolus doses of apomorphine (0.5, 1, 2, 4mg) were ~ subcutaneously 
to ten patients with Parkinson's disease[60]. The authors demonstrated the existence of a 
steep sigmoidal relationship between dose and response, with a minimal effective threshold 
dose (the percentage of patients who resporided at 0.5, 1, 2 and 4mg was 0, 20, 60 and 75, 
respectively), and whereby a dose increase above the threshold resuhed in an extension,to 
the duration of effect, but not to an augmentation of the response. 
A direct relationship between concentration and effect was evident in five (out of forty) 
serieS .. Conversely in other cases proteresis was displayed (PF6), whilst in seven series 
counterclockwise hysteresis was apparent. In three series, no clear relationship between 
coneentration and effect could be detected, and in the remaining series modelling was 
precluded due to the absence of detectable plasma apomorphine concentrations and/or a 
lack of demonstrable effect. 
A hypothetical effect compartment was incorporated to account for the cotmterclockwise 
hysteresis observed in a sub-set of the study population. The effect site equilibration half-
life was short (approximately 6 minute8) thus accounting for the rapid onset of clinical 
. ' 
effects. 
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1.3. Pharmacodynamic Assessmf!fnts in Parkinson's Disease. 
A tool1employed for pharmacodynamic assessment should be·objective, reliable, and . 
valid[63). The method•must:be standardised. with attention paid to all the steps·ofthe test. 
e.g. executive~instructions and conditions[63], ·In terms of the study of apomorphine 
· pharmacodynamics, it must be feasibJe to complete the assessment within a very short time 
frame.(approximately one minute) due to rapid changes in motor performance. 
The methods used to quantify symptoms in movement disorders such as'Parkinson's 
disease include rating scales and instrumented measurements. The Unified Parkinson's 
Disease Rating Scale[64) (UPDRS) (see Appendix 8.1) was designed to provide a measure · 
of signs and symptoms ofParkinson's disease in clinical practice and research. The 
UPDRS Part Ill sub-score is intended to assess parkinsonian severity, but not necessarily 
disability. The UPDRS is considered to be the "gold standard" for assessing therapeutic 
efficacy in clinicaHrials in Parkinson's disease and is the most widely used standardised 
quantitative measure in Parkinson's disease[63]. However, the time taken to complete the 
assessment is too long to obtain replicate measurements in a study of apomorphine (bolus 
injection) in Parkinson's disease. 
Rating scales which have been used previou51y in pharmacokinetic-pharmacodynamic 
studies of apomorphine in Parkinson's disease include a four-point tremor score(4, 54, 62], 
a four-point dyskinesia score[4, 54, 62] and the Columbia University Rating Scale 
(CURS)[60]. The major disadvantage of the latter rating scale is that the task takes 
approximately five minutes to complete[60]. 
The tapping test Is oommonly used as an assessment of parkinsonian bradykinesia because 
it is simple, rapid and objective[4, 54, 57, 65, 66]. The subject is required to alternately 
depress two counters which are (usually) placed 30cm apart, using one hand only, for a 
period of(usually) 30 seconds. (Figure 1-6). The task must be performed at the maximal 
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rate of movenient using the hand of the side of the body most affected with parkinsonism. 
Tapping speed has been shown to correlate with other measures of parkinsonism, such as 
the bradykinesia and rigidity assessments of the CURS[67"69]. Disadvantages of the 
tapping test are that the task is subject to learning effects[68, 70, 71] and,~ COIIlUlOn wit~ 
many other assessments of symptoms in movement disorde~ relies on the active eo-
· operation and motivation of the subject. 
I 
" 
Figure 1-6 The tapping tester used in the study presented in this thesis. 
The Bradykinesia Akinesia Inco-ordination Test (BRAIN TESTO) is a computerised 
keyboard too~ which has been used to quantify upper limb motor function in movement 
disorders[72]. This test is based on the tapping test but generates a dysmetria score (i.e. 
the number of incorrectly hit keys corrected fur speed) and an inco-ordination score (i.e. 
the variance of the time between keystrokes) in addition to a kinesia score (or tap rate). 
Both the kinesia score and inco-ordination score correlate with the UPDRS Part m su~ 
section. 
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AmbuJation tasks have been> used to monitor antf..parkinsonian response,,e.g, in_the forin ~f ·· 
. . 
a simple walking test iMYiiich the subject is required'to watk 8t maximaltspeed oVer- a 
distance of 12m[65, 66], and aiso,in,the form of an analysis of gait parameters such as 
strideclength, which correlated1With'the CURS bradykinesia score[70],·and velocity, Which 
correlated with BPDRS ID Axial, motor score(13] 
. . . 1 
There are other techniqUes which have not been widely USed, probably because theSe 
involve the,use of specialist equipment and are therefore less aceessible. EXmilples inClUde 
the·use of activity monitors and 1accelerometers[74], computer-derived -indices of 
handwriting kinematics[75], and;computer-assisted analysis of whole body (posturo-
locomotion-nianual) movement patterns and motor performance[76]. 
-' 
' 
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1.4. The Intranasal· Route·for"Df11g. Delivery. 
Nasal respiratory.epithelium consists of ciliated pseudostratified colunmar epithelial cells, 
many of which are covered with mierovilli[77, 78]. Hence the nasal cavity possesses a 
' ' 
'large and permeable surfilce area fur the absorption: of drugs. The sub-epithelium, layer is 
- -
highly vascularised, and'since the venous blood passes directly into the syStemic. 
circulation, first .pass hepatic metabolism is avoided[78]. 
-As a resuh of experiments iD rodents, it has ;been proposed that intranasally administefed 
drugs may be transferred (more) directly to the central nervous system[79], i.e. directly 
along the olfactory pathway to the brain following nasal administration(80lmfby 
diffusion through theiperineural space, a· compartment which is conti1luous with the sub-
arachnoid space£78]. Transneuronal absorjrtion (in·humans) is considered to be slow in 
relation to absorption by the supporting mucosal cells and capiUary bed(Sl]. 
A two layered mucus covers the respiratory epitheliUm. 1be mucus consists of a low 
Viscosity fluid (sol layer) which surrounds the cilia and a inore viscous gel layer wbich is 
situated on the·surfiu:e ofthe sol layer[77, 78]. The:typical pH of nasal secretions is 5.5 to 
6.5[77, 78]. 
Inhaled particles are cleared from the nasal cavity by mucociliary clearance, i.e. mucus 
(and the particles that are bapped in or on the mucus layer) is transported posteriorly in the 
nose and down the throat by the movement of the cilia. Mucus flow rate in humans is 
approximately 5mm·per minute[77, 78].~ theoretically the mucus layer is renewed every 
15 to 20 minutes[78]. The volume ofmllcus in the rulsai cavity is typically 0.5 to lmL[82]. 
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1.4.1. Appli~on m Intranasal Delivery ofApomorphine .to Parkinson's Dise-ase. 
The nasal mucosa.represents a route for apomorphine- adininistration• for which first pass 
metabolism is·avoided~ Being highly lipophilic, apomorphine.has the potential ~or 
extensive.absorptio~ via the nasalimucosa.- Hawever witli a pK.,of7.2[83], ~morphine is · 
predominantly.(approximately95 to 100"/o) charged-at the localenvironmerit pH(pH S.S,to 
6.5[77, 78]);hence the likelihood of absorption is very much reduced. 
The nasal route has been investigated for efficacy, tolerability and bioavailability in 
patients with Parkinson's disease[84-90]. These were.all relatively small scale studies, 
with patient numbers ranging :from 5 to 10. 
The intranasal formulation used was, in the majority of sttijlies, an:aqueous solution of 
apomorphine which was delivered by means-of a metered dose nebuliser[84, 87, 89]or 
nasal spray[85, 86, 88]. A single actuation :from the inhaler delivered I mg of-
apomorphine in 0.1 mL of sofution[84, 86-89] or 1.3mg apomorphine in 0.065rnL of 
solution[85]. The intranasal doses used in these studies ranged from 1 to 10 mg 
apomorphine[84-90]. 
Patients·were titrated to doses ofintranasal apomorphine that elicited an optimum clinical 
response[84-89], optimum clinical response being defined as a satisfuctory "on" -phase. 
The intranasal dose required for an optimum response was reported to be the same as[87]; 
similar to[84] or higher than (up to five times bigher[85], but with a mean of 
approximately two times bigher[85, 89]) that required for an equivalent motor 
improvement using the subcutaneous route. A comparison of the peripheral 
pharmacokinetics of a{lomorphine administration via the intranasal and subcutaneous 
routes was undertaken by Sam[85], and a partial comparison of the two routes has been 
reported by van Laar et a/[84]. 
-Apomorphine was rapidly absorbed after intranasal administration, as evidenced by the 
rapid absorption half life (mean was 9 minutes, range was 2 to 24 minutes[85]), short T max 
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(ineans were 23[85]:and 7[84] minutes, with ranges of l·i toJ7·and 4 to 9 minutes, 
respectively) and brieflag-time (mean ofJ minutes, range ofO to 9 minutes[85]), 
Variation,imthe estimates ofTmax followirig.iirtranasaladministration!betweenthe.tWO 
studies may be due to differences in the performance ofthe devices uSed,,e,g. deposition of 
. 
drug, or·the number of puffs required· to deliver total.dose; 
Both the mean absorption half life and T max for intranasal apomorphine administration 
were longer th8n those given for subcutaneous administratiOn, whereas the Jag time was 
shorterthanthatfor subcuta.nOOus ~ion[85). However', there were no sigriificUnt 
differences between the two routes with regard to these parameters which descn"be 
. . 
absorption•kinetics[85]. There was a positive correlation·between intranasal dose and 
c....J84]. 
The bio~vailability of intranasal apomorphine-administration, in terms of the area uDder tlie 
plasma concentration-time curve for an intranasal dose conipai'ed to that estimated for a 
subcutaneous dose, was highly variable. Sam et a/ reported that the mean relative 
bioavailability for the whole group (1F6 patients) was 45%. In filet for five ~;>fthe six 
patients, the relative bioavailability was in the range of 13 to 46%, but was 117 %for the 
remaining patient[85]. Van Laar et a/ reported the relative bioavai1abiJity of the intranasal 
route for one of the seven patients in their study; this was estimated to be 90 to I 00%[84]. 
'The mean latency to onset of effect following intranasal dosing ranged from 9 to 18 
minutes[84-88, 90]. In,the two studies which made a direct comparison ofthe 
pharmacodynamic effects of apomorphine administration using the intranasal and 
subcutaneous routes, the mean delay to onset of effect was longer following intranasal 
administration, however tfte difference in latency did not reach statistical significance 
(where p<0.05 was considered statistically significant)[85, 87]. Nor was there a significant 
difference in the duration of the apomorphine-induced response between the two routes 
(where p<0.05 was considered statistically significant)[85, 87]. "The mean duration of 
c 
effect following intranasal dosing ranged from 44 to 61 minutes[84-88, 90]. 
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Dyskiitesia was a common·adverse effect of~ apomorphine administriltion,:but 
was' considered to be comparable in•severity to;tbat which• occurred following levodopa£86. 
88) :or subcutaJteous apomorphine[84) ·administration. Yawning wits·repoited'in a minority 
of patients as a resuh of intranasal apomorphine. administration[84, 86, 88], as was 
paresthesia[84) and nausea (despite anti-emetic.therapy)[86, 88]. The aforementioned 
signs are commonly experienced adverse effects·of (subcutaneous) apomorphine therapy. 
The•adverse effects specific ·to intranasal·administration of apomorphine were .mild nasal 
stinging and the oci:urrerice of a bitter taste following the intranasal dose[86, 89]. 
After approximately 4-6 weeks of usage, up to half of the patients in thC long-term studies 
had beerraffected with mild to moderate local adverse reactions to intranasal apomorphine, · 
ie. slight vestibulitis with nasal blockage and nasal crusting (which was black in co1our in 
one case[84]), and did not limit the use of intranasal apomorjJhinC[84, 86, 87]. Whilst this 
was.the case, the local ad\'ei'Se effects of intranasallise were considered to be more 
disabling than those resulting from subcutaneous use[87]. 
Adverse events at the nasal mucosa, including erythema and crusting, also occurred in 
(unknown number of) asymptomatic patients receiving placebo~ spray [86]. 
However, up to one third of patients receiving intranasal apomorphine developed severe 
and disabling (reversible) localtissue reactions (e.g. severe nasal vestibulitis, with 
secondary infection, crusting with pain and bleeding on intranasal administration, 
superficial mucosal ulceration) leading to the discontinuation of treatment in some 
cases[84, 86, 87, 89] .. Severe adverse reaction of this nature was reported to substantially 
lower absorption at the nasal mucosa[84). 
Patient acceptability was good; in the absence of severe .local adverse reaction· the 
intranasal route was preferred over subcutaneous administration. Patients who were unable 
to administer subcutaneous injections were able to self-administer intranasal 
apomorphine(89]. 
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It has been demonstrated that preferentialrdelivery to,the CNS occurred following riasal 
administration:ofwatersoluble prodtugs ofL-dopidn rats (evidenced by the fiilding that 
· olfuctory bulb and CSF'l.-dopa·concentration were.bigher compared to an equivident . 
. intravenous do5ej[91] and.that dopamine·was;transferred·into the'olfiietory bUlb folloWing· 
nasall.ldministration in mice[ SO]. It is reasonable to suggest that the SIUDe oUtcome-would' · 
apply to intranasal adminiStration of apomorphine, especially given the high lipophilicity 
of apomorphine. 
Ahhough the delivery of apomorPhine via the olfactory pathway and/or via CSF represents 
the opportunity for enhanced eNS· delivery, there· is no-evidence for an aUgmented 
apomorphine-induced response in the literature, i.e. the intranasal dose required for 
pharmacodynamic equivalence with subcutaneous injection, in terms of the magnitude and 
. duratio~ftbe response, is greater than that for stibcutaneous·injection, with a similar -
latency to onset reported for each route. This·suggests that the contribution of the olfactory 
transneuronalahd/or direct CSF routes in the delivery of apomorphine to the CNS is· 
inferior to absorption at the respiratory mucoSa into the capillary bed. however, the relative 
contribution of the delivery mechanisms following intranasal administration of 
apomorphine remain to be established. 
It is well established.tbat patients with Parkinson's commonly eXhibit olfactory dysfunction 
[33_, 92, 93] and that the olfactory deficit is severe and present in early ~e Parkinson's 
disease[94, 95]. Whilst the underlying mechanisms remain contested, it has been•proposed 
that olfactory dysfunction in Parkinson's disease is a consequence of a lesion in the 
olfactory neural pathway[96], including the•olfactory neuroepithelium[97]. In this case, 
the absorption of drugs across the olfactory epitheliUm and subsequent delivery to the brain 
via the olfactory pathway may be precluded. The olfactory function of the patients with 
Parkinson's disease in the published studies of intranasal administration of apomorphine 
was not commented upon by the authors. 
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. .It bas:also beeu;reported that patients with Parkin!KJn's disease display reduced sniffing 
capability compared to healthy controls (and that this impairment contributes.to olfuctory 
dysfunction in Parkinson's disease}[98]. One patient in the study by•Sam et a/ exhibited a . 
poor sniff effort[8S]. This finding ·has implications for the intranasa11 delivery of 
apomorphin~ using self~powered delivery· devices. 
1.5. The Buccal Route:.for Drug Delivery. 
Oral epithelium consists of a mitotically active basal ceU layer, progressing through a 
number of differentiating intermediate layers to the superficial layers. where.cells are shed • 
from the epithilial swface. Oral membranes are covered in;mucous and.are continually 
provide4 with fresh serous and mucous saliva The pH of human saliva varies from 6:0 to 
" 
7.4. [99]. 
Administration: of drug via the buccal mucosa results in rapid. absorption into the systemic 
circulation due to the rich local network of systemic veins and lympbatics. Buccal tissue is 
better perfused than gingival, sublingual and palatal tissue (in that order)[99), 
The buccal mucosa is considerably more permeable than·gingival and palatal mucosae, but 
is less permeable than that at the sublingual region, and as such• the buccal mucosa is 
generally not considered to .be able to provide the rapid absorption and higb bioavailability 
possible with sublingualadministration[99]. 
A limitation of the oral mucosa as a site for drug delivery is the challenge of retaining the 
dosage form in place, despite the presence of food arid beverages, and without interfering 
with mastication and speech. Drug delivery via the buccal mucosa is also limited by the 
possibility that the recipient may chew or swallow the dosage form. 
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1.5.1. Application of Buccal' Delivery of Apomorphine toJPatkinson:s Disease. · 
. . 
The;buccai mueosa represents a route for apomorphine administration for which firSt1pass . 
metabolismiis avoided. Being highly lipidisoluble, apomorphine has the potential for 
efficient absorption via the oral mucosa. However with a p~ of7.2, apamorphine is 
predotoirumtly cbarged at salivary pH (pH 6.0-7A), whiCh indicates that absOrption is 
The sublingual route:bas been investigated for efficacy, tolerability and bioavailability in 
patients with Parkinson's disease[65, 66, 100-105]. These Were all relatively small scale 
studies, with.patient numbers ranging from 5 to 10. The sublingualdose of apomorphine 
' used· in the above studies varied from 3 to 57 mg, and comprised of either single or 
multiple tablets, which were allowed to dissolve under the tongue. Dose titration was 
performed as a prelude to acute[1 00~ 103] and chrooic[1 02] pbarmacokinetic studies by 
certain groups. The efficacy ofsublingually administered apomorphine was stated• as 
being similar to that achieved using levodopa, with the exception of two (out of five) 
patients in a single study[66] who did oot exhibit improvement in motor function following 
a sublingual dose.of18mg. 
Generally it was reported that Cmax andAUC were correlated to the administered 
sublingual dose. The meanT max observed in the!studies of sublingual apomorphine 
administration ranged from 35 to 62 minutes. The variation in T mu: (and in onset of effect) 
was related by some authors to the dissolution time of the tablet(s)[65, 101, 103], a process 
whichtook an average oflO to 30 minutes [66, 101-104]. Notably in one study was it 
reported that the dissolution time of the sublingual formulation used was not related to 
Tmax[105]. The dissolution time quoted in the latter study was, at 10 to 20 seconds, 
cOnsiderably faster than·that reported by the other investigators. 
The mean bioavailability, in terms of the AUC following sublingual administration relative 
to that for subcutaneous admioi~ion in the same patients, ranged from 
1-32 
10 to 18%[65, 66, 104, 105]. The reliltively poor'bioavailability was attnbuted to a 
proportion of the administered doile being:swallowed by the patients[l01', 105]. 
The mean latency to onset of effect was, at 15 to 40 mins, relatively long compared to that -
reported for subcutaneous administration of apomorphine[ lOO, 103,105]. -1he·eXtended 
- . . 
delay to-onset of effect was identified as'a disadvantage in the application· of the sublingua] 
· route to apomorphine administration, especially· in the cases of severely akinetic -patients 
with Parkinson's disease. 
The·mean duration of response varied from 55 to 137 mins, and as such was considered to -
be equivalent or longer than that which was achieved following subcutaneous 
administration[IOO, 103, 105]. 
Acute apomorphine administration via the sublingual route resulted in adverse (systemic) 
_effects ~eh were typical of the adverse events commonly reported following 
subcutaneous administration, i.e. dyskinesia[ I 00, 103, I 05) in many patients, yawning and 
dizziness in a minority[l03]) and were generally mild to moderate in nature. In addition, 
an unpleasant (bitter or acidic) taste was reported in some studies[IOl, 102, 104). Chronic 
sublingual administration of apomorphine resuhed in the development of stomatitis[65, 
101] and ulceration[65] of the oral mucosa which was severe enough to lead to.the 
discontinuation of treatment in some cases[65]. 
Based on the latency to onset of effect which has been reported for sublingual delivery of 
apomorphine, it was envisaged· that the buccal mucosa represented a site which may be 
useful for sustained release of apomorphine, rather than rescue action. 
Salivary secretion rate decreases with increasing age[]06) and furthermore "dry mouth" 
can resuh as a consequence of the use of anti-cholinergic drugs in the management of 
Parkinson's disease. However in contrast to this, patients with Parkinson's disease often 
exhibit hypersialorrhea and/or drooling. a-characteristic which has been attributed to 
diminished motor function relating to swallowing, and also to changes in autonomic 
function[107, 108]. Such extremes of salivary flow that may occur in Parkinson's disease 
have the potential to affect the administration of apomorphine via the buccal mucosa. 
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SECTION2: 
INTRODUCT][ON 
2 . .. Introduction. 
2.1. Pharmacokinetic-Pharmacodynamic Study of Subcutaneous 
Apomorphine Administration in Patients with Parkinson's 
Disease. 
Previous studies'on apomorphine in Parkinson's diseasdmve revealed the large inter-patient 
variation in pharmacokinetics and pharinacodynamics, and also the existence of a narrow 
therapeutic window[l-3]. These factors clearly demonstrate the,need for individualised 
dose optimisation of apomorphine in the management of Parkinson's d~. 
Currently apomorphine dose optimisation consists of a basic threshold dose-finding . 
protocol (Section 8.2). Given that apomorphine has a narrow therapeutic window, a 
threshold dose~ :finding protocol might not be the most appropriate procedure for dose 
c 
optimisation. Certain clinical issues are important here: are all patients who do not respo~ 
to the higher (7mg or 1 Omg) doses non-responders? Can the transition from multiple bolus 
dosing to continuous infusion be facilitated? 
With these issues in mind, a pharmacokinetic study involviQg two patients on established 
clinically effective subcutaneous infusions of apomorphine was undertaken in-house[ 4 ], and 
a potential correlation between (peripheral) pharmacokinetics and general therapeutic 
outcome in the two patients was identified, i.e. despite a difference in dosing requirements 
and in pharmacokinetic parameter estimates between the two patients, values calculated for 
the beta-phase intercept (Box 2-1) were consistent (Figure 2-1 and Table 2-1 ). The 
beta~phase inte~pt was also estimated from published apomorphine concentration-time 
profiles; the values were similar to those obtained in the in-house study, irrespective of 
dose and route and despite large variation in other pharmacokinetic parameters (Table 2-2). 
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Thus, under the assumption that the peripheral compartment contains the effect site (i.e. the 
CNS), it was proposed that the beta-phase intercept might function as a marker of drug 
concentration at the effect site, and furthermore that the consistent value observed in 
optimised patients, i.e. approximately 1 Ong!mL, might therefore represent a threshold 
concentration for effect. In this context the beta-phase intercept would be predictive of 
anti-parkinsonian response and could therefore be exploited in a dose-optimisation scheme 
whereby patients could be dosed to a ~utic apomorphine concentration at the effect 
site. 
In this thesis the significance of this relationship between the beta-phase intercept and anti-
parkinsonian effect of apomorphine in patients with Parkinson's disease was examined. 
~~------------------------------------------, 
40+---~-------------------------------------
5 
._.Patient A 
--PatientB 
,_..,.Infusion. 
o~~,_~-r~~~--r-~~~-r~~~~~~~--~ 
0 120 240 360 480 600 720 840 960 1080 1200 
Tilae (millute) 
Figure 2-1 Pluma apomorphine- concentration following 12h subcutaneous 
infusion of apomorphine in two patients with Parkinson's disease. 
Reproduced from Priston[4), with permission. 
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Patient Dose emu• Auc.-.....,• tYa a t% p B 
(m g) (nglmL) (ng.mL-1.h) (min) (min) (nglmL) 
A 35 1.1 6.7 8.2 76.4 10.9 
(2.9mg/h X 12h) 
B - 141 0.3 . 2.9 46.6 166.5 10.8 
(11.8mg/h X 12h) 
Table 2..1 Selected pbannaeokinetic parameter estimates from a. study of 
subcutaneous apomorphine infusion to dose-optimised patients with 
Parldnson's disease. 
Reproduced from Priston[4) with permission 
Abbrel'UtioiU! t% a =distribution balf-1iv~ t% p =(apparent) 
elimiaatioa half-live.. 
Route Dose B Publicatioa 
{nglmL} 
subcutaneous bolus 2.6mg 13.2 Nicolle[3] 
3.0mg 8.0 • ij:ofsteef5J 
subcutaneous infusion 4.9mg/h X 24h 11.3 Nic_olle[3] 
57mg 14.4 * Hughes[6] 
sublingual 57mg 14.8 • Hughes[6] 
0.6mglkg 9.7 • Durif{7] 
intravenous bolus 2.6mg 10.5 Nicolle[3] 
intravenous infusion 0.6mg/h X 12h 11.3 Gancher[2] 
3lling/kg X 15min 13.8 van der Geest[8] 
intranasal lmg 5.5 vanLaar[9] 
4mg 16.2 van Laar[9] 
rectal lOmg 18.2 * van Laar[IO] 
Table 2-2 Estimates of the beta phase intercept (B) from published articles. 
Asterisked values indicate that it was stated in the publieation that the 
administered dose bad eticited a therapeutic effect. In the remaining 
publications, the nature of the effect was not stated. 
• Normalised to lmg dose. 
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The two-compartment pharmacokinetic model resolves the body into two distinct 
mathematical compartments: (i) a central compartment which consists of blood and rapidly 
equilibrated organs (e.g. liver), and (it) a peripheral (or "deep") compartment which consists 
of more slowly equilibrating tissues (e.g. tissues which are surrounded by protective 
membranes), and which is usually inaccessible to direct measurement[ It , 12]. 
The assumptions of this model are that (i) irreversible drug elimination (e.g. by hepatic 
biotransformation) takes place only from the central compartment, and (ii) reversible 
distnoution occurs between the central and peripheral compartments[ll, 13]. 
For a drug wbieh exluoits two-compartment pharmacokinetics, drug disappearance from the 
sampling window (plasma) following extravascular dosing is described by the linear sum of 
exponential terms:-
C(t) = A.e (-o.t> + B.e (-fJ.t> + D.e (-teou> 
Alpha and beta correspond to the initial and terminal slope fuctors, respectively, and A and 
B to they-axis intercepts of the ihltial and terminal slopes, respectively. D is given by 
-(A +B), and KOI is the absorption rate[l2, 13) (Figure 2-2). 
The· beta~phase intercept represents the concentration of drug in the peripheral compartment 
bad the total dose been instantaneously distributed to this compartment[14]. 
~ y---~----~-=-~=-==-======~~~----~~~~ 
:I 
... 
e. 
A 
B 
-Cp 
- Alpha phase 
- Beta phase 
o n~ 
Figure 2-2 Drng disposition (according to a two compartment model) following 
extravascular (1st order input) dosing. 
Box 2-1 The beta-phase intercept. 
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2.2. Studies on Novel Apomorphine I!Jelivery Systems with 
Application to Parkinson's Disease. 
There are:inherent 'limitations associated with:subcutaneous ~ection or infusion of 
apomorphine to,patients with Parkinson's,disease, The high risk o~developing cutaneous 
' 
nodules, first descn"bed;by Stibe et al£15], cant be treatment.,-Iimiting. The technique itself 
can be problematic for some patients[l6-l8], indeed "oft" period disability adversely affects 
the capability of the patient to self-inject using a syringe or ''Penject®" (Britannia 
Pharmaceuticals Ltd)[6, 19, 20). ManuaJ.difficulties sueh as the8e have·led to dependence 
on others to administer the drug on behalf of the patient[?, 19, 20); 
Furthermore there are issues surrounding the use of needles for drug delivery, including fear 
or anxiety associated with (self) injection[21;], and the range of health and safety imperatives 
and soci81 issues involved[22]. Additionally, the requirement for parenteral delivery may 
result in a reluctance to prescn"be by some neurologists[23]. Such limitations have 
prompted research of alternative modes of delivery of apomorphine, e.g. intranaSal 
spray[24], rectal suppositories[25] and transdermal iontophoresis[26]. 
As a contnbution to .the research of alternative delivery systems for apomorphine, studies 
were undertaken on the properties of three novel systems, i.e. intranasal administration of 
apomorphine powder to heahhy volunteers, buccal !!dministration of an apomorphine 
hydrogel fonnulation to healthy volunteers, and subcutaneous administration of . 
apomorphine (Britaject®) by needle-free injector to patients with Parkinson's disease. 
Where applicable the beta-phase intercept was included as an outcome measure in these 
studies as,part of the research outlined in Section 2.1. 
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SECTION3: 
MATERIALS 
3. Materoals. 
3;1. Analyticai'Reagents. 
Product. Souree. 
alumina~for column chromatography, type Sigma-Aidrich Company Ud,.Poole, Dorset, UK. 
WA-A, activity grade: super I 
ammonium chloride BDH Merck, Leicester, Leics, UK. 
' 
ammonium hydroxide Sigma-Aidrich Company Ltd, Poole, Dorset, UK. 
L- ascorbic acid ACS reagent Slgma-Aidrich Company Ltd, Poole, Dorset, UK. 
citric acid BDH Merck, Leicester, Leics, UK. 
diaminoethanetetra-aoetic acid sodium salt Fisher Scientific, Loughborough, Leics, UK. 
(EDTA) 
diethyl ether . Fisher Scientific, Loughborough, Leics, UK. 
diphenylboric acid 2-aminoethyl ester Sigma-Aidrich Company Ltd, Poole, Dorset, UK. 
" 
ethyl acetate Fisher Scientific, Loughborough, Leics, UK. 
heptane Fisher Scientific, Loughborough, Leics, UK. 
1- heptanesulphonic acid sodium salt BDH Merck, Leicester, Leics, UK. 
"HiPerSolv for HPLC" 
hydrochloric acid Fisher Scientific, Loughborough, Leics, UK. 
hydrogen peroxide (6%) 20vol BDH Merck, Leicester, Leics, UK. 
2- mercaptoethanol· (electrophoresis reagent) Sigma-Aidrich Company Ltd, Poole, Dorset, UK. 
methanol, HPLC Grade Fisher Scientific, Loughborough, Leics, UK. 
octanol Sigma-Aidrich Company Ltd, Poole, Dorset, UK. 
orthophosphoric acid Fisher Scientific, Loughborough, Leics, UK. 
~ 
-
perch loric acid BDH Merck, Leicester, Leies,.UK. 
sodium dihydrogen orthophosphate Fisher Scientific, Loughborough, Leics, UK. 
sodium dodecyl sulphate BDH Merck, Leicester, Leics, UK. 
sodium hydroxide BDH Merck, Leicester, Leics, UK. 
sodium metabisulphite Fisher Scientific, Loughborough, Leics, UK. 
tetraoctylammonium bromide Sigma-Aidrich Company Ltd, Poole, Dorset, UK. 
TRlZMA pre-set crystals pH 8.4 Sigma-Aidrich Company Ltd, Poole, Dorset, UK. 
( tris(hydroxymethyl)aminomethane and, Iris 
hydrochloride, reagent grade) 
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3.2. Clinical Equipment. 
Prod art. Souru. 
blood coUection tubeS: Southern Syringe Services, Soutbgate, London, 
. Vacuiainer Hemogard tubes (EDTA K3, 7mL) UK. 
venOon flush solutions: 
:o hepsol 
• 0.9% wlv NaCJ.i.v. infusion BP Braun Medical Ltd, Sheffield, S. Y arks, UK. 
3.3. Laboratoty Equipment. 
Produet. Source. 
autosampler: 
• AS-950 Jasco, Gt Dunmow, Essex, UK. 
0 ASJOOO Thermo Separations ProductS, Manchester, UK. 
autosampler vials: 2mL; Gold grade glass Cbomacol Ltd, Welwyn Garden City, Herts, UK. 
' 
bulk column packing: 
0 Columbus (CIB, Sum) Phenomenex, Macclesfield, Cheshire, UK. 
• Prodigy (CIB, IOum) 
data acquisition software: 
0 Borwinvl.22 Build03 MBS Developpments, Grenoble, France. 
• Chromquest Thermo Separations Products, Manchester, UK. 
HPLC analytical columns: 
• Columbus (CIB; 5j.llll, 150 x 4.6mm) Pbmomenex, Macclesfield, Cheshire, UK. 
• Techopak /0 (CIB, IOJ.Illl, 250 x 4.0mm) HPLC Tedmology, Macclesfield, Cheshire, UK. 
HPLC pre-oolwnns: Secwity Guard, CIB Pbenomenex, Macclesfield, Cheshire, UK. · 
pharmacodynamic tool: tapping tester Dept ofBioinedicai•Engineering, Derriford 
Hospital, Plymouth, Devon, UK. 
photodiode array detector: UV6000P Thermo Separations Products, Manchester, UK. 
solid phase extraction columns: 
.. Bond Elut CB columns (lmL, IOOmg). Varian Sample Preparation Ltd, Walton-on-
• Bond Elut Cl8 columns (lmL, IOOmg) Thames, Surrey, UK . 
solid phase extraction vacuum manifold: Techelut HPLC Technology Co. Ltd, Macclesfield, 
(12 position) Cheshire, UK. 
solvent delivery system: constaMetric 3100 LDC Analyticalffhermoquest,. Manchester, UK. 
spectroOuorometer: 
• FP-811 Jasco, Gt Dunmow, Essex, UK. 
• FP-910 
test tubes: polypropylene (7 and 15 mL) Sarstedt, Leicester, Leics, UK. 
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3.4:. Refel'ence,Compounds. 
-~· -
,,,_-_, _____ ,; 
Product. i Source. 1 
.RH- apocodeilie hydrochloride I Sigma-Aldrich•cOmpanyLtd, Poole, Dorset,.UK. 
R(-}- apom~hilie-hydrochloride I Sigma-Aldrich Company Ltd; Poole, Dorset, UK 
R(-}- apomorphilie hydrochloride (Britaject®) ' Britannia Pharmaceuticals Ltd, Redhill, Surrey, 
UK. 
apomorphine orthoquilione SPA Contract Synthesis, Coventry, UK. 
benserazide hydfocliloride (DL-serine 2- Sigma-Aldrich Company-Ltd, Poole, Dorset, UK. 
(2,3,4-trihydroxybenzyl)-hydrazide) 
boldilie. Sigma-Aldrich Company Ltd, Poole, Dorset, UK. 
(1,10-dimethoxy-2,9-dihydroxyaporphine) 
bromoaiptine mesylate (2-bromo-a- 1 Sigma-Aldrich.Company Ltd, Poole, Dorset, UK. 
ergocryptine methanesulphonate salt) 
bromoaiptine mesylate capsules Novartis Pharmaceuticals UK., Camberley, Surrey, 
(Parlodel®) I UK. 
I 
cabergoline (Cabaser®) J Pharmacia & Upjohn Ltd, Milton Keynes, UK 
1 
carbidopa (S(-)-a-hydrazino-3,4-dihydoxy- i Sigma-Aldrich Company Ltd, Poole, Dorset, UK. 
2-methylbenzenepropanoic acid) ! . 
co-beneldopa capsule (Madopar®): Roche Products Ltd, Welwyn Garden City, Herts, 
benserazide HCl + levodopa I Ul(_ 
I 
! 
co-Careldopa tablets (Sinemet®): j Du Pont Pharmaceuticals Ltd, Stevenage, Herts, 
cabidopa 111011ohydrate + leyodopa j.UK. 
' 
domperidone maleate tablets (Motilum®) I Sanofi Winthrop Ltd, Guildford; Surrey, UK. 
I 
entacapone tablets (Comtess®) I Orion Pharma (UK) Ltd, Newbury, Berks, UK. 
levodopa (L-3,4-dihydroxyphenylalmilie) I Sigma-Aldrich Company Ltd, Poole, Dorset, UK. 
! 
\isuride maleate tablets (Revanil®) j Cambridge Laboratories, Newcastle-lipon-Tyne, 
I UK. 
i 
paracetamol I Sterlilig Health, Brentford, Middx, UK. 
I 
pergolide mesylate (Celimce®) Eli~Lilly & Co. Ltd, Basingstoke, Himts, UK 
pramipexole HCl {Mirapexin®) Pharmacia & Upjohn Ltd, Milton Keynes, UK 
R(-)- propylnorapomorphine hydrochloride Sigma-Aldrich Company Ltd, Poote, Dorset, UK. 
(NPA) 
ropinerole HCI tablets (Requip®) SmithKiine Beecham Healthcare, Brentford, 
Middx, UK. 
selegiline HCI oral .liquid (Eidepryl®) Orion Phanna (UK) Ltd, Newbury, Berks, UK. 
selegiline HCl tablets (Eidepryl®) ·J Orion Pharma (UK) Ltd, Newbury, Berks, UK. 
! 
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3.5. Stock Solutions. 
Name. 
apomorphine stock solution(s) 
-
2-mercaptoethanol 
propylnorapomorpbine stock solutioo(s) 
(internal standard) 
3. 6. Working Solutions. 
diluent A 
; 
c 
Name. 
HCI in methanol wasb solution 
propylnorapomorpbine 
sodium metabisulpbate solution 
solid phase extraction eluting solution 
Composition, eooditions of use. 
lmg/mL R(-)-apomorpbine hydrochloride powder in 
diluent A (prepared in silanised, amber glassWar-e, stored 
at 4-B"C for 28 days) .. 
Intermediate stock solutions oH OJ.lg/mL, I J.lg/mL and 
75nglmL were prepared in diluent A, as required. 
- ~-
1% (v/v) 2-mercaptoetbanol in water, stored at·room 
temperature. 
O.lmg/mL R(-)-propylnorapomorpbine powder in diluent 
A (prepared in silanised, amber glassware, stored at 4-B"C 
. I fur 28 days). 
Composition, coaditioos of me. 
I 
1 O.Hl"lo (w/v) EDTA, 0.15% (w/v) ascorbic acid, 
1 stored at 4-B"C. I . . . 
j O.OIM HCI in 50:50 methanol:water 
I 
aliquots of 5J.lg/mL in diluent A, stored at 4-B"C. 
2% (w/v) sodium metabisulphate in diluent A, stored 
at 4-B"C. 
0.25M NaH2P04 to pH 3.30 with ortbopbospboric 
I 
acid containing 40% (v/v) methanol, stored at 4-B"C. 
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SECTION4: 
ME mons 
4. ,Methods. 
4.1. Pharmacokinetic-Pharmacodynamic Study of Subcutaneous 
Apomorphine Administration iT~ Patients ,w;fh Parkinson's 
Disease: Development of Clinical Protocol. 
4. f 1. Investigators. 
The!protocol was devised in collaboration with Drs V. Pearce and D. MacMahon. The 
clinical, study was,undertaken under the supervision ofDr D. MacMahon at The Cambome 
and Redruth Community Hospital, Drs V. Pearce andT. Malone at The Royal Devon and 
Exeter Hospital, and Or J. O'Sullivan at The National Hospital for Neurology and 
Neurosurgery. 
4.1.2. Objectives. 
" The aim of this work was to examine the pharmacokinetic-pbannaco<Jynamic relationships 
of apomorphine in Parkinson's disease. The primary objective was to detennine the 
significance of the proposed relationship between the beta-phase intercept and clinical 
response. (Betails on the proposed correlation between beta-phase intercept and clinical 
response are given in Section 2.1, pages 2-1 and 2-2). 
4.1.3. Treabnent Administered. 
Apomorphine·HCI (Britaject® 10mg/mL, Britannia Pharmaceuticals Ltd.). 
4.1.4. Study Design. 
Open, controlled. 
4.1.5. The Study Population. 
It was proposed that apomorphine phannacokinetic-pharmacodynamic relationships were 
initially investigated in those patients who had previously been individually optimised on 
sulx:utaneous apomorphine therapy, as a means ofpiloting the study in the group known to 
respond to apomorphine. 
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The recruitment criteria were as follows:-
Inclusion' Criteria. 
Include subject if a// the following apply:-
i) an established diagnosis of idiopathic Parkinson's disease according to the United 
Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria[l1] 
(Appendix 8.3), 
ii) current~ receiving apomorphine therapy for Parkinson's disease, 
ill) exhibits a clear and predictable response to subcutaneous apomorphine, 
iv) experiences well-defined "on" and "oft" phases, 
v) given informed consent to participate in the study. 
Exclusioh Criteria. 
Exclude if any of the following apply:-
i) significant concomitant medical condition, 
ii) significant and current psychiatric morbidity, 
fu) physical disability wbicb,precludes the use of the primary efficacy variable (the tapping 
tester), 
iv) pregnancy, 
v) current participation in other clinical,study. 
Twelve patients were recruited in total; however two patients were. withdrawn from the 
study at their own request, patient 03 at approximately sixty minutes post-apomorphine 
dose and patient 06 at approximately ninety minutes prior to dosing with apomorphine. 
Both patients cited the severity of parkinsonian symptoms .that they each experienced as a 
consequence of the provoked "oft"-state as the reason for withdrawal (see page 4-4 
Induction of''Of' Period). Whilst no pharmacokinetic or pharmacodynamic sampling was 
performed fur patient 06, a limited nwnber of observations were made for patient 03. 
4-2 
Quantification of plasma apomorphine was not possible in the case of one·patient .(patient 
11:) due·to the presence·ofa compound in the plasma samples which co-eluted•with 
apomorphine•. 
Thus the'studY group was comprised often individuals: six males and four females. Of the 
tent patients recruited, seven were currently being treated with intermittent subcutaneous 
bolus apomorphine, whilst the remaining tbree'patients were currently receiving 
apomorphine by 24-hour subcutaneous infusion. The mean (range) ~e of the patients was 
63 (49 to 77) years. Patients had been diagnosed' with Parkinson's disease for a mean 
(range) of 13 (10 to 17) years. The mean (range) duration of levodopa and apomorphine 
therapy was 12 (5 to 20) years and 3 (1 to 9) years, respectively. The mean (range) 
UPDRS sc.oreb when .. on" was 50 (35 to 74), rF9. The median (range) Hoehn and Yahr 
r. 
score" when "on" was 4 (2 to 4), n=9. Detailed patient demographic data are given in 
Appendix 8.4. 
4.1.6. lnvestigational Plan. 
Patients were admitted to either the Cambome and Redruth Community Hospital, Roy8.1 
Devon and Exeter Hospital, or National Hospital for Neurology and Neurosurgery for the 
duration of the study. 
The study protocols differed depending on· the mode of apomorphine administration used, 
ie. subcutaneous bolus or subcutaneous infusion, therefore each is presented separately. 
"The contaminant was subsequently shown (using UV--iliode array detection) to be dantron, which was 
present as a consequence of the concomitant administration of dantron-base<Uaxatives (see Appendix 8.5) . 
b UPDRS score range: 0 to 206, where 0 represents normal and 206 represents maximal parkinsonian 
disability (see Appendix 8.1). 
• Hoehn and Yahr score range: 0 to 5, where 0 represents normal and 5 represents maximaJ.parkinsonian 
disability (See Appendix 8.1 ). 
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4.1~6.1. Protocol for Subcutaneous Bolus Apomorphine Administration. 
Induction of "Off' Period. 
AllluJti.parkinsonian medication wali withdrawn from midnight preceding the study day in 
order to avoid potential p~kinetic,and pharmacodynamic interferences, with the 
effect that the-patient was "oft" at the:start of the study day. This element of,the protocol is 
common practice in published pbarmacok:inetic studies of apomorphine in Parkimon's 
disease{2-8], efficacy studies [3, 9-16] and in the current dose titration protocol[l7]. 
Administration of Apomorphine. 
Following insertion of a peripheral intravenous cannula and baseline measurements (blood 
sample, UPDRS assessment, tapping test and walking test), a single bolus of apomorphine 
was administered at the dose routinely used by individual patients for therapeutic effect. 
The mean'(range) dose was 5.3mg{2 to 10), i.e. 711Jg/kg (35 to 167), n=8 (Table 4-2, page 
4-7). 
In order to· avoid potential diurnal variation in apomorphine pharmacokinetics, the 
apomorphine dosing time was standardised; a window between 8am and I Oam was deemed 
appropriate (to accommodate patient travelto hospital and to limit length of provoked 
parkinsonian "oft" period). 
The use of further anti-parkinsonian medication was disallowed until the ~ blood sample 
was collected so that pharmacodynamic interferences were avoided. All other necessary 
medication required by the patient was made available. 
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Blood~Sampling Scheme. 
The development of the blood sampling schedule was:based on an examination of published 
concentration-time courses[4, 7, 13, 18]. These data were used to construct semi-log plots 
which were then used as a guide to the. time CO\D'Se of sampling points. Emphasis was . 
placed on,obtaining sufficient samples to characterise the beta-phase. It was deemed 
appropriate to aim to sample on at least two occasions for each phase of the plastila 
concentration-time curve. Thus samples (of7mL) were taken pre- apomorphine dose and 
at 5, 15, 30, 45, 60, 90, 120, 180, 240 and 360 minutes post-dose. A summaryof 
simultaneous blood and pharmacodynamic sampling is given in Table 4-1 (page 4-6). 
Pharmacodynamic Sampling Scheme (relevaritto bolus and infusion treatments). 
Two timed tests of motor function were employed in the quantitative assessment of 
apomorphine-induced effects: the tapping test and the walking test. Both are conunonly 
used tools in Parkinson's disease:[J-6, 12]. The tapping test was designated as the primary 
pharmacodynamic test on the basis that the test was objective, self-evident and could be 
completed in a short time period (thus allowing multiple measurements to be made during 
the relatively short duration ofdrug effect), and also because the tapping tester itself was 
portable (Figure 1-6, page 1-24). 
The tapping test was standardised in terms of the hand used, ie. the hand of the side of the 
body most affected with parkinsonian symptoms was selected, and in terms of the 
conditions of the test and executive instructions (Appendix 8.6). 
Similarly, the conditions of the walking test were standardised (Appendix 8.7) in that the 
6m course was consistently kept clear of obstacles that might induce freezing, and the 
flooring was.non-patterned to avoid the use of a visual cue[19, 20]. 
No encouragement was given during the testing period of each of the two tests, and patients 
were blinded to results, although it could not be ruled out that patients kept a mental record 
of their own tapping test scores. 
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The apomorphine-induced response was described qualitatively by observation of 
parkinsonian symptoms and apomorphine-related effects, and by patients' self-reporting of 
symptom changes. 
A summary of simultaneous blood and pharmacodynamic sampling is given in Table 4-1 . 
Time Blood Observation Tapping Walking Blood 
(mins sample of test test pressure 
post volume parkillsonian and pulse 
bolus) {7mL) symptoms 
pre- ./ ./ ./ ./ 
Administer bolus apomorphine or stop infusion . 
'·s· -: _- ., .r ·-· ;{ I~ 
~~,)5- .., . '"' " .f. ,. , ~ . f +-
. 
.·"' 
./ .,/ ' -30 .~ < 'Fobe 
~5 " - ./.. .,:; ./. 
" 
1~ mQnitored 
-
,, 
I« . "" 
.,f" ~~ 0.. · ~'SF·><' ./, J ~;., 
"60.1' ~· 
. - -~ -~~"' "~ .. as .... 
90 ./ ./ ./ ./ appropriate 
120 ./ 
180 ./ 
240 ./ 
~60 ./ 
Table 4-1 Simultaneous bloOd/pharmacodynamic sampling scheme. 
Where multiple tasks eiist at a single time point, the priority was as 
foUows: (1) blood sampling, (2) tapping test, (3) walking test 
Shaded region indicates predicted apomorphine-induced "on" phase. 
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Patient Apomorphine dose Time of Site of Position of patient Washout 
ID administration administration on administration period 
T - · 
mode (m g) (~2fk2) (h) 
I 
01 bolus 2 41.7 09.56 thigh sitting 8.0 
02 bolus 5 47.6 09.41 abdomen sitting NR 
03 bolus 10 142.8 09.54 abdomen lying 11.9 
04 bolus 10 166.7 10.02 abdomen sitting 11.0 
05 bolus 5 77.5 09.22 abdomen sitting 12.4 
07 infusion 180 mg/24h (87.5 f.tg/kg/h X 24h) stopped at 10.30 upper back NA NA 
08 infusion 45 mg/24h (25.8 J.tg/kg/h x 24h) stopped at 10.52 upper back NA NA 
09 bolus 2 35.1 10.09 thigh standing 8.2 
10 bolus 3.5 47.3 09.50 thigh sitting 4.6 
12 bolus 5 55.6 11.04 thigh sitting 7.6 
Table 4-2 Administration of apomorphine (by subcutaneous route) to patients with Parkinson's disease. 
Abbreviation: NA = not applicable, NR = not recorded. 
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4.1.&.2. Protocol for Subcutaneous Apomorphine !Infusion Administration; 
Administration of Apomorphine. 
Apomorphine was administrated at the individual patients' typical:dose and schedule (Table 
4-2, page'4-1). Following insertion of a peripheral intravenous cannula and baseline 
measuiements (blood sample and pharmacodynamic measurements), the apomorphine 
infusion was stopped{at approximately lOam). 
The use of further anti-parkinsonian medication was disallowed until. the last blood saniple 
was collected so that pharmacodynamic interfurences were avoided. All other necessary 
medication requuoo by the patient was made available. 
Blood Sampling Scheme. 
Blood samples (of7mL) were taken prior to stopping the infusion, i:e. 15 minutes prior to 
stopping the infusion· and also immediately prior to stopping the infusion. The time that the 
infusion·was stopped was designated as time= 0. Blood sampling was perfurmed at 5, 15, 
30, 45, 60, 90, 120, 180, 240 and 360 minutes from time = 0. A swnmary of simultaneous 
blood and pbannacodynamic sampling iS given in Table 4-I (page 4-6). 
Pharmacodynamic Sampling Scheme (relevant to·bolus and infusion treatments). 
The rationale for the pharmacodynamic sampling scheme is detailed previously (page 4-6). 
A summary of simultaneous blood and pharmacodynamic sampling is given in Table 4-1. 
(page 4-6). 
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4.1.7. Pre-TreatmentofBiood Samples. 
Treatment ofbloO(hampleswas carried,out:according to·Priston[l8], i.e. each blood 
sample was collected into a pre-cooled (4-8°C) EDTA vacutainer tube, immediately 
transferred in~o a polypropylene tube containing 6mg ascorbic acid and mixed If required 
' 
the sample was stored at this stage at 4-8°C for up to three hours. The sample was then 
centrifuged at 4°C(l250g for 5 minutes):and the·plasma immediately aspirated into a 
polypropylene·tube. The plasma was stored at -20°C untif! required for analysis. 
4.1.8. Plasma Apomorphine Quantification. 
Plasma samples were prepared for assay according to the protocol gi,ven in Section4.3.3.3 . 
(page 4-35}and assayed using the methods given in Section 4.4 (pages 4-50 and 4-S I). 
4.1.9. Criteria for Evaluation. 
Plasma apomorphine concentration and apomorphine-induced anti-parkinsonian respome 
over six hours post-dose. Pharmacokinetic parameters: C....X, T """'' AUC>.iDfioity, and beta-
pbase.intercept. Respome variables: omet and duration of response, extent of improvement 
in tapping test score and ambulatory time from baseline. 
4.1.10. Data Handling. 
Pharmacokinetic and pharmacodynamic parameters were estimated using WmNonlin 
modelling program (Standard version 2.0, Pharsight, CA, USA) according to the method 
given in Section 4.6 (page 4-103). Bivariate correlations were.performed for salient 
pbarmacokinetic parameters using SPSS (version 9.0.0, SPSS Inc.). 
4.1.11. Study Ethics. 
Ethical approval was sought and obtained from the Local Research Ethics Committees of 
and Cornwall and Isles of Scilly (September 1997) and Exeter and North Devon (October 
1991). Written informed consent from all volunteers was obtained using the Patient 
Information Leaflet (Appendix 8.8) and Consent Form given in the protocol (Appendix 
8.9). 
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4.1.12. ProtocoiReview. 
A review of the study protocol was undertaken following the first five patients in the light 
of patient recruitment difficuhies. 
Withdrawal of Anti-ParKinsonian Medication. . 
The withdrawal of anti-parkinsonian medication was identified as a major barrier to 
recruitment. Experience with the first five patients had shown that prolonged wash-out 
exerted a detrimental effect on therapeutic response, i.e. doses of apomorphine that had 
previously evoked a therapeutic response produced a sub-optimal effect following 
withdrawal of anti-parkinsonian medication from midnight. This effect has been . 
documented in the literature[2l]. In view of this the wash-out period was reduced, i.e. 
-~ 
patients were instructed to m8intain their anti-parkinsonian regimens until the early morning 
(approximately 6am) dose on the day of the study. This allowed a baseline "off' period to 
be.established prior to the apomorphine dose, but avoided·a protracted "off' state. 
Additionally the withdrawal of anti-parkinsonian medication during the sampling time 
course was rescinded. Consequently the anti-parkinsonian regimen, with the exception of 
additional apomorphine, was re-established following the cessation of the a{lomorphine-
induced "on" period. 
Blood Sampling Scheme. 
The blood sampling scheme was evaluated after the study of five patients. Using parameter 
estimates generated for these patients, the schedule was restructured in order to include:-
i) time points at which.the model was most sensitive to changes in the model parameters. 
These points were identified by inspection of the relationship between the partial 
derivatives of the predicted function with respect to each ofits.parameters and time. 
The time at which a maximum or minimum occurs indicates the point at which the 
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model is most sensitive to changes in the model parameters. This is illustrated in Figure 
4-1 where a turning point in the temporal relationship of the partial derivative of 
predicted concentration with respect to alpha occurred at 30 minutes (Patient 01). 
5.---------------------------------------------~ 
120 150 180 210 240 2 0 
~ -5 
~ 
·~ 
~ 
Q -10 
-15 
-20 ......__----+-------------------------------'-----------' 
Time (minute) 
Figure 4-1 Sensitivity analysis (Patient 01). 
ii) time points given by the reciprocal of the macro constants alpha and beta[22]. 
ili) a sufficient distribution of samples in order to define multiple compartments of an 
(individual) phatmacokinetic model. It was found that at least three samples per 
disposition phase were required in the modelling process. Thus additional sampling 
times were interspersed between the key sampling points derived from (i) and (ii) 
according to the traditional approach of constructing blood sampling schemes, i.e. with 
increasing time intervals at later times[22]. 
The restructured sampling schedule was evaluated using variance inflation factor (VIF) 
analysis. The variance of a model parameter can be expressed as the product of the 
underlying variance of the residuals and a multiplier which is known as the VIF (variance = 
ci .VIF). VIF does not depend on the actual data values; it is dependent only on the 
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sampling schedule. In comparing experimental designs, the design for which VIF values are 
the .lowest yields more precise estimates of the model parameters. 
Competing designs were compared by nmning simulations of each using WmNoolin. VIF 
were computed for the,model parameters and predicted:plastna apomorphine concentrations 
of each design. It could be demonstrated that the VIF associated with the updated schedule 
had the impact of considerably improving the precision with which modeltparameters were 
estimated (Appendix 8.10). 
In addition to· the timing of samples, the issue of sample volume was addressed. Experience 
with the first five patients demonstrated that the sample volume could be reduced to 4mL 
over the first 30 minutes, and to. 6mL up to 180 minutes post-dose, whilst allowing a 
sufficient quantity of apomorphine for analysis (see Section 4.5.2, pages 4-88and 4-89). A 
" 
summary of the restructured blood sampling scheme is given in Table 4-3 (page 4-13). 
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Pharmacodynamic Sampling Scheme. 
Following a review of the protoco~ the UPDRS Part Ill was included as a further 
measurement of apomorphine-induced changes in parkinsonian motor symptoms. The 
assessment was made immediately prior to apomorphine bolus administration and also 
during the period of effect. 
A summary of the restructured pharmacodynamic sampling scheme is given in Table 4-3. 
Time Blood Obsof UPDRS Tapping Walking Blood 
(mins post sample Par kiD- Test Test Pressure 
SOiliu bolus) volume sym~ and Pulse 
pre- 4mL ./ Part m ./ ./ 
Administer apomorphine bolus or stop infusion . 
5 ~ (5) 4mL ./ 
10 4mL ./ ./ 
15 (15) 4mL Parts ./ 
22 4mL I - VI ./ ./ To be 
30 (30) 4mL ./ ./ monitored 
50 (45,60) 6mL ./ ./ ./ as 
80 (90) 6mL ./ ./ appropriate 
125 (120) 6mL 
180 (180) 6mL Until other anti-
240 (240) 7mL parkinsonian 
310 7mL medication is taken 
360 (360) 7mL 
Table 4-3 Restructured simultaneous blood/pharmacodynamic sampling scheme. 
The original sampling times are given in parentheses. 
Where multiple tasks exist at a single time point, the priority was as 
foOows: (1) blood sampling, (2) tapping test, (3) walking test. 
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4.2. Clinical Protocols for Studies on Novel Delivery Systems of 
Apomorphine, in Humans. 
Studies were undertaken on the properties of three novel modes of administration of 
apomorphine,..namely, intranasal administratioq. in healthy volunteers, buccal administration 
in healthy vohmteers, and subcutaneous administration by needle-free injector to.patients 
with·Parkinson's disease. 
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4.2.1. Preliminary'Study of Needle-Free Subcutaneous Injections of ApoinO'l'hine 
in Parkinson~s Bisease. -
To date there are no references concerning the use of needle-free technology with 
application to apomorphine administration. It was surmised that the needle-free technique 
might provide a treatment option for those patients with Parkinson's disease for whom the 
conventional system:presents a barrier to therapy, i.e. those who experience a feat of needle 
injection or who are unable to self-injeet due to parkinsonian disability. It was also 
specuJated that the mode of action of the needle-free delivery system may confer an 
advantage over the standard method to a wider population of patients with Parkinson's 
disease should there be an (even) fitster onset of action as,a consequence ofmore mpid 
absorption. or should the risk: of nodule fonnation be reduced. 
4.2.1.1. ·Investigators. 
The protocol was developed by John O'Sullivao\ Steve Barker2, Kirsten Turner1 and 
Hasmet Hanagasi1 (Departments ofNeurology1 and Vascular Surgeif, Middlesex Hospital, 
London, UK). 
4.2.1.2. Objectives. 
The aim of this work was to examine the pharmacokinetics, pharmacodynamics and 
tolembility of apomorphine following subcutaneous needle-free delivery in comparison with 
subcutaneous delivery using. the conventional apparatus, ie. needle and syringe or Penject® 
(Britannia Phannaceuticals Ltd). 
4.2.1.3. Needle-Free Delivery Device. 
The needle-free injection system used was the J-TIP® (National Medical Products, lnc, 
California, USA), see Figure 4-2. The device is a single use, disposable syringe which 
delivers drug solution by jet (pressurised) injection. Injection is powered by compressed 
4-15 
carbon dioxide contained in a cartridge within the device, and is activated manually by 
depressing the trigger. This causes the release of compressed carbon dioxide into the 
compartment behind the plunger which is then driven forward. The contents of the syringe 
are expelled through the micro-orifice, thus producing a pressurised stream of liquid. The 
drug solution punctures the epidermis and dermis and is delivered into the subcutaneous 
space, reaching a depth of approximately 3-8mm in 0.2s[23]. A spray-like dispersion 
pattern is achieved, in contrast to the depot of drug which is produced by injection through 
a needle[24]. It is claimed that the injection is almost pain free as a consequence of the 
transfer of solution through a micro-orifice at high velocity[23, 25]. 
trigger (beneath 
safety cakb) 
Figure 4-2 Needle-free delivery device: J-TIP® (National Medical Products, Inc.). 
Reproduced from website(25]. 
4.2.1.4. Study Design. 
Open, controlled, within-subject comparison. 
4.2.1.5. The Study Population. 
The utility of the J-TIP® needle-free system was studied in three patients with Parlcinson's 
disease. Recruitment criteria are given in Section 4.1 .5 (page 4-1 ), but included the 
additional criteria that patients who were unable to attend the Hospital for the study days, 
or who refused to try the novel system were excluded. 
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Two males and one female were recruited The·mean (range) age of the patients was 61 (55 
to 70)'years .. Patients,had'been diagnosed with,Parkinson's disease fora mean'(range) of 
14·(10.to '16) years. The mean (range) duration oflevodopa and apomorphine·therapy was 
12:(5 to 20) years and 5 (3 to.9) years, respectively. The mean (range) UPDRS score" 
when "on" was 42 (36 to 48). All patients had' a Hoehn and Yahr scoreb of2 when "on". 
In the case of one patient (patient 12). parkinsonian motor fluctuations were currently being 
managed with pallidal stimulation. 
4.2.1.6. Treatment Administered. 
Apomorphine HCI (Britaject® lOmg/mL, Britannia Pharmaceuticals Ltd.). 
4.2.1. 7. lnvestigatlonal Plan. 
Patients kre admitted to The National Hospitru for Neurology and Neurosurgery. London. 
for the duration of the study. Each patient received two doses of apomorphine: one dose 
was delivered using the conventional device and. on a separate day, one dose using the 
needle-free device (Table 4-5, page 4-20). An exception was made to this schedule in the 
case of one patient (patient 1 0) whereby. due to an uriexpected adverse local tissue reaction 
following needle-free delivery. a seoond trial of apomorphine administration using the 
needle-free device was performed. The additional trial of needle-free apomorphine in 
patient I 0 was performed on a separate, Le. third. day. 
Within each patient the doses used were identical. both in terms of the amount of 
apomorphine and the volume of drug solution (Britaject®, Britannia Phannaceuticals Ltd). 
The dose used was that which the individual patients has previously been titrated to in the 
• UPDRS score range: 0 to 206, where 0 represents normal and 206 represents maximal parkinsonian 
disability (see Appendix.S.I). 
b Hoehn·and Yahr score range: 0 to 5, where 0 represents normal and 5 represents maximal parkinsonian 
disability (see Appendix 8.1). 
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management of their Parkinson's disease symptoms. All· apomorphine doses. were 
administered to the patients!bythe same clinician. 
An attempt was made to randomise the order of the treatments, thus two patients received 
apomQrphine by conventional delivery first, whereas one patient received needle-free 
apomorphine first (Table 4-5). However, neither the,patients nor the investigators were 
blinded to,the treatments. Given that the release of solution from the needle-free device 
was accompanied with a loud "pop" and,a "hiss" as the propellant was discharged, blinding 
of the study was not practi.chl. 
There was a difference in the design of the needle-free device used for patient 12 compared 
to those used for the first two subjects, i.e. patients 09 and 10, in that the capacity of the 
> drug reservoir used fur patient 12 was greater. All other aspects ofthe needle-free injection 
system were identical 
Methods were common to those given in Section 4.1.6.1 (see Table 4-4 fur a summary, 
page 4-19) with the notable inclusion of (i) a pain rating of the injection event using a visual 
analogue scale, where zero represented absence of pain and ten represented the maximum 
pain rating, and (ii)the inspection of the injection site during the course of the study day 
and reporting on the condition of the injection site to the clinician following the study day. 
Pre-treatment of blood samples was performed according to the protocol given in Section 
4.1. 7 (page 4-9). Plasma samples were prepared for assay according to the protocol given 
in Section 4.3.3.3 (page 4-35) and assayed using the methods given in Section 4.4 (page 4-
50). 
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Time Blood Clinical Pain UPDRS Tapping Walking 
(mins post- sample observations rating test test 
bolus) volume (btchldhlg 
iupectioa of 
iujectioa site) 
pre-bolus 4mL ./ Part m ./ ,/ ' 
Administer apomorphine 
,/ 
5 cl•~. 
. ~ 4Jn.L. ' " . ' . <· " -~.: .-;I 01! 
.;; ,..~ ~ IQ .... 
' 4JPL , ,}\,>f .. ;,T . _:-;t- ~ J << 
. IS · ' "< 4fuL . ~ -· Parts ., -22 ....... , ~ 4d.. ~ I-VI 7 .J -;;;-
30 " 4lbL · .. J ·~..,:J "' 
. so ~,.; .61fiL J ' I' .!,,.:'~~~ .. 
" 
- ~ - -I .t !;, 
80 6mL ,/ ,/ 
125 6mL 
180 6mL Until other anti-
240 7mL parkinsonian 
3.10 7mL medication is taken 
360 7mL 
Table 4-4 Simultaneous bloodlpllannacodynamic sampling scheme used in the 
study of needle-free subcutaneollS injections of apomorphine in 
Parkinson's dUeue. 
Shaded region indicates predicted apomorphine-induced "on" phase. 
Where multiple tasks exist at a single time point, the priority is as 
follows: (1) blood sampling, (2) tapping test, (3) walking test. 
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Patient Order of Apomorphine Time of Site of Patient's posture Washout Stimulator 
ID Treatment bolus dose administration administration on administration period" downtimeb 
7" 
No. Treatment (mg) (JJ.glkg) (h) I (h) 
CON 1st 10.09 8.2 
09 2 35.1 Right thigh Standing NA 
NF 2nd 09.57 8.0 
CON 1st 09.50 Right thigh 4.6 
10 NF 1 2nd 3.5 47.3 10.20 Left thigh Sitting 5.3 NA 
NF2 3rd 10.29 Right thigh 5.5 
-
CON 2nd 11.04 7.6 0.8 
12 5 55.6 Right thigh Sitting 
NF 1st 12.16 8.8 1.5 
Table 4-5 Subcutaneous administration of apomorphine to patients with Parkinson's disease by conventional (needle) and novel (needle-free) 
delivery devices. Abbreviations: CON = conventional, NA = not applicable, NF = needle-free. 
• Defined as the time period between the last anti-parkinsonian medication that was taken and administration of the study dose ofapori:!orphine. 
b Defined as the time period between stopping the pallidal stimulation and administration of the study dose of apomorphine. 
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4.2:1.8. Criteria for Evaluation. 
Plasma, apomorphine concentration and apomorphine-induced anti~parkinsonian response 
over six hours post-dose. 
Pharmacokinetic parameters: Cmu. Tmu,AU~. and beta~pbase intercept. 
Response variables: onset and duration of response; extent of improvement in tapping test 
score, ambulatory time and UPDRS rating frOm,baseline. 
Tolerability indices: condition of the injection site, pain rating ofthe injection event. 
4.2:1.9. Data HanciRng. 
Pbarmacokinetic panimeters were estimated using WmNonlin ~Uing software (Standard 
version 2.0, Pharsight, CA, USA) using the method given in Section 4.6 (page 4-103). 
4.2.1.10. Ethics. 
Ethical approval was obtained from the University College London Hospitals Committee on 
the Ethics ofHwnan Research by the investigative team given in Section 4.2.1.1 (page 4-
15). Written informed consent from all volunteers was obtained by the investigative team 
given in Section 4 .2.1.1. 
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4.2.2. Pharmacokinetic Study of Singi&"Dose Intranasal Apomorphine Powder 
(Three Doses) ,in Healthy Volunteers. 
Much of the information given in this section has been summarised from the study 
protocol[26). 
4.2.2.1. Investigators. 
The protocol was developed by Dr. J. Whittington (Mediscience Services Ltd), Dr. M. 
Bqlio (LCGBioscience, Bourn Hall Clinic, Cambridge), Dr. D. Anderson Davies 
(Britannia Phannaceuticals Ltd), Mr. K. Davies (Britannia Phannaceuticals Ltd) and Ms. S. 
Mercer (Britannia Pharmaceuticals Ltd). 
4.2.2.2. ObJectiv,es. 
The aim of this work was to examine the pharmacokinetics and bioavailability of single, 
ascending doses of apomorphine powder given by the intranasal route to healthy volunteers, 
in comparison with subcutaneous delivery using the conventional apomorphine formulation 
and app8ratus. 
(The secondary objective was to determine the safety and tolembility of single, ascending 
doses of intranasal apomorphine powder in healthy volunteers; however this was not within 
the remit of this thesis). 
4.2.2.3. Intranasal Delivery Device. 
Apomorphine is predominantly formulated for intra-nasal use as a liquid nasal spmy(27-32]. 
In contmst to this, a dry powder formulation was the focus of this study. Hence, this was 
an explomtory study of the viability of the intranasal delivery of apomorphine powder using 
the "Turbospin" insuffiator (CBFS, UK, Figure 4-3). Potential benefits to be gained by the 
departure from intranasal solutions are the avoidance of significant drainage from the 
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application site ~ in the specific case of apomorphine, an improvement over the limited 
stability of apomorphine in solution[33]. 
Under the conditions of use, the chamber of the insufllator is loaded with a capsule 
CQntaining the pharmaceutical preparation. The capsule is then pierced using the retractable 
prongs attached to the base section of the device. The nozzle is inserted into the selected 
nostril, the other nostril having been occluded. The intranasal formulation is delivered into 
the nasal cavity when the recipient makes a dehl>erate inhalation through the device. As air 
is inspired through the vents a simple spin mechanism is activated which, in turn, drives the 
expulsion ~fthe powder from the chamber into the nasal cavity. 
Figure 4-3 Turbospin nasal insufDator, disassembled (CDFS, UK). 
4.2.2.4. Study Design. 
Open, controlled, non-randomised, ascending dose, within-subject comparison. 
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4.2.2.5. The Study Population. 
Six volwiteers were recruited from a volunteer panel by LCG Bioscience. 'Fhe main 
recruinnent criteria were:-
i) able to provide written informed consent, 
it) male, 
iii) in good health, 
iv) a body mass index between 18 and 28 kg/m2, 
v) nasal inspiratory flow of at least 30 Umin, 
Vl) no history of nasal disorders or abnormalities including any current medical condition 
that affects the nose or throat. 
4.2.2.6. Treatments Administered. 
Apomorphine HCI (Britaject® IOmg/mL, Britannia Pharmaceuticals Ltd.). 
Apomorphine intranasal powder capsules: clear size 2 gelatine capsules containing 1, 3. or 5 
mg apomorphine HCI, 1% w/w ascorbic acid, made up to 10 mg total powder weight with 
dextrose monohydrate (UnivalCiinical Trials Management, Bolton, UK). 
4.2.2.7. lnvestigattonal Plan. 
Volunteers were resident at Bourn Hall Clinic, Cambridge, during the clinical phase. 
The use of prescription or over-the-counter medication was disallowed for 28 days prior to 
the onset of apomorphine dosing, with the exception of domperidone which the volunteers 
were required to take for three days.prior to the trial (20 mg three times daily) as a 
prophylactic anti-emetic. The use of prescription or over-the-counter medication was also 
disallowed for the duration of the trial, with the exception of paracetamol 
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. Each'volunteer received a single dose of each of the four treatments on consecutive days 
and m the following order: i),subcutaneous injection 3 mg (to the anterior abdominal wall), 
iJ.) intranasal powder I mg, fu) intranasal powder 3 mg, iv) intranasal powder 5 mg. 
Capsules were recovered from the delivery device after use and assayed for residual drug 
content (performed by Pemi Pharmaceuticals Ltd, Gwent, UK.) 
For each of the treatl'nents administered blood samples were collected for apomorphine 
assay, via a peripheral intrav~us caruiula, at baseline, i.e. within the 60 minute,period 
prior to administration, and at 5, 10, 15, 20, 25, 30, 60, 90, 120,240 and 360 minutes post-
dose. 
Pre-treatment of blood samples was performed according.to the protocol given in Section 
4.1, 7 (page 4-9) by LCG Bioscience staff. Plasma samples were prepared for assay 
" 
according to the protocol given' in Section 4.3.3.3 (page 4-35) and assayed using the 
methods given in Section 4,4 (page 4-50). 
4.2.2.8. Criteria for Evaluation. 
Plasma apomorphine concentration over six hours post-dose. 
Pharmacokinetic parameters: Cmax, T rmx. AUCo-infinity· 
· 4.2.2.9. Data Handling. 
Pharmacokinetic parameters were estimated using WmNonlin modelling software (Standard 
version 2.0, Pharsight, CA, USA). Bivariate correlations and ANOV A with repeated 
measures (significance level (a)= 0;05) were performed for salient pbarmacokinetic 
parameters using SPSS (version 9.0.0, SPSS Inc.). 
4.2.2.1 0. Ethics. 
Ethical approval was obtained from Local Research Ethics Committee of Addenbrook's 
Hospital, Cambridge, by the investigative team given in Section 4.2.2.1 (page 4-22). 
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Informed consent.from all volunteers was obtainediby the investigative team given in 
Section 4.2.2.1. 
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4.2.3. Phannacokinetic Study of Single-Dose BuccatApomorphine Powder (Three 
Doses) in Healthy Volunteers. 
Much of the information given in this :Section has'been summarised from the study 
· protocol[34~. 
4.2.3.1. Investigators. 
The protocol was developed by Dr. J. Wbittin&ton (Mediscience Services Ltd), Dr. M. 
Buraglio (LCG Bioscience, Bourn Hall Clinic, Cambridge), Dr. D: Anderson Davies 
(Britannia Pharmaceuticals Ltd), Mr. ICDavies (Britannia Pharmaceuticals Ltd) and Ms. S. 
Mercer (Britannia Pharmaceuticals· Ltd). 
4.2.3.2. ~bjectlves. 
"· 
The aim of this work was to examine the pharmacokinetics and bioavailability of 
apomorphine administered to healthy volunteers by the buccal route in comparison with 
subcutaneous delivery using the conventional apomorphine formulation and apparatus. 
(The secondary objective was,to determine the safety and tolerability of single, ascending 
doses of buccal apomorphine in healthy volunteers; however this was not within the remit of 
this thesis). 
4.2.3.3. Treabnents Administered. 
Apomorphine HCl (Britaject® IOmg/mL, Britannia Pharmaceuticals Ltd.). 
Apomorphine buccal formulation: hydrogel containing 5, 10 or 20·mg apomorphine HCI 
powder (Controlled Therapeutics(Scotland) Ltd, East Kilbride, UK). 
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4.2.3.4. Buccal Delivery1Device. 
Hydrogels are cross-linked polymers which have the ability to absorb and retain (aqueous) 
solvent(s), forming a swollen gel~phase in the process,,and remaining un-dissolved[35J. 
When loaded with drug, hydrogels can function as drug delivery systems, The release of 
drug :from a hydrogel involves the absorption of water into the polymer and simultaneous 
desorption of drug via diffusiori[35J. 
The hydrogel used was a poly( ethylene glycol} matrix which has approval :from the MCA 
for vaginal delivery of prostaglandin E2 in the induction of labour (Propess®, Ferring 
Pharmaceuticals)[36J. The use of this particular hydrogel as a buccal delivery system for 
apomorphine administration constituted a novehpplication, both in terms oftlre drug used 
and the ;ite of administration. In fact, the use of any hydroge~ regardless of composition, 
has not been previously documented for apomorphine administration. Furthermore, the 
buccal mucosa itself is a novel route for delivery of apomorphine (regardless of delivery 
device). 
The hydrogel polymer was fonnulated as an ''insert" which was 5mm wide x I 7mm long x 
l.l mm thick (Controlled Therapeutics(Scotland) Ltd, East Kilbride, UK), The in vitro 
swelling profile of the inserts used in this study was commensurate with in vitro 
. . . 
apomorphine release· (Figure 4-4). In vitro swelling was determined using the USP paddle 
method[ J, and apomorphine was quantified using a spectroscopic method (Controlled 
Therapeutics (Scotland) Ltd, East Kilbride; UK). 
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Figure 4-4 In vitro buccal insert swelling and apomorphine release tests. 
(Controlled Therapeutics (Scotland), East Kilbride, UK). Reproduced 
with permission. 
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Figure 4-5 In vivo buccal insert swelllilg test. 
The mean pe~entage swelling of placebo buccal inserts is presented, 
n= five individuals (Controlled Therapeutics (Scotland), East Kilbride, 
UK). Reproduced with penni.ssion. 
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The:swelling-time profile of the buccal insert in vivo was sigmoid in nature, .i.e. there was a 
Jag in•. the swellin~ process,over the first 30 minutes in situ, followed by a period of 
relatively rapid swelling which oontinued until a.plateau was reached at about lOO minutes. 
The:plateau lasted until (at least) 120 minutes, this being the finali.sample.point in the 
experiment (Figure 4-5, page 4-29). 
The.plateau achieved in vivo in the latter stage ofthe time course corresponded to a degtee 
of swelling that was approximately 75% of the maximum achievable in vitro for the insert. 
In this condition the hydrogeltended to detach from the mucosa. 
Under the conditions of use the dry buccal insert is placed between the upper gingiva and 
buccal mucosa, and is held in place by the upper lip. The insert is inconspicuous in situ and 
does not. interfere with drinking or speaking, however eating usually causes the insert to 
c 
detach from the mucosa. Hydration of the insert by saliva at the site of administration 
confers muco-ad.hesive properties to the surface ofthe ·insert, resulting in rapid attachment 
of the insert to the gingivahirucosa. As water is absorbed the hydrogel swells up 
progressively, becoming gel-like in consistency. Consequently the apomorphine contained 
in the polymer is dissolved and di1fuses (via multidirectional release) from the hydrogel 
matrix to the absorption site(s) in the oral,cavity. 
4.2.3.5. Study Design. 
Open, controlled, non-randomised, ascending dose, within-subject comparisoiL 
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4.2.3.6. The'Study Population. 
Six volunteers were recruited from a volunteer panel by LCG Bioscience. The main 
recruitment criteria were:-
i) able to provide written infonned,consent, , 
ii) male, 
ill) m good health, 
iv) a body mass index between 18 and 28 kg/m2, 
v) no histocy of oral disorders or abnormalities or any current medical condition that 
affects the mouth or gums. 
4.2.3.7.1nvestigationai,Pian. 
~. 
Volunteers were resident at Bourn Hall Clinic, Cambridge during the clinical phase. 
The use of prescription or over-the-counter medication was disallowed for 28 days prior to 
the onset of apomorphine dosing, with the exception of domperidone which the volunteers 
were required to take for three days prior to the ~ (20 mg three times daily) as a 
prophylactic anti-emetic. The use of prescription or over-the-counter medication was also 
disallowed for the duration of the trial, with the exception of paracetamoL 
Each volunteer received a single dose of each of the four treatments on consecutive days 
and io,the following order: i) subcutaneous infusion 2 mglh x 2 h, ii) buccal insert 5 mg, ill) 
buccal insert 10 mg, iv) buccal insert 20 mg. The buccal inserts were positioned on the 
upper gum and held in place by the upper lip. The buccal inserts were left in situ for 120 
minutes post-commencement of administration; specifically the insert was removed :from the 
mouth directly after the blood sample designated at 120 minutes was collected. 
Subsequently the used inserts were analysed for residual apomorphine content (Controlled 
Therapeutics (Scotland) Ltd, East Kilbride, UK). 
For each ofthe·treatments administered' blood samples were collected for apomorphine 
assay, via a peripheral intravenous cannulil, at baseUne, i.e. within the 60:minute period 
prior to adininistration, and•at5, 15, 30, 60, 90, 120,.240 and'360 minutes after the 
insertion of the buccal device. 
Pre-treatmenfofblood samples was perfonned:accordingto the protocol given in· Section 
4.1.7(page 4-9) by LCG Bioscience staff. Plasnla samples were prepared for assay 
according to the protocol given:in Section 4.3.3.3 (page 4-35).and assayed using the 
methods given in Section 4.4 (page 4-50). 
4.2.3.8. Criteria for Evaluation. 
Plasma apomorphine concentration over six bours.post-dose. 
P~kinetic parameters: C.,.,., T """'' and AUCo.ummty. 
4.2.3~9. Data Handling. 
Pbarmacokinetic parameters were estimated using WmNonlin mOdelling software (Standard 
version2.0, Pharsight, CA, USA). Bivariate correlations and ANOV (\with repeated 
measures (significance level(a) = 0.05) were performed for salient pharmacokinetic 
parameters using SPSS (version 9.0.0, SPSS Inc.). 
4.2.3.10. Study Ethics. 
Ethical approval was obtained froni Local Research Ethics Committee of Addenbrook's 
Hospital, Cambridge, by the investigative team given in Section 4.2.3.1 (page 4-27). 
Informed consent from all volWtteers was'obtained by the investigative team given in 
Section 4.2.3.1. 
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4.3. Development of Analytica/Methods 
Given that plasma apomorphine concentrations in the post-distribution phase were likely to 
be low, i.e. in the.region of lng/mL at tlrree,hours,post~bolus[7], an assay thatwas•capable 
of determining drug concentration· pertaining to this period was developed. The.assay was 
based'on the published method ofPriston and Sewe~18], details of which are:given below 
(Sections 4.3.1 and'4.3.2) .. 
4.3.1. Solid Phase Extraction of Apomorphine According to Priston. 
A Bond-Elut Cu lmlJlOOmg solid.phase extraction column (HPLC Technology, 
Macclesfield, UK) was attached to a Techefut vacuum manifold (HPLC Technology, 
Macclesfield, UK). The column was conditioned with 2mL methanol followed by 2mL 
r, 
water. A lmL sample was then aspirated, followed ,sequentially by 2mL water, ImL 10% 
(v/v) methanol in water, ImL 20% (v/v) methanol in water and ImL 50% (v/v}methanol in 
water. The column was not allowed to dry out at any of the conditioning and washing 
stages. 
Apomorphine (and boldine, the internal standard) were eluted with 2 x 200J,LI:. O.lM 
hydrochloric acid in methanol into a silanised I mL volumetric flask containing 400J!L I% 
(w/v) sodium metabisulphite and made up to volume with diluent A (see Section 3.6). 
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4.3.2. HPLC Method for Apomorphine Determination According to·Priston. 
The HPLC system consisted of an LllC AnalYtical ConstaMetric 3200 solvent delivery 
system (Tbermoquest, Manchester, UK) and a Jasco FP-821 spectrofluorometer(Jasco, 
. . 
Great Dw:unow, tJK:) set at M:x 270nm, M:m 450nm, attenuation I, gain 1000. 
Data acquisition was performed by a Mihon-Roy Computing Integrator 4000'(Stone, Staffs, 
tlK) and, later, Borwin Chromatography software (version l.O,.JMBS Devei.Oppements, 
France). 
The HPLC column was a Techopak Cl8 lOJ.UD. 250 x 4mmi.D. column used in conjunction 
with a 2cm pre-colwnn containing the same stationary phase as the main column (HPLC 
Technology, Macclesfield, UK). 
The mo~ile phase contained 700/o (v/v) aqueous and 30 %(v/v) methanol portions. The 
constituents of the aqueous portion, expressed as final concentrations in the mobile phase, 
were: 0.25 M sodjum dihydrogen orthophosphate and 0.25 % (w/v) heptane sulphonic acid 
which were adjusted to pH 3.30 with orthophosphoric acid, and 0.003% (w/v) EDTA. 
The flow rate was l.SmUmin. Injection of sample was made using a Rheodyne injection 
system and was 50J.1L in volwne. 
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4.~.3. Preparation of Matrix for Use in Analytical Method Development. 
Blood collection and .preparation was based on methods described by Priston[,l8). 
4.3.3;1. Control Blood Collection and Pre-Treatment 
Venous blood was collected from volunteers (number of individuals~ 3) into 7mL EDTA 
k3 vacutainer tubes. Blood was transferred into polypropylene tubes containing ascorbic 
acid to give a final concentration of SmM ascorbic acid. and centrifuged ( 4 °C; 1250g x 5 
minutes). The resuhing plasma was pooled and stored in polypropylene tubes at 4-S"C until · 
required. 
4.3.3.2. Preparation of Plasma Samples (1) 
r. 
Plasma was spiked to I and 20ng/ml R(-)-apomorphine HCI using stock apomorphine 
solutions in diluent A (see Section 3.6). These concenti'ations were selected because they 
represented the range of aJX>morphine concentrations reported in'published pharmacokinetic 
studies[ 4, 7], Aliquots of appropriate volumes were stored in polypropylene tubes at-
4.3.3.3. Preparation of Plasma Samptes,(2) 
When required, aliquots of plasma were thawed at 4-8°C. On thawing, 1% (v/v) 2-
mercaptoethanol solution was added to give a final concentration ofO.Ol% (v/v) 2-
mercaptoethanol. Plasma was then centrifuged (4°C, 1250g x 5minutes) in order to pellet 
precipitated protein and the resultant supernatant was transferred to a polypropylene tube. 
Plasma was then spiked to give a final concentration of IOOng/mL internal standard using a 
stock solution of internal standard in diluent A (see Section 3 .5), mixed gently and left to 
equilibrate at 4-8°C for 5 minutes prior to solid phase extraction. 
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4 .. 3.4. DevelopmentofApomorphine Assay. 
4.3.4.1. Choice of HPtC Column. 
A recently marketed HPLC column, the Columbus8 (Phenomenex, Nl<.), was selected fur 
evaluation ag~ the existing column. ie. the Techopakb (HPLC Technology, NK). 
Whilst the functional group was the·same fur each column, the Columbus bonded phase 
consisted of extremely high purity silica onto which the octadecylsilane had been bonded. 
F~re residual silanol groups bad been extensively deactivated, using a process 
known as "double endcapping", resulting in an inert bonded surfilce. Such properties 
potentially improve chromatography by limiting non-specific interactions· between the 
analyte and stationary phase. 
4.3.4.1.1. Development of Mobile Phase. 
~ . 
Experimental. 
A solution of 50ng/mL R(-)-apomorphine HCI and 5ng/mL R(-)-boldine HCI in diluent A 
were assayed according to the method given in Section 4.3.2 (page 4-34), with the 
exception that the alternative HPLC cohmm (the Columbus) was employed. 
The retention times of boldine and apomorphine were approximately 13 and 30 minutes, 
respectively, at lmUminute flow rate using the ahemative analytical column. In order tO 
allow rapid assay of apomorphine (at lmUmin), the percentage of methanol in the mobile 
phase was increased so as to shorten the assay run.time. A range of30 to 45 % (v/v) 
methanol concentration in the mobile phase, run at a flow rate of lmllminute, was 
investigated. 
• Cl8, carbon loading: 19"11., spheric:ai51Jlll particles, 150 mm x 4.6 mm I.D. 
b Cl8, carbon loading: 14%, irregular IOIJID particles, 250 mm x 4.0 mm I.D. 
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Results. 
Given that (i) the greater the value for resolution factor•, the greater the resolution between 
two compounds, and (ii) a resolution factor of 1.5 is considered to be desirable for the rapid 
assay of given analyte(s)[37], it was evident that a mobile phase methanol content of 45% 
or greater would be required for optimal assay performance in terms of resolution of 
apomorphine and boldine (Figure 4-6). However, at a mobile phase methanol content of 
45%, the resolution between the unretained solute (ascorbic acid) and boldine was 
compromised, i.e. the resolution fuctor was 0.9. Therefore a mobile phase composition of 
400/o (v/v) methanol was deemed satisfilctory for use in the assay of boldine and 
apomorphine. At a methanol content of 40% (v/v), the retention times ofunretained solute, 
boldine and apomorphine were 1.5, 3.9 and 6.9 minutes, respectively. 
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Figure U Effect of mobile phase methanol ~ntent on retention behaviour of 
apomorphine and boldine. 
• Computational formula for resolution factor ~) of two peaks A and B: Rs = 2.(t8 - tA)/(W A + W 8) , where 
t is retention time and W is peak width[37]. 
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4.3.4.1.2. Comparative Perfonnance of HPLC Columns. 
ExperimenJal. 
Apomorphine:(50ng/mL) was extracted from diluent A according to the method given in 
Section 4.3.1 '(page 4-33). A direct comparison, of the Techopak and Columbus columns 
was made whereby both non-extracted and extmcted solutions were assayed under the 
conditions given in Seetion 4.3.2 (page 4-34) using each of the two columns. N.B. the 
mobile phase developed in Section 4.3.4.1.1 (page 4-37) was employed. 
Results. 
Assay of the extract using the Columbus column demonstrated that apomorphine had 
degraded as a result of the solid ·phase extraction process and furthermore that the · 
r, 
constituent peaks were not resolved using the Techopak column (Figure 4-7). 
ThiS indicated that a modified solid phase extmction procedure was necessary, and that the 
Columbus analytical column should be used in favour of the Techopak column in. the assay 
of apomorphine. The development of a modified solid phase extraction procedure is 
addressed in Section 4.3.4.3 (page 4-41 ). 
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Panels A and B: standard (non-extracted) apomorphine solution. 
Panels C and D: extracted apomorphine. 
Retention times are given as peak labels. 
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4.3.4.2. Choice of Internal Standard. 
During the initial stages of method development there was, intermittently, a peak observed 
at the retention time of boldine, i.e. 4 minutes. It was therefore decided to evaluate an 
alternative internal standard, i.e. R(-)-propylnompomorphine (NPA) (Figure 4-8). This 
compound was utilised as an internal standard in the HPLC apomorphine assays developed 
by Smith et a/ [38], Gancher et a/ [4], Essink et al [39], Sam et a/ [40] and Ameyibor et a/ 
[41], and in subsequent publications[?, 12, 42-44] which employed modified versions of 
these assays for apomorphine determination. 
A 
HO 
B 
HO 
Figure 4-8 Structures of internal standards used. 
Panel A: Boldine. 
Panel B: R(-)-propylnorapomorphine: X = CHzCBzCB3. 
NB. Structure of R(-)-apomorphine: X = CIL. 
Using the mobile phase composition developed in Section 4.3.4.1.1, NPA eluted at 
approximately 13 minutes. NB. The retention time of apomorphine under these conditions 
was approximately 8 minutes (see Figure 4-13, page 4-52). 
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4.3.4.3. Modmc.tton to Solid Phase Extraction Eluting Solution. 
The role of the eluting S(>lution (O.IM hydrochloric acid in methanol) in the degradation of 
apomorphine as a result of solid phase extraction was investigated. 
Experimental 1. 
R(-)-Apomorphine HCI (50ng/mL) in diluent A was assayed using the method developed 
thus fur, i.e. under the conditions given in Sections 4.3.1 and 4.3.2 (pages 4-33 and 4-34) 
but using the Columbus column in place of the Techopak column, and a mobile phase which 
contained 400/o (v/v) methanol (see Section 4.3.4.1, page 4-36). Alternative eluting 
solutions were employed in the solid phase extraction procedure. These are given in Table 
4-6 with the associated outcome. 
Results I. 
Eluting Solution. Outcome. 
Solutions based on acidified methanol 
0.01 M HCl in methanol Degradation of apomorphine. 
O.OOIM - l.OM CH3C(hH in methanol Degradation of apomorphine. 
Solutions based on mobile phase. 
[Na2H2P04] pH methanol(%) 
0.25M 3.30 10 No degradation of apomorphine, 
but poor reco~ (~200/o). 
0.25M 3.30 35 No degradation of apomorphine, 
recoveif: - 50%. 
0.25M 3.30 40 No degradation of apomorphine, 
recov~rt_: ~ 70%. 
0.25M 4.20 40 No degradation of apomorphine, 
recoverY': ---60%. 
0.25M 3.30 50 Deterioration in peak shape. 
0.25M 3.30 60 Degradation of apomorphine. 
Table 4-6 Evaluation of alternative eluting solutions for solid phase extraction of 
apomorphine. 
• Recovery of apomorphine in terms of peak area in comparison to that of(non·extracted) standard. 
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A suitable eluting solution wasiidentified, i.e. 0.25M sodium dihydrogen orthophosphate, 
adjusted.to pH 3.30 with orthophosphoric acid, in 400/o (vlv) methanol However it became 
apparent that, whilst a satisfuctory outcome was!achieved in the extraction of apomorphine 
from·diluent A. degradation of the same nature as shown in Figure 4-7D:(page 4-39) 
- . 
occurre<f.in the extraction of apomorphine -from:plasma when this eluting solution was used 
(see Figure 4-9C). 
The retention behaviour of the additional peak present in _the plasma extract was concordant 
with the peak produced by forced degradation of apomorphine under mcidative conditions 
(see Figure 4-20F, page 4-71). Thus it was proposed thitt apomorphine oxidation had 
occurred as a coDsequence of the solid phase extraction procedure. Based on this an anti-
oxidant was introduced into the solid phase extraction procedure. This development is 
described in Experimental 2 (below). 
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Experimenta/2. 
R(-)-Apomorphine HCI(50ng/mL) in:diluent A was assayed using the method developed 
thus.fur, i:e. under the conditions given· in. Sections 4.3.1 and 4.3.2 but .with the following 
modifications:-
o . theTechopak column was superseded by the•Columbus column (see Section 4.3.4.1.2, 
page 4-38), 
o the mobile phase contained 40% (v/v)methanol (see Section 4.3.4.1.1, page 4-36), 
• the eluting solution consisted of 0.25M sodiurh dihydrogen orthophosphate, adjusted to 
pH 3.30 with orthophosphoric acid, in 40% (v/v) methanol (Section 4.3.4.3 Experiment 
I). 
Sodium metabisulphite in diluent A, in the form of either 200~L x 2%. ( w/v) or I OO~L x 4% 
f-(w/v), was aspirated through the solid phase extraction column after the 50% (v/v) 
methanol in water wash step.and, therefore, prior to application of eluting solution. 
Results 2. 
Degradation of apomorphine following extraction from plasma persisted when I OO~L x 4% 
. (w/v)solution was used, but was prevented by the inclusion of200~ x 2% (w/v) sodium 
metabisulphite in diluent A (Figure 4-9). 
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Figure 4-9 Modifieation of solid phase extraction procedure. 
Panel A: staadard (n01t-utraded) solutioa: 50 ng/mL R(-)-apomorphiae HCI ia 
d.UueatA. 
Panel B: 50 ag/mL R(-)-apomorphine HCI in diluent A, enrac:ted in absenee ofl•!. 
sodium metabisulpbite in diluent A wash step. 
Panel C: 50 DglmL R(-)-apomorphine HCI in plasma, extracted in absence ofl•fe 
sodium metabisulpbite in diluent A wash step. 
Panel D: 50 llglmL .R(-)-apomorphine HCI in plasma, enraction procedQre included 
2•1. sodi11111 metabis1:4lphite in dilueat A wash step. 
4.3~4.4. MC)dlflcatlori to Solid Phase Extraction!Eiuting Solution Volume. 
An examination of the elution: profiles. of apomorphine and NPA was performed in order to 
optimise recoyery following solid phase extraction. 
Experimental. 
The elution.profile of apomorphine at two concentrations{l and 20·ng/mL in plasma) in the 
presence and absence ofNPA (100 ng/mL in plasma) was investigated (in duplicate) for 
potential concentration·or competition·effects. 
Apomorphine and NPA were extracted accordingto·method given in Section 4.4.1 (page 4-
33), will! the exception that eluting solution was applied to the solid phase extraction 
column in six successive 200 ~ portions. The extracts that were yielded from each 
discrete (200~L) portion of eluting solution were individually collected in succession into 
vials containing 200~L of2% sodium metabisulphite·in diluent A for assay using the 
method descnbed in Section 4.4.2 (page 4-51). 
The solid phase extraction colunm was not allowed to dry out, except after the final 200~L 
portion of eluting solution had been applied. Consequently the volume of eluting solution 
collected at this stage included the volume contained in the sorbent bed and port manifold, 
measured at 180~L, in addition to the 200~L directly applied. 
Recovery was estimated by comparing analyte Peak areas in the portions of eluting solution 
to that of a non-extracted standard in diluent A. 
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Results. 
There was no evidence of concentration effects in the recovery of apomorphine, nor was 
there an indication that the presence ofNP A in plasma affected the extraction of 
apomorphine from that plasma (Figure 4-1 0). However it could be shown that there w~ a 
difference in the elution characteristics of apomorphine compared to NP A, with the greatest 
recovery of apomorphine occWTing in the second portion of eluting solution whereas the 
third portion contained the highest concentration ofNP A (Figure 4-11 ). The prolonged 
retention ofNP A (relative to apomorphine) was to be expected due to the greater degree of 
non-polar interactions between the sorbent functional groups and analyte molecule that is 
afforded by the additional alkyl group ofNP A (see Figure 4-8, page 4-40). 
I• 1st El 2nd 0 3rd 0 4th 0 5th • Not Recovered J 
Analyte(s):- 0 20 40 60 80 100 
Apomorphine (1 nglmL) 
Apomorphine (20 ns'mL) 
Apomorphine (20 nglmL as combined standard with NPA) 
NPA (as combined statldard with apomorphine 20 nglmL) 
Mean Reeovery (%) 
Figure 4-10 Recovery of analyte from plasma in successive portions of eluting 
solution. 
A volume of 800 J.LL eluting solution was considered to be optimal, since this volume was 
the maximum that could be used to elute analytes without having the effect of diluting 
apomorphine extracted from samples of lmL or less. 
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Portion of Eluting Solution 
Figure 4-11 Elution profiles of apomorphine and NP A extracted from plasma. 
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4.3.4.5. Capacity of Sorbent:Bonded Phase.for Apomorphine andiNPA. 
'Hle capacityofthe:bonded phase, ie. the·mass ofanalytethat a specific sorbentmass can 
maximally retain in a given solvent environment, was investigated. It was anticipated that 
clinical samples would yield approximately 2.5mL ofplasma,per sample point. Thus the 
linearity of response over a volume range of0.25 to 2.5mL was studied. 
Experimental. 
Plasma was prepared according to Section 4.3.3 (page 4-35) such that 6.5mL aliquots of3 
and 20 nglmL R(-)-apomorphine HCI in plasma were produced. Volwnes ofO.i5, 0.5, 1.0, 
2.0 and 2.5mL of plasma at each apomorphine concentration were extracted using the · 
method given in Section 4.4.1 and assayed according to Section 4.4.2 (pages 4-50 and 4-
51). 
Results. 
The mean concentrations of apomorphine for the extractions of3 and 20 ng/mL were 
calculated to be 3.0 ng/mL (S.D. = 0.2ng/mL, C. V.= 5.3%) and 19.0 ng/mL (S.D. = 0.5 
nglmL, C. V.= 2.4%), respectively (n=6). 
There was no indication that the capacity of the solid phase extraction bonded phase had 
been reached. This was evidenced by the linearity of the response with increasing mass of 
analyte (y = l.3x105x- 1.9xl05, K= 0.9936,p<0.001, see Figure 4-12). 
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Figure 4-12 Evaluation of the tapacity of sorbent (lmg x Cl8, Bond Elut, V arian, 
UK) in the extraction of apomorphine and NP A from plasma using 
method given in Sedion 4.4.1. 
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4.4. Final Analytical Method 
4.4.1. Solid Phase Extraction 
Apomorphine_was extracted under vacuum using Bond~Elut C18 1mL, 100mg SPE columns. 
Wrth.the columniattached to a port in the extraction row" of the manifold, conditioning 
washes were applied, i;e. 2 x lmL methanol followed by 2 x 1mL water. The·sample was 
then passed through the column under negative pressure {approximately 9in Hg) and 
washed with 2 x lmL distilled water followed sequentially by lmL 10% (.v/v) methanol in 
distilled water, 1mL 200/o (v/v) methanol in distilled water, 1mL 50% (v/v) methanol in 
distilled water and finally 200J.1L of2% (w/v) sodium metabisulphite in diluent A The 
column matrix was not allowed to dry out at any of the conditioning and washing stages. 
The co~ was transferred to a port in the elution rov/' and analytes were eluted with 
800J.1L SPE eluting solution (0.25M sodium dihydrogen orthophosphate (pH 3.30), 40% 
(v/v) methanol) into an autosampler vial containing 200J.1L 2 % (w/v) sodium metabisulphite 
in diluent A The vial was sealed and placed at 4°C prior to assay by L.C. 
In order to avoid contamination of subsequent extractions with residual analyte, the elution 
port manifold was washed with SmL x 0.01M HCI in 50 % (v/v) methanol, followed by 
1 OmL distilled water and air-dried using suction generated by the vacuum pump. 
• The front row of the solid phase extraction manifuld was designated as the extraction row. 
b The back row of the solid phase extraction manifold was designated as the elution row. 
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4.4.2. HPLC System 
The solvent delivery system (LDC Analytical constaMetric 3200) supplied mobile phase at a 
flow rate of 1 mUmin. The mobile phase contained 60% (v/v) aqueous and 40% (v/v) 
methanol port!ons. The constituents of the aqueous portio~ expressed as final 
concentrations in the mobile phase, were: 0.25 M sodium dihydrogen orthophosphate and 
0.25 % (w/v) heptane sulphonic acid which were adjusted to pH 3.30 with orthophosphoric 
acid, and 0.003 % (w/v) EDTA 
The L.C. column employed was a Cl8, 5 J.Ul1, 150 mmx 4.6 mm I.D. (Columbus, 
Phenomenex, UK) used in conjunction with a 2 cm pre-column containing the same 
stationary phase as the main column. 
The spectrofluorometer (FP-821 and later tbe FP-920, both Jasco, UK.) configurations 
were: A.ex 270nm, A.em 450nm, attenuation 1, gain 1000. 
Samples were injected onto the column using the autosampler (AS-950, Jasco, UK), 
whereby an injection of 100 J.LL was made and the injection manifold was flushed (x3) with 
diluent A 
Data acquisition was perfonned using Borwin Chromatography software (v. 1.13, JMBS 
Developpements, France), according to parameters given in Table 4-7. Example 
chromatograms are presented in Figure 4-I 3. 
Peak Parameters Value 
minimum slope (J.L V /minute) 0.500 
minimum area (J.L V .minute) 4000 
smoothing factor 13 
minimum height (J.L V) 10 
peak width calculated at: 50% height 
number of theoretical plates calculated at: 50% height 
peak asymmetry calculated at: 10% height 
run time (minute) 18 
Table 4-7 User-defined peak panmeter settings. 
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analytical method. 
Panel A: diluent A. 
Panel B: 50nglmL R(-)-apomorphine HCI and lOOnglmL R(-)-NPA HCI 
in diluent A. 
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Panel C: blaa.k plasma extract (patient..,., t=lO minutes prior to apomorplliae bolus 
dose, l.lmL of plasma extracted) .. 
Panel D: patient plasma extract (patient (W', t=240 minutes post-bolus, l .OmL of 
plasma extracted): apomorphine concentration = 0.2 aglmL. 
Panel E: patient plasma extract (patient (W', t=6 minutes post-bolus, 1.4mL of plasma 
extracted): apomorphine concentration = 16.6 nglmL. 
Panel F: control plasma extract (l.OmL of plasma extracted): upected apomorphine 
conceatration = l.Ong/mL, observed apomorphine concentration= l.lnglmL. 
Panel G: control plasma extract (lmL of plasma extracted): expected apomorphine 
concentration= lOng/mL, observed apomorphine concentration= 19.7nglmL 
• (Needle-free) apomorphine bolus dose of2 mg. 
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4.4.3. Evaluation of Published Extraction ;Methods. 
As:part of the apomorphine assay development, the extraction methods described' by Durif 
eta/ [42], Silmeta/[43), van,der Geest eta/'[44], Bohter et al'[45]'and Ameyibor et a/ [41] 
were evaluatcihsing the HPLCassay given in· Section 4.4.2-(page-4-51 ). These particular 
methods were,selected for evaluation since they were representative of the range of 
published techniques for apomorphine assay (see Appendix 8.11). 
Experimental. 
The perfonnance of the extraction procedures was assessed using solutions of 
R(-)-apomorphine HCl in diluent A and in pooled plasma ( e;g. I and 20,ng/rnL ), and also 
using blank matrices. Chromatographic peaks were identified on the basis of retention time; 
no fUrther analysis leading to the definitive identification of peaks was performed. The 
recovery of apomorphine was determined by comparing the peak area of the extracted 
standard in plasma to that of a known standard in diluent A which had not been extracted 
(having taken account of the dilution or concentration of analyte-in a· given extraction 
method). Where satisfactory extraction was achieved,,a precision ofreplicate:extractions of 
apomorphine (and internal standard; i.e. NPA) was performed. The performance of the 
published methods was·compared to the extraction method developed in-house (Section 
4.4.1, page 4-50) using performance characteristics such as recovery and intra-batch 
precision as indicators of merit. 
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· Durif et a/[42]. 
Durif etatdescnbe a solvent{ethyl acetate) extraction'method'which involves:back-
extraction of apomorphine (and internal standard): into an acidic aqueous phase for 
subsequent quantification by HLPC. 
Resulls. 
An unsatisfactory outcome was observed following extraction of apomorphine from,both 
diluent A and,pooled plasma (Figure 4-14), ie. there was an absence of a peak at the 
retention window of apomorphine, coupled with the presence of additional1peaks that were 
not evident in the .blank matrices. 'Fhe cause·ofthe degradation was investigated; it was 
found that apomorphine was unstable in the presence of the ethyl acetate and that, from a 
practical point of view, it was difficult to entirely eliminate the organic solvent from the 
aqueous portion used for HPLC analysis. 
Sameta/[43]. 
This method is the same as that given by Durif et. a/ (above) with the exception that the 
solvent used is diethylether, and 2-mercaptoethanol is included in the acidic aqueous phase. 
Results. 
The outcome was similar to that descnbed for Durifel al. Similar practical difficulties were 
experienced. 
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Figure 4-14 Extraction of apomorphine according to Durif[42). 
Panel A: R{-)-apomorphine HCI standard (not extracted): 20 ngfmL in 
diluent A. 
Extraction of blank plasma (Panel B) and 20 nglmL R(-)-apomorphine 
HCI in plasma (Panel C). 
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Van der Geest et al. 
Van der Geest eta/ describe·a solvent extraction method in which plasma samples 
containing apomorphine are reacted with diphenylborinic acid ethanolamine ester (DPBEA) 
in an alkaline medium. Under these conditions the borate,group ofDPBEA specifically 
binds to the diol group of apomorphine, resuhing in a· negatively charged'complex which·is 
reported to confer stability to apomorphine during the extraction[39]. Organic solvent 
(octanol:hexane, 1:10) containing tetraoctyl ammonium bromide (TOABr) (as a cation) is 
mixed with the aqueous portion. with the resultthat an ion pair is formed with the 
apomorphine-DPBEA complex andTOABr. Consequently the ion pair is extracted into the 
organic phase, followed by back-extraction into an aqueous acidic phase, where, at low pH, 
apomorphine dissociates from the borate group ofDPBEA. 
The meah recovery of apomorphine from plasma (20ng/mL) compared to a standard in 
diluent A was 47% (S.D = 5%, n=5). (The percentage recovery given in the published 
article was, at 79% for a 25ng/mL standard of apomorphine in plasma. substantially higher 
than that achieved in this evaluation). In this the extraction method given by Van der Geest 
compared unfavourably to the in-house method (page 4-50), for which a mean recovery of 
74% (S.D = 5, n=1) was demonstrated for the extraction of20ng/mL apomorphine in 
plasma (see Section 4.5.2.3, page 4-89). 
The performance of the two methods were similar with regards to intra-batch precision of 
extractions of apomorphine in plasma (20nglmL), 1.9% (n=5) for the method described by 
van der Geest, and 2.1% (n=J> for the in-house method (see Section 4.5.3.1, page 4-90). 
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Figure 4-15 Extraction of apomorphine according to van der Geest[44]. 
Panel A: R(-)-apomorphine HCI standard (not extracted): 40 nglmL in 
diluent A, represents 100% recovery of sample in Panel C 
Extraction of blank plasma (Panel B) and 20 nglmL R(-)-apomorphine 
HCI in plasma (Panel C). 
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Bolner et al. 
Bolner et .ti/1describe an extraction method whereby apomorphine is extracted from plasma 
using afumina. The extraction;of analytes from.plasma is performed1in tbe.presence o(tris 
buffer. The;aJwnina pellet is repeatedly washed with distilled water, and apomorphine is 
eluted:into perchloric acid in acetonitrile. One volume of the acid supernatant is·then mixed 
with two volumes of phosphate buffer, and·a sample of this mixture is injected onto the 
HPLC column. 
Results. 
An.unsatisfactory outcome was observed following extraction of apomorphine from both 
diluent Aand:pooled plasma (Figure 4-16), i:e. recovery was only 3 %and 4%, 
respectively, and there were additional peaks present that were not evident in the blank 
matrices.-
The cause of the degradation was investigated; it was found that apomorphine was not 
stable in, the extraction nor the injection mixture. This is illustrated in Figure 4- I 6F. 
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Figure 4-16 Extraction of apomorphine according to Bolner(45). 
Panel A: R(-)-apomorphine HCI standard (not el:tracted): 6. 7nglmL ia diluent A, 
represents 1 00~. recovery of sample in Panel E. 
Panel B: R(-)-apomorpltille HCI standard (not e:rtracted): SOnglmL in diluent A. 
Panel C : Eitraction of: blank plasma 
Panel D: Extraction of blank diluent A. 
Panel E: E:rtraction of lOaglmL R(-)-apomorphine HCI in plasma 
Panel F: R(-)-apomorphine HCI standard (not e:rtracted): SOaglmL in injedion 
mi:rture, Le. O.lM perc.Joric acid in acetoaitrile and 0.6M phosphate boft'er pH 3.6 
(l:l, v/v) 
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Ameyibor et a/[41 ]. 
This method:involves solid phase extraction ofapomorpbine, whereby, having·applied a 
sample of apomorphine solution to the conditioned·solid phase extraction;column, .the 
colwnn is washed'with a solution of potassium dihydrogen phosphate (pH 7.4) and 
methanol (7:3"; v/v), and apomorphine (plus interilalistandard) is eluted with a solution.of 
potassium dihydrogen phosphate (pH 3.0) and methanoli{3:7, v/v). The eluant is evapomted 
under nitrogen prior to reconstitution of extracted:analytes with mobile phase.{the volwne 
of which did not constitute concentmtion-step), and subsequent injection onto the HPLC 
column. 
Results. 
There was evidence that apomorphine bad degraded as a result of the .extraction procedure, 
i.e. peaks with equivalent retention times to those resulting from the forced degradation of 
apomorphine were present {Figure 4-17, also see Section 4.5.1.3, page 4-73). The mean 
recovery of apomorphine from plasma{20ng/mL) compared to a standard in diluent A was 
58% {S.D = 9%, n=S). {The percentage recovery given in the published article was, at 98% 
{n=3), substantially higher than that achieved in this evaluation). The extraction method 
given by Ameyibor compared unfavoumbly to the in-house method (page 4-50), for which a 
mean recovery of74% {S.D = 5%, rF1) was demonstmted for the extraction:of20ng/ml.. 
apomorphine in plasma (see Section 4.5.2.3, page 4-89). 
An assessment of intm-batch precision of extractions of apomorphine· in plasma (20nglmL) 
was made using the method given by Ameyibor and compared to in-house data. In this the 
two methods were similar; precision being 2.2% {IFS) for the method descnbed by 
Ameyibor, and 2.1% {n=7) for the in-house method (see Section 4.5.3.1, page 4-90). 
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Figure 4-17 Extraction of apomorphine according to Ameyibor[41). 
Panel A: R(-)-apomorphine HCl standard (not extracted): 20 nglmL in 
diluent A. (represents 100% recovery of sample in Panel C) 
Extraction of blank plasma (Panel Bj and 20 nglmL R(-)-apomorphine 
HCl in plasma (Panel C). 
• Samples were contaminated by cany-over of apomorphine. Carry-over was estimated to be at a level of 
1.4% of the peak area of the standard (20ng/mL in diluent A). 
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General Outcome ofthe Evaluation of Published Methods. 
Theoretically the ·published extraction methods offered certain potential advantages over the 
in-house method, e.g. a concentration-step[42, 44] or smaller volume ofiplasma[42, 43], 
however, ,the (brief) evaluation,revealed that in general;there were no major benefits 
afforded I by the publishec:liniethods·in comparison with the in~house method: The 
performance ofthe·extraction methods given in the published articles coUld not be not 
reproduced in.the!evaluation performed. Factors which may:have contnbuted to this 
include deficiencies in the robustness or in the stability indicating properties, of the 
published·methods. Also, certain practical difficulties were experienced, e.g. in the isolation 
of the aqueous (analyte-containing) portion in the solvent extraction methods ofDurif et a/ . 
and Sam et. a/, which greatly contributed to the·poor performance of the methods in 
comparison to published· data 
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4.5. Analytical Method Validation. 
4,5.1. Assay Selectivity, 
The ability of the assay to detect the analyte:in:the presence of endogenous compounds and 
( 
' 
to separate the•analyte from degradation products, eo-administered drugs:and metabolites, 
was investigated. 
4.5.1.1. Assay Speclficity. 
Experimental. 
Blood was. collected from six individual normal controls using the method given in Section 
4.3.3 (page 4-35) and assayed according to methods given in Section 4.4 (pages 4-50 to 4-
51). 
Results. 
A lack of response across the retention time windows of apomorphine and NPA wa5 
demonstrated in six independent sources of plasma. There was no evidence of interference 
from endogenous compounds,in the sample matrices that were anaJysed (Figure 4-18). 
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Figure 4-18 Assay specificity. Retention times are given as peak labels 
Panel A: R(-)-apomorphine HCI (lnglmL) and R(-)-NPA HCI 
(lOOnglmL) in diluent A. 
Panel B: Typical chromatogram of blank plasma coDected from normal 
controL 
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Conventional spectroscopic deteciors monitor at a•discrete wavelength only. Photodiode 
may detection,(DAD) allows the•continuous monitoring of column effiuent overa 
wavelength nii:Jge of 190 to 800nm, resulting in an·absorption spectrum for. any point of 
interest on the chromatogram. 
Thus·the use of DAD permits· the purity of a peak to·be calculated. Spectra from within a 
peak are compared against other spectra in that same peak, to give a spectral similarity 
index (S.S.I.)", where S.S.I. = 1 represents a pure peak. 
Having obtained the UV spectrum for a given peak, this can be stored electronically in a 
spectral hbrary and compared against other spectra of interest. In the comparison of spectra 
" 
for identification purposes, a S.S.I. of greater than or equal to 0.98 is indicative that a 
match has been obtained[46]. However, since UV spectm are not as distinctive as mass 
spectra, or indeed infrared spectra,.further analysis is desimble for unequivocal 
identification. 
The peak purity for apomorphine and NP A, both in diluent A and· extracted from plasma, 
were obtained. 
Experimental. 
The assay was identical to the method given in Section 4.4.2 (page 4-51), with the 
exception of the detector. A detector with DAD capabilities{UV6000LP, Tbermo 
Separations Products, UK) was employed specifically for the determination of peak purity. 
The detector operated over a wavelength mnge of 198 to 798nm. The data acquisition 
• Computational furmula fur spectral similarity index: S.S.I. = A *8 I (N-l ), where A is the first normalised 
spectra (a vector of normalised absorbance ver.rus time), B is the second normalised spectra, and N is the 
number of points in the vector. 
4-66 
software used was Chromquest(Thermo Separations Products, l:JK). Peak1purities were 
calculated using a scanrthreshold of5mAU and a peak coverage requirement of95% .. 
Solutions ofR(-)-apomorphine HCI and RH-NPA HCI(both lJ!g/mL in diluent A) were 
assayed under the conditions given above. R( -)-Apomorphine HCl and R(-)-NPA HCl 
(both lJlg/mL) were extracted'from plasma according:to the method given in Section 4.4.1 
and assayed under the conditions1givenabove. 
Results. 
S.S.I. of0.995 and 0.990 were obtained for apomorphine and NPA in diluent A, 
respectively, and 0.995 and 0.992 for apomorphine,and NPA extracted from plasma, 
respectively. These results indicate that there was no evidence of eo-elution of an additional 
product~ apomorphine or NPA in the standard solutions used or following extraction of 
each from plasma. 
Furthermore, having stored the. spectra of the non-extracted and extracted analytes in a 
spectral hbrary (Appendix 8.12), the identity of the peaks present in the chromatogram (at 
the retention times of apomorphine and NPA) following extraction from plasma were 
verified in that (i) the spectra of extracted apomorphine matched that of non-extracted 
apomorphine in diluent A with an S.S.I. of0.995, and (ii) the spectra of extracted NP A 
matched that of non-extracted NP A in diluent A with an S.S.I. of 0. 993 (Figure 4-19). 
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Figure 4-19 Peak spectra. 
Panel A: R(-)-apomorphine HCI (lJ.LgfmL) in diluent A. 
Panel B: R(-)-NPA HCI (lJ.Lg /mL) in diluent A. 
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4.5.1.3. StabHity Indication. 
A stability indication study was performed in order to establish whethenpomorphine and 
NPA couldibe distinguished, in terms of retention .time, :from their degradation products. 
Thus apomorphine and NP A in solution were forcibly degraded under acidic, alkaline and 
oxidative conditions, and by heating. 
Experimental 1. 
Aliquots ofR(-)-apomorphine HCI(l mL x 0.5J.1g/mL in distilled water) and R(-)-NPA HCI 
(lmL x l.OJ.1g/mL in distilled water) were reacted separately with the fullowing:-
• lm.L x O.IM hydrochloric acid for: 
- 30 minutes at 63+/-l 0 C" 
10 minutes at 63+/-1°C" 
(minute at room temperature (approximately 25°C)" 
- 3 seconds at room temperature (approximately 25°C), 
• 1mL x O.IM sodium hydroxide for 
- 30 minutes at 63+1-l 0 C" 
10 minutes at 63+/-1 °C" 
1 minute at room temperature (approximately 25°C}8 
- 3 seconds at room temperature (approximately 25°C}, 
• lmL x 6 voL hydrogen peroxide at 63+/-1°C for 30 minutes, 
• lmL x distilled water at 6J+/·1°C for 30 minutes, 
• I mL x distilled water at 4-8°C for 30 minutes as a control for the effect of heating. 
Solutions ofR(-)-apomorphine HCl (50 nglmL) and R(-)-NPA HCl in diluent A (100 
nglm.L) stored at 4-8°C.acted as controls fur the use of distilled water as a diluent. 
"The acidic and alkaline solutions were neutralised after the reaction period by addition of 
1m.L 0.1M sodium hydroxide and O.IM hydrochloric acid, respectively. 
• Performed for apomorphine only. 
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Subsequently, each reaction mixture and control solution was made uprto volume with 
distilled water to give a finalrconcentration of 50 nglmL for apomorphine and 100 ng/mL 
for NPA. All solutions were protected from light throughout. Finaholutions were then 
assayed using:.the method givenin·Section 4.4.2 (page 4-51). 
Results 1. 
The solutions of apomorphine and NP A remained colourless during the reaction and/or 
incubation period. 
Chromatograms which illustrate the following results are given in Figures 4-20 and 4-21 
(pages 4-71 and 4-72). A sunnmuy of results is given in Table 4-8 (page 4-73). The effect 
of using water as a diluent was to reduce the peak area of apomorphine by 19 % and NP A 
by 2% a8 compared to control solutions in diluent A. Incubation of the analyte solutions in 
distilled water at approximately 60°C for 30 minutes caused a reduction in peak area of 21 
and 75% for apomorphine and NPA, respectively, as compared to peak areas ofthe control 
solutions stored at 4-8°C. 
There was a large instantaneous reduction·(90- 96 %) in peak area of both analytes when 
exposed to an acidic or alkaline environment. 
Compounds were detected in the test solutions that were absent from the control solutions 
of analyte in diluent A. The reactions of apomorphine with hydrochloric acid, sodium 
hydroxide and distilled water generated a peak which eluted at 2. 7 minutes. The reactions 
ofNPA with hydrochloric acid, sodium hydroxide and distilled water resulted in a peak at a 
retention time of 3.2 minutes. 
The reaction of both apomorphine and NP A with hydrogen peroxide resulted in a peak at 
7.2 minutes retention time. This peak was consistent, in tenns of retention behaviour, with 
the peak produced as a result of solid phase extraction of apomorphine using the method of 
Priston[l8) (see Figure 4-7, page 4-51). 
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Figure 4-20 Fo~ed degradation ofR(·)-apomorphine HCL 
Panel A: R(-)-apomorphine HCI (SOnglmL) and R(-)-NP A HCI 
(lOOnglmL) in dlluent A (4-8°C, standanl). 
Panel B: Control in distilled water ( 4-8°C). Panel C: Control in 
distilled water (60°C). Panel D: Reaction with HCI (3s at 25°C). Panel 
E: Reaction with NaOB (3s at 25°C). Panel F: Reaction with Hz~. 
Retention times are given as peak labek. 
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Figure 4-21 Forced degradation ofR(-)-NPA HCL 
A: R(-)-apomorphine HCI (50nglmL) and R(-)-NPA HCI (lOOnglmL) in 
diluent A (standard, 4-8°C). 
B: Control in distilled water (4-8°C), C: Control in distilled water 
(60°C}, D: Reaction with HCI (3s at 25°C), E: Reaction with NaOH (3s 
at 25°C), F: Reaction with H202. 
Retention times are given as peak labels. 
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% Apomorphine Additional peaks %NPA Additional· peaks 
Reaction Conditions. remaining: ta.(mins) remaining: ta.(mins) 
cfHzO cfdiluent cfHzO cfdiluent 
control A control control A control 
.. 
Control in diluent A 30 minutes 4-8°C. NA NA None NA NA None 
Control in H20 30 minutes 4-8°C. NA 81 2.6 NA 98 3.2, 3.4 
30 minutes 60°C. 79 65 2.6 25 28 3.1, 3.3 
+Hydrochloric acid 30 minutes 60°C. 0 0 2.6 NA NA NA 
10 minutes 60°C. NA 4 2.7 NA NA NA 
1 minute 25°C. NA 8 2.7 NA NA NA 
3 seConds 25°C. NA 4 2.7 10 11. 3.2 
+Sodium hydroxide 30 minutes 60°C. 0 0 None NA NA NA 
10 minutes 60°C. NA 2 2.2 NA NA NA 
1 minute 25°C. NA 1 2.7 NA NA NA 
3 seconds 25°C. NA 8 2.7 4 5 3.2 
+Hydrogen peroxide 30 minutes 60°C. 122 79 7.2 312 77 . 7.3 
Table 4-8 Stability indication of apomorphine and NPA (final concentrations of 50 and 100 nglmL, respectively) lising f1uore5cence detection. 
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EXperimenta/2. 
On a separate occasion• the forced degradation of apomorphine was repeated:and the 
resultant solutions were assayed.using E>AD (see Section 4.5.1.2,,page 4,.66). The· 
degradative conditions used were as ,those given previously (in Experimentall, page. 4-69), 
however a more concentrated solution of apomorphine in-distilled water was used, i;e. 
l JJg/mL final concentration, due to the comparatively poor absorbance of apomorphine at 
UV wavelengths as opposed to the response obtained using fluorescence detection. 
Peak spectra were obtained for the control solution of R(-)-apomorphine HC~ Le. I JJg/mL 
in diluent A stored at 4-8°C, and for all peaks present in the test solutions as a result of 
forced degradation. Spectra were stored for reference in a spectral library (Appendix 8.12). 
Results 2. 
A summary of results is given in Table 4-9 (page 4-77). The outcome regarding percentage 
of parent peak remaining following the degradation process was comparable to that 
reported previously in Results 1 (page 4-73)' 
Also in common with the initial findings was the presence of a peak at a retentiontime of 
2.6 minutes when apomorphine was in solution with distilled water, and when subjected to 
acidic and alkaline environments. A comparison of the spectra of such peaks was 
performed. Wrth an S.S.I. of0:998, the spectra of the peaks produced on contact with acid 
and alkali exlubited high similarity, the peak produced on incubation with distilled water 
being below the scan threshold (see Section 4.5.1.2, page 4-61). On incubation of 
apomorphine with hydrogen peroxide, two peaks which were not present in the control 
solutions were detected (Figure 4-22), one of which (with a retention time of9.3 minutes) 
was not detected using fluorescence detection(see Figure 4-20F, page·4-71). 
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Figure 4~22 Forced degradation ofR(~)-apomorphine BCI under oxidative 
conditions (detection wavelength of270nm). 
Panel A: Standard (1J1g/mL) in diluent A (~8°C). 
NB. Seale: 0 to 17 minutes, 0 to 100 mAU. 
It was demonstrated that the assay was stability indicating for degradation products forcibly 
produced under acidic, alkaline, and oxidative conditions. 
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% Apomorphine Additional Pe'aks 
Reaction Remaining: Spectra Library S.S.I. ApomorPhine 
Conditions Match Peak Purity 
cfHzO cfdiluent tR• Peak Spectra Library S.S.I. 
control A control (mins) Puritv Match 
Control in diluent A NA NA NA NA 0.996 None NA NA · ·NA 
(30 minutes, 4-8°C). 
Control in H20 
(30 minutes, 4-8°C). NA 94 Apomorphine in dil. A 0.998 0.999 2.7 ... ... NA 
Apomorphine in H20 0.998 
(30 minutes, 60°C}. 47 42 Apomorphine in dil. A 0.999 0.920 2.7 ... ... NA 
Apomorphine in H20 0.999 
+Hydrochloric acid 6 6 . ... NA ... 2.7 ... Apomorphine 
(3 seconds, 25°C}. degradation by NaOH 0.998 
. 
+Sodium hydroxide 3 3 ... NA ... 2.7 ... Apomorphine 
(3 seconds, 25°C}. degradation by HCI 0.998 
+Hydrogen peroxide 219 96 Apomorphine in dil. A 1.000 0.987 6.5 0.977 None 
(30 minutes, 60°C). Apomorphine in H20 1.000 9.5 0.987 NA 
-· 
Table 4-9 Stability indication of apomorphine (final apomorphine concentration of l~glmL) using UV-DAD system. 
Abbreviations: dil =diluent,""= peak below scanning threshold ofS mAU. 
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4.5.1.4. Co-AdministerediDrugs. 
Brugs which are commonly encountered in anti-parkinsonian drug regimens were assayed 
using the method given in Section 4.4.2 (page 4-51). Paracetamol was also investigated 
since this drug was made available to volunteers in the studies of intranasal and .buccal 
apomorphine formulations in healthy subjects (see Sections 4.2.2 and 4.2.3, pages 4-24 and 
4-31:). 
Experimental. 
The following preparations were assayed according to the method given in Section 4.4.2:-
• broJllDcriptine (approximately IO mg/mL in distilled water) 
• cabergoline (approximately 40 Jlg/mL in water) 
• co-beneldopa,(approximately 3l mg/mL levodopa in distilled water, approximately 8 
mg/mL benserazide in distilled water) 
• co-careldopa (approximately I 0 mg/mL levodopa in distilled water, approximately I 
mg/mL carbidopa in distilled water) 
• domperidone (approximately IO mg/mL in distilled water) 
• entacapone (approximately 67 mg/mL in distilled water) 
• lisuride (approximately 20 JJ.g/mL in distilled water) 
• paracetamol (approximately I 00 JJ.g/mL in distilled water) 
• pergoline (approximately I mg/mL in distilled water) 
o pramipexole (approximately ISO Jlg/mL in distilled water) 
o selegiline (500 Jlg/mL in distilled water). 
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Results. 
Whilst compounds were detected in each of the solutions given above, generally these were 
not retained on the analytical column to any significant extent and thus eluted mainly at the 
solvent front. _ This is illustrated using co-beneldopa in Figure 4-23. 
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Figure 4-23 Assay of co-beneldopa. 
Panel A: distilled water. 
min 20 
B 
m in 20 
Panel B: co-beneldopa (approximately 33 mgfmL levodopa in distilled 
water, approximately 8 mglmL benserazide in distilled water). 
Retention times are given as peak labels. 
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There were no cases of interference with,apomorphine orNPAdeterminatimi, withithe 
exception of the selegiJine,solution; in which a peak at the retention time of apomorphine 
was detected. It was demonstrated that, following solid phase extraction according to the 
method· given' in Section 4A.l (page·4-50), the interference was entirely removed1 from,the 
extract, with• approximately 93% (in·tenns of peak area·compared to.the non-extracted 
solution) of the interfering compound eluted·in·the.SO %·methanol wash and approximately 
6%.in,the sodium metabisulphite in diluent A wash (Figme 4-24). 
'Fhus it was;proposed that eo-administration of any of the drugs tested would not adversely 
affect the assay of apomorphine, at least in terms ofco-elution.ofthe constituents (parent 
drug and excipients) of the aforementioned drugs with apomorphine or NPA However, eo-
elution of the metabolites of the drugs tested with either apomorphine or NPA was not 
examined and therefore.remained a possibility. 
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Figure 4-24 Assay of selegiline. Retentioa times are given as peak labels. 
Panel A: R(-)-apomorpbine BCI (SOnglmL) and R(-)-NP A HCI 
(lOOng/mL) in diluent A. 
Panel B: Selegiline (O.lSmg/mL) and R(-)-NPA HCI (lOOng/mL) in 
distilled water (prior to solid phase extraction). 
Panel C: Result of extraction of solution given in Panel B. 
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4.5.1~5. Metabolltes. 
Experimental. 
The .proposed apomorphine metabolites, R(-)-apocodeine HCI'(Sigma-Aldrich Company 
Ltd,.UK.),and R(-)-apomorphine orthoquinone (SPA Contract Synthesis,UK) were assayed 
according to the method giVen in$ection 4.4.2. 
Results. 
Apocodeine typically eluted at approximately 17 minutes (Figure 4-25B). There were two 
peaks present due to apomorphine orthoquinone, the retention times·ofwhich were 
approximately 9 and I 0 minutes (Figure 4-25C). 
It was d~monstrated that apomorphine and NP A could beidistinguished in terms of 
retention time from both apocodeine and apomorphine orthoquinone. 
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Figure 4-25 Assay selectivity with respect to proposed apomorphine metabolites. 
Panel A: R(-)-apomorphine HCI (SOnglmL) and R(-)-NPA HCI 
(lOOnglmL) in diluent A. 
Panel n•: R(-)-Apocodeine (SOnglmL) in diluent A. 
A 
20 
c 
20 
Panel ctt: R(-)-Apomorphine orthoquinone (0.14mglmL) in diluent A. 
Retention times are given as peak labels. 
• The detector used in the assay of apocodeine, apomorphine and NPA, i.e. left-hand paneJ, was the FP-82 I 
(Jasoo, UK). 
11 The detector used in the assay of apomorphine orthoquinone, apomorphine and NP A, i.e. right-hand 
panel, was the FP-920 (Jasco, UK). 
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4.5.2 .. Assay·Calibration. 
4.5~2;1 .. Apomorphlne Calibration Curve In Plasma. 
Experimental. -
Caliblation standards were· prepared using.plasma·which·was:obtained according to.the 
method given in Section 4.3.3.1 (page 4-35). The cahbration curve was constructed:using 
fifteen·standards which represented the;expected range of apomorphine concentrations, ie. 
up to 75.0ng/mL. The standards were.prepared by adding. the appropriate volwne of stock 
R(-)-apomorphine HCI solution (lOJ.lglmL, 1 Jig/mL, 75nglmL or 1 OnglmL in diluent A) to 
plasma, whereby the volwne used was between 0.30 and 2.50% of the total volume of the 
cahbration standards. Sufficient volwnes of calibration standards were prepared to allow 
for extraction of 1mL of plasma for the 1 to 75ng/mL standards, and 2.5mL of plasma for 
0:03 to 0.5 nglmL standards. Calibration standards in plasma were then stored in 
polypropylene tubes at -20°C. Preparation of the standards was completed using the 
method given in 4.3.3.3 (page 4-35) and assayed according to methods given in Section 4.4 
(page 4-50). Linear regression analysis was performed using MS Excel. 
Results. 
It was found that the response was not linear over the entire range of concentration 
standards, as evidenced by systematic deviation in the relative error" of predicted 
apomorphine concentration with respect to expected apomorp~ concentration (Table 
4-1 0). Residual plots were used as a guide to the identification of linear relationships within 
the concentration range used. The calibration•ciD'Ve was defined by three such partial 
concentration ranges, Le. 0.05 to 0.75nglmL (n=5), 0.75 to 10nglmL (n=5) and 5 to 
70nglmL (n=6), see Figure 4-26 and Table 4-10. 
• Relative error (%) = ((expected [apomorphine] -observed [apomotphine])l(expected [ apomorphine])).IOO 
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The poirit ofintersection,ofthe linear regression,equations were:used to defirie,the useful 
range ofthe1curves, Le. 0,80 ng/mL.for the low and1mid range:plots, and 12. 7nglmL. fur the 
mid andihigh~range plots, The range of the lower concentration calibmtion curve was 
defined as the. limit ofquantitation (0.05 ng/mL, see Section4.5.2.2, page 4-88). up to the 
poirit of intersection of the curves 
The mean (S.D.) relative error of the observed versus calculated data points was -2.6 (11.2) 
%, n=I4. The mean absolute value of the relative error of the observed versus calculated · 
data points was 8.3%. 
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Expected Observed Relative Observed Relative Observed Relative Observed Relative 
(apo] I apomorphine] error (apomorphine) error (apomorphine] error (apomorphine] error 
(nglmL) (nglmL) (%) (nglmL) (%) (nglmL) (%) 
x, y=O.Ol58x+0.0068, R2=0.9960 y=0.0339x+0.0020, K=9709 y=O.Ol42x+O.Ol81, _RZ=0.9995 
(nglinL) (%) 
y=O.OI60x-0.0047 .. K=0.9930 
0.030 <3N NA 
0.050 -0.21 521.4 0.06 9.8 
0.075 -0.11 245.7 0.09 -23.0 
0.100 -0.05 145.8 0.12 -21.7 
0.500 0.63 -25.3 0.41 17.9 
0.750 1.43 -90.0 0.81 -7.4 0.78 -4.6 
1.00 2..19 -ll9.3 2.90 3.2 
3.00 3.34 -11.3 5.02 -0.4 
5.00 5.25 -5.0 7.60 -1.4 5.89 -17.9 
7.50 7.58 -l.l 9.94 0.6 
10.00 9.69 3.1 10.28 -2.8 
20.00 17.99 10.1 18.45 7.8 
35.00 36.84 -5.3 37.03 -5.8 
50.00 46.57 6.9 46.62 6.8 
70.00 72.08 -3.0 71.76 -2.5 
Table 4-10 Calibration curve standards: relative error analysis. 
Abbreviations: <3N =apomorphine peak area was less than three times the baseline (blank mobile phase) noise, NA =not appficable. 
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Figure 4-26 Calibration curve ofR(-)-apomorphine BCI in plasma. 
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A 
B 
4.5.2.2. Assay Detection Limits. 
The limit of quantitation (LOQ), ie. the lowest concentration of apomorphine that could be 
distinguished .from the noise level at a signal:noise ratio of 10:1 [ 4 7] was 0.05ng/mL 
(extracted from 2.5mL of plasma). This is illustrated in Figure 4-27, where the baseline 
noise in blank mobile phase across the retention window of apomorphine was visually 
estimated to be approximately 700JLV, and the peak height of0.05ng/mL apomorphine 
extracted from plasma was measured as 6880J.l V. The limit of detection (LOD) is defined 
as the lowest concentration of apomorphine that could be distinguished from the noise level 
at a signal:noise ratio of3:1[47]. The LOD was therefore defined as the concentration of 
apomorphine which corresponded to an apomorphine peak height 21 OOJL V; this was 
0.03ng!mL (extracted from 2.5mL of plasma), with a peak height of24l6J.lV. 
7.5 m in 10.5 
Figure 4-27 Definition of assay lower detection limits. 
(i) Baseline noise in blank mobile phase across the retention window of 
apomorphine. 
(ii) Extraction of O.OSnglmL apomorphine in control plasma (2.5mL of 
plasma extracted) . 
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4.5.2.3. Recovery;of Analyte. 
The recovery ofanalyte, ie. the peak: area of the standarddn:plasma expressed as a 
percentage of the ,peak area of a standard which had' not been subjected to ~pre-treatment, 
was calcu1ated' for all lmL extractions of apomorphine;and NP A over a calibration curve 
range (n=8, range I to 50 ng/mL), 
Experimental. 
The cahbration,standards in plasma which are descn"bed in Section 4.5:2.1 (page 4~84)were 
used The.control solutions of apomorphine were prepared'in:diluent A by adding the 
appropriate·volume of stock R(-)-apomorphine HCI solution (lOj!g/mL, ljlg/mL or 
75nglmL in diluent A), whereby the volume used was:between 035 and 2.000/o of the final 
volume of the control These were then spiked to a final concentration ofl OOng/mL R(-)-
NP A HCI using a stock solution of 5j!g/mL in diluent A, gently mixed, and' stored at 4-8°C 
prior to assay using the method given in Section 4.4.2 (page 4-51). 
REsults. 
Data are presented in Table 4-11. The mean recovery of apomorphine was 72% with a S.D. 
of5% and C. V. of7% (n=8). The mean recovery ofNPA was 67% with a S.D. of2% and 
a C. V. of3%:(n=8). The recovery of each analyte, whilst being less than,maximal, was 
considered to be acceptable given the consistency in recovery throughout the cahbration 
standard range[48]. 
Apomorphine standard (ng/mL) Recovery of apomorphine Recovery of NP A 
+ NPA (lOO nglmL) (%) (%) 
1.0 79.9 66.8 
3.0 79.0 65.0 
5.0 70.2 68.7 
7.5 66.9 68.3 
10.0 74.1 68.2 
20.0 68.3 64.5 
35.0 68.8 68.8 
50.0 69.7 67.5 
Table 4-H Recovery of analyte foUowing solid phase extraction from plasma. 
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4.5:3 .. Assay Precision. 
4.5:3.1.tlntta-8atch Precision: Quantificatlon·of Apomorphine In Plasma. 
Experimental. 
Apomorphine standards were prepared according to Section·4.3.3 (page 4-35), with the 
exception that the following concentrations of apomorphine were prepared: 0.5, 20 wtd 
50ng/mL. Solid phase extraction (Section 4.4.1, .page 4-50) wa8 perfonned with seven 
individual aliquots of each apomorphine standard in a single sessioiL The resultant extracts 
were assayed using the method given•in Section 4.4.2 (page 4-51 ). 
Results. 
Data are presented in Table 4-12. Using the criteria that the precision around the mean 
should not exceed 15% ofthe C. V., and the mean value should be within •t-15% of the 
deviation of the nominal value for accuracy[49], it was concluded that the assay operated 
within acceptable limits for precision wtd accuracy; 
Apomorphine Mean S.D C. V. Mean Mean Recovery(%) 
standard [apomorphine) relative 
error 
(nglmL) (nglmL) (nglmL) (%) (%) Apomorphine :NPA 
0.5 0.54 0.09 8.13 7.14 73.4 58.6 
20 18.26 0.76 2;08 -8.70 74.4 70.9 
50 48.23 0.79 1.63 -3.54 67.6 55.9 
Table 4-12 lntra-bateh precision ofR(-)-apomorphine HCI extraeted from plasma 
(n=7). 
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4.5.3.2. lnter~atch.Precision: Quantification of. Apomorphine :in· Plasma. 
Experimental . 
. Apomorphine standards were prepared according to Sectio0'4.3.3 (page 4-35) with the 
-
exception that thefollowing·concentrations ofapomorphine were additionally prepared: 0.5, 
and SOnglmL. Solid·phase extraction (Section 4.4.1, page 4-50) was performed on,single 
aliquots of each apomorphine standard once a day for seven days and the resultant extract 
was assayed according to method given in Section 4.4.2 (page 4~51 ). 
Results. 
Data are presented in Table 4-13. l!Jsing the criteria that the precision around the mean 
should 119t exceed 15% of the C. V., and the mean value should be within +/-15% ofthe 
deviation of the nominal value for accuracy(49], it was concluded that the assay operated 
within acceptable limits for precision wtd accuracy. 
Apomorphine Mean s.o. C. V. Mean 'Mean Recovery (n=3) 
Standard (Apomorphine] relative (%) 
error 
(nglmL) (nglmL) (nglmL) (%) (%) Apomorphine NPA 
0.5 0.49 2.s x w-2 1.48· -1.14 75.6 65.9 
I 0.87 3.4 x 10-2 3.94 -l.l4 78.3 55.9 
20 19:69 1.1 5.66 -1.59 66.1 60.9 
50 50.46 2.1 4.14 0.91 73.1 65.0 
Table 4'-13 Inter-day precision ofR(-)-apomorpbine HCI extracted from plasma 
(n=7). 
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4.5;3.3.1ntra,.Batch Precision: Quantification,ofApomorphlne ln,Extract 
Experimental. 
Apomorphine standards were prepared according to Section 4.3.3 (page4-35). Solid phase 
extraction{Section 4.4.1, page 4,50) was .performed on 2 x 1 mL aliquots,of each 
apomorphine:standard in plasma. For each standard concentration, the,resuhing extracts 
were pooled in an autosampler vial and five injections were made from each using the assay 
method given in Section 4.4.2 (page 4-51). 
Results. 
The C. V. of the apomorphine:NPA peak area ratio was 0.39 and 0.75% for I and 20 nglmL 
apomorphine, respectively (1F5). This compared favourably to the intra-batch precision of 
apomorphine:NP A peak area ratios demonstrated for apomorphine standards of I and 20 
ng/mL in diluent A. Le. C.V.s of0.66 and 0.52%, respectively, tF5 (Section 4.5.3.4, page 
4-93). 
Using the criteria that the precision around the mean should not exceed I5% ofthe 
C.V.[49], it was concluded that the assay operated within acceptable limits for precision and 
accuracy. 
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4.5;3.4. Intra-Batch Precision: Quantification of· Apomorphine In Diluent A. 
ExperimentaL 
Solutions of] and 20ng/mL R(-)-apomorphine HCHn diluent A were prepared according to 
-
Section 3.5 (page 3-4) and each was•assayed in replicate (n=5 iqjections)according to 
Section 4A.2 (page ~51). 
Results. 
The C. V. ofthe.apomorphine:NPA peak area mtio Wall 0.66%for lng/mL and 0.52% for 
20ng/mL (IFS). It was dernonstrated•that the assay operated within the acceptable limits 
given for precision ofanalyte in simple diluent. ie. a C.V. of<l%. 
4.6.3.5. Intra-Batch Precision: NPA In Diluent A. 
A solution oflOOnglmL R(-)-NPA HCI in diluent A was prepared· according to Section 3.5 
(page 3-4) and assayed in replicate (n=S injections) according to Section 4.4.2 (page 4-51 ). 
Results. 
The C. V. ofthe apomorphine:NPA peak areamtio was 0.18%; thus it was demonstrated 
that the assay operated within the acceptable limits given for precision of analyte in simple 
diluent, i.e. a C. V. of <1 %. 
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4;5.4. Stability Studies. 
"Fhe,stability of apomorphine and'intemal standard under working assay conditions and at 
pertinent stages .of the plasma preparation;procedures ·was' investigated. 
AUapomorphine stability studies were performed at two concentrations, i.e. l and 
20ng/mL. 
'The assessment of stability was based on the following criteria:-
• potency of analyte; the acceptabJe;Jimits for analyte stability were defined as +/~2 x S.D. 
from-the analyte concentration at time =;Q, whereby the C. V. used was that obtained at 
time = 0 under directly comparable experimental conditions. 
• appearance of degradation products. e.g. those identified in Section 4;5.1.3 (page 4-73). 
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~5A.1 .. Stabmty of Apomorphine ln1Piasma.at -20°C Containing Ascorbic Acid. 
The.objective was:to assess the long term stability of apomorphine in plasma stored·at 
The. limits for analyte stability were defined. as +/-2 S.D. from. the analyte concentration at 
time"" 0, whereby the C. V. used were those obtained for the intra- (and:inter-day) precision 
of apomorphine in plasma (Sections 4.5.3.1 and 4.5.3.2, pages 4-90.and 4-91). Thus the 
acceptable variation from time zero was +/-7.88% fur lng/mL apomorphine and +/-1 1.32% 
for 20ng/mL apomorphine. 
Experime1fllll. 
On three.separate occasions pooled plasma was prepared and spiked with apomorphine and 
internal standard as detailed in Section 4.3.3 (page 4-35). An aliquot from one of the three 
batches was assayed as given in Section 4.4 (page 4-50).on days 0, I, 2, 4, 7, 10, 14 and 
weekly thereafter until day 161. 
Results. 
Cbromatograms were scrutinised for the presence of peaks with equivalent retention times 
to those resuhing from the forced degradation of apomorphine (see Section 4.5.1.3, page 4-
73); no such peaks were found. 
Although individual calculated concentrations went beyond pre-defined limits of variation 
for apomorphine in plasma, there was an absence of consecutive observations beyond the 
acceptable limits until day 126 and day 98 for I and 20 ng/mL apomorphine concentrations, 
respectively (Figure 4-28 and Figure 4-29), therefore the time period of refrigerated storage 
for apomorphine in plasma was defined as 98 days. 
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Figure 4-28 Stability ofR(-)-apomorphine HCI (lnglmL) in plasma at -20°C. 
Limits (-) are defined as + 1- 2 x S.D. from the concentration at t=O, 
whereby the S.D. used was that demonstrated for the inter-batch 
predsion of apomorphine in plasma (lnglmL). 
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Figure 4-29 Stability ofR(-)-apomorphine HCI (20nglmL) in plasma at -20°C. 
Limits are defined as+/- 2 x S.D. from the concentration at t=O, whereby 
the S.D. used was that demonstrated for the intra-batch (-) and 
inter-batch(-) p~ision of apomorphine in plasma (20nglmL). 
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4.5.4~2. Freeze-Thaw Cycles: Apomorphine• In Plasma. 
'The objective was to investigate the stability of apomorphine in plasma samples when 
,. 
subjected to repeated :freeze-thaw cycles. 
'The limits for analyte stability were defined as +/"2 S.D. from the analyte concentration at 
time= 0, whereby the C. V. used were those given for the precision ofthe·experimental 
controls (see below). Thus the acceptable variation from•time zero was +/-4.38% for 
lng/mL apomorphine and +/-4.72% for 20ng/mL apomorphine. 
Experimental. 
Duplicate aliquots of stock plasma (6;0mL) were prepared according to Sections 4.3.3.1 
and 4.3.3.2 (page 4-35), with the exception that, prior to placing the stock plasma at -20°C, 
l.2mL of each stock was removed, spiked with 2-ME to a final concentration ofO.Ol % 
(v/v), centrifuged (2000RCF, 5mins, 4°C) and assayed according to Section 4.4 (day 0). 
On days l, 2, 3 and 4 the stock plasma was thawed at 4-8°C, one aliquot (l.2mL) was 
removed and processed as descnbed in Section 4.4 (page 4-50), and the remaining stock 
plasma was replaced in the -20°C freezer. 
On each sampling day, individual aliquots (l.2mL) of plasma, prepared according to Section 
I 4.3.3.1, were assayed as described in Section 4.4. These acted as controls, not having been 
subjected to multiple :freeze-thaw cycles. 
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Results. 
It was demonstrated that during the course of four freeze-thaw cycles, apomorphine 
concentration did not go beyond the defined acceptable limits (Figure 4-30). Furthermore 
there was an ~bsence of chromatographic peaks at the retention time windows of 
apomorphine degradation products (the latter having been identified as such by the forced. 
degradation of apomorphine, see Section 4.5.1.3, page 4-73). 
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Figure 4-30 Stability ofR(-)-apomorphine HCI in plasma following multiple freeze-
thaw cydes. 
Limits (-)are defined as+/- 2 x S.D. from the contentration at t = 0, 
whereby the S.D. used was (the mean of) that given for the precision of 
the experimental controls (at 1 and 20 nglmL). 
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4.5A.3. NPA In Diluent A at 4-8°C. 
The objective was to·assess the long term stability ofNPA, at a concentration of5J.1g/mL in 
diluent A, at fridge temperature. This concentration Was chosen as it represented a suitable 
working concentration ofNP A, i.e. the working solution contributes only 2% of the final 
volume of sample to be assayed. This experiment was perfurmed,on two~ separate 
occasions. 
The limits for analyte stability were defined as +/-2 S.D. from the analyte concentration at 
time= 0, whereby the C:V. used was that demonstrated for the intra-dayNPA in diluent A 
(IOOnglmL). Thus the acceptable variation fromtime zero was +/-1.44 %. 
Experimental. 
On 12 occasions over a period of24 weeks, aliquots {lmL) of5J.1g/mL were prepared from 
a stock solution ofNP A in diluent A (0.1 mglmL, stored at fridge temperature, see Section 
3.5) and stored in polypropylene microtubes in a light-proof container at fridge temperature. 
At 24 weeks each 5J.1g/mL aliquot was used to spike lmL of diluent A to lOOng/mL. The 
lOOng/mL solutions was assayed according to the HPLC method given in Section 4.4.2 
(page 4-51 ), bracketed' with an external standard in the form of a solution of I OOng/mL 
NP A which bad been made that day from a freshly prepared stock solution ofNP A in 
diluent A The peak area of a test solution was compared to that of the. external standard in 
order to calculate the concentration of the test. 
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Results. 
It was demonstrated that for a period of20 weeks, (mean) NP A concentration did not go 
beyond the pre-defined acceptable limits, see Figure 4-31. There was an absence of 
chromatograpjllc peaks at the retention time windows ofNP A degradation products for all 
samples assayed. (NP A degradation products were identified as such by the forced 
degradation ofNP A, see Section 4.5.1.3, page 4-73). It was considered that NP A, at a 
concentration of5J.1g/mL in diluent A, was stable at fridge temperature for a period of20 
weeks. This defined the conditions of use for the working concentration of internal 
standard in the assay of apomorphine. 
1M ~-------------------------4 0 Batch 1 J: Batch 2 -
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- · - ·Mean -limits 
16 20 24 
Figure 4-31 Stability ofR(-)-NPA HCI (lOOnglmL) in Diluent A at 4-8°C. 
Limits are defined as + 1- 2 x S.D. from the concentration at t = 0, 
whereby the S.D. used was that demonstrated for the intra-day 
precision ofNPA in diluent A (lOOnglmL). 
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4.5.4.4 .. Plasma Extract at ~oc. 
The objective was to exarnine,the stability of apomorphine (and internal! standard) following 
. extraction froJD plasma, i.e. as analytes ·in the eluting solution. The extract was stored• at 4-
The acceptable limits for analyte stability were defined as +/-2 KD. from the 
apomorphine:NPA peak area ratio at time= 0, whereby the C. V. used was that obtained for 
the intra-batch precision of the apomorphine:NPA peak area ratio .of the extract (Section 
4.5.3.3, page 4-92). Thus the acceptable variation from time zero was+;_ 2.98% for 
lng/mL apomorphine and+;_ 1.66% for 20ng/mL apomorphine. 
Experime,ta/. 
Blood collection and preparation of plasma was performed according to Section 4.3.3 (page 
4-35). The eluate which was produced on extraction (Section 4.4.1, page 4-50) of four 
individual aliquots of I mL was pooled in a polypropylene tube and then distn'buted between 
two autosampler vials, which were stored at fridge temperature. A sample from ahernate 
vialswasassayed(Section4.4.2,page4-5l)ondays0,1,4, 7,l0,14,21,28and31. The 
apomorphine:NPA peak area ratio, rather than the absolute potency of the analytes, was 
used as a functional marker of stability of the extract. 
Results. 
There was an absence of chromatographic peaks at the retention time windows of 
apomorphine and NPA degradation products for all samples assayed. (Degradation 
products were identified as such by forced degradation of both analytes, see.Section 4.5.1.3, 
page 4-73). Although.individual observations went beyond pre-defined limits, there was an 
absence ofa consecutive observations beyond the acceptable limits (see Figure 4-32 and 
Figure 4-33), therefore the time period for storage at fridge temperature of extracts of I and 
20. ng/mL apomorphine in plasma was defined as 31 days. 
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Figure 4-32 Stability at 4-8°C of apomorphine (lnglmL) and NP A following 
extraction from plasma. 
Limits are defined as + 1- 2 I S.D. from the concentration at t = 0, 
whereby the S.D. used was that demonstrated for the intra-day 
precision of plasma extract (lnglm.L apomorphine). 
110~-----------------------------------------, 
-f!. 
- 105 f 
e 
=: 100 "*----*- - --liE---_* ___ --•----------:.- ----- ----x,' , , 
~ 
e-
o 
[ 95 
< 
0 5 10 15 20 25 30 35 
Day 
Figure 4-33 Stability at 4-8°C of apomorphine (20nglmL) and NP A following 
extraction from plasma. 
Limits are defined as + 1- 2 x S.D. from the concentration at t = 0, 
whereby the S.D. used was that demonstrated for the intra-day 
precision of plasma extract (20nglm.L apomorphine). 
4-102 
4.6. Pharmacokinetic.andPharmacodynamic Modelling Strategy. 
The standard two-stage approach wasused·inthe analysis ofpbarmacokinetic and 
pharmacodynamic data. Modelling was•performed using WmNonlin.Standard version 2.0. 
(Pharsight Corporation, Palo Alto, CA , USA). 
Inspection of the (log-linear) relationship between observed plasma apomorphine 
concentration versus time, or observed plasma apomorphine conCentration versus observed 
improvement in tapping test score, was performed in the first instance in order to determine 
(i) the fundamental structure of the relationship, e;g. the number of compartments itl the 
case ofpharmacokinetic models, or linear versus hyperbolic relationship in the case of 
pharmacOdynamic models, and (ii) initial estimates for model parameters, e.g. A, alpha, or 
Em.,., ECso. 
Having identified the likely structural model(s) for each dataset in this way, modelling was 
performed using, in the main, the Guass-Newton algorithm with Hartley and Levenberg-
Marquardt modifications. This was used since it is a powerfulalgorithm that performs weD 
on most data sets[ 50]. Upper and lower constraints (botmdaries) on initial parameter 
estimates were routinely applied, since the use of boundaries can prevent the.situation 
where unrealistic parameter estimates are generated, or where the model actually fuils to 
converge. 
Weighting was applied to data in order to account for heterogeneity in·the variance ofthe 
data. In most cases the protocol used was that of iteratively reweighted least squares 
(IRLS). The weighting scheme often employed is one where an observation is weighted by 
the reciprocal of the variance of that observation (I I variance ofY), however Gabrielsson 
and Weiner advise that IRLS, i.e. weighting by the reciprocal of the predicted value (I I 
variance ofS'), is a superior approach[ 50]. The authors give the following rationale: the 
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true variance·ofthe observed value is generally unlrnown. but is often taken to be the square 
of the observed concentration (vl). However, ~suniing the model is correct, ,the predicted 
concentration is actually a better estimate of the true concentration than•is the observed 
concentration. It is therefore more appropriate to use the variance.ot:the predicted value 
'Fhe'advantage conveyed by this approach can be demonstrated by the effect on outlying 
data; the IRLS process does not incorporate,the observed:outlying data value, rather, it is 
the predicted value derived from the model that. is used. 
Wrtb each iteration of the minimisation process the predicted value.changes, and the 
associated weight is updated for use in1the subsequent iteration. This process is continued 
until convergence is achieved. 
The goodness of fit was assessed using diagnostic features such as residual analysis (see 
Section 1.1.3, page 1-7). In the situation where competing models existed, model 
discrimination was performed according to the following criteria: WSSR, S, residual 
analysis, parameter correlation, the condition number, rank, Akaikelnformation.Criteria and 
the C. V. offinal parameter estimates(see Section 1.1.3, pages 1-7 to 1-9). 
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5. Results. 
5.1. Pharmacokinetic-Pharmacodynamic Study ofSubcutaneous 
Apomorphine Administration in Patients With Parkinson's 
Disease. 
The time courses,ofapomorphine-induced.effect are described for each patient as follows 
(see Table 5-1 on.page 5-23 for a summary and Appendix 8.13 on page 8-26 for raw 
data):-
Patient 01. 
A change in facial expression was identified by the patient as a qualitative marker of 
parkinsonian status, i.e. when "off" the face was often masked or fixed, and when "on" the 
face was often more expressive and relaxed. 
Following a washout period of eight hours the patient displayed mild to marked rigidity of 
major joints, moderate action tremor of the hands, ~ild to moderate resting tremor of the 
hands, and moderate to severely impaired perfonnance in tests of rapid, alternating·hand 
movement. The patient also exhibited a moderate hypomimia (''masked face") and slight 
impairment in speech (in terms of volume and expression). 
rhe walking test was attempted at baseline however, due to impaired postural stability and 
severe disturbance of gait, the patient was unable to walk unaided. Therefore the walking 
test was aborted at this time and was not attempted during the remainder of the sampling 
period. 
The time course of plasma apomorphine concentration and clinical status following 
apomorphine bolus administration is given in Figure 5-IA. The onset of effect was defined 
by the patient's comment that the drug was "just beginning to have effect". This event 
coincided with urinary urgency (which might have reflected a resolution of possible "off'' 
phase urinary retention[ I]) and the patient walked with assistance, to the bathroom. On the 
patient's return (three minutes later) there had been an improvement in mobility which 
5-1 
allowed the patient to walk unaided back from the bathroom. Additionally there was a 
substantial change in facial expression and quality of speech, and an improvement in 
tapping score was observed. 
The patient became somewhat anxious immediately prior to venous blood sampling, on 
which occasions tremor (e.g. affecting the lower extremities) was observed to increase in 
severity. 
There were no observations of adverse effects resulting from apomorphine administration. 
In fact there was a notable absence of yawning, this symptom being a common 
apomorphine-related (adverse) effect. 
At 38 minutes post-dose, the patient experienced a worsening in parkinsonian symptoms, 
culminating in a return to an "off" state which, in terms of the tapping test, was more 
pronounl;:erl than that at baseline. A second period of improvement in parkinsonian state 
subsequently ensued whereby an improvement in symptoms, e.g. facial expression, was 
evident and was reflected in the improved performance in the tapping test. This "second 
wind" was potentially facilitated by the patient stretching and standing (with assistance). 
Cessation of effect was defined by the patient stating that she was 'just fully turning 
"off'"'. The patient rated the response following the apomorphine bolus as sub-optimal in 
terms of quality and duration in comparison to her typical experience. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
effect plot ~Figure 5-1 B) revealed that no clear relationship existed between effect and 
plasma concentration. 
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Figure 5-1 Panel A: Plasma apomorphine concentration/clinical status profile 
following apomorphine bolus administration (2mg) to Patient 01. 
Panel B: Relationship between plasma apomorphine concentration and 
anti-parkinsonian effect. 
Arrows indicate chronological order of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine-induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "oft" phase. 
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Patient02; 
At the culmination ofthe wash-out period the·patient admitted to feeling "very lousy". Due 
to the extent ofparkinsonian,disability, walking unaided was not possible at this time. The 
time course of plasma apomorphine concentration and clinical status following 
apomorphine~bolus administration is illustrated in Figure 5-2A. 
In the twenty-five minutes following apomorphine administration, there was mild 
improvement in some parkinsonian symptoms, e.g. speech,quality, and by twenty-nine 
minutes post-dose the patient stated that he felt "a sensation of wanting to move". Yawning 
occurred at this time (thirty and thirty-three minutes post-dose). Although the 
aforementioned signs:and symptoms were indicative of a response to apomorphine, the 
response was considered to be sub-optimal as compared to the patient's typical experience. 
Indeed, the patient felt a sensation of being "underwater" at a time during the period of 
improvement in parkinsonian symptoms. Given the limited improvement in parkinsonian 
state; the walking test was not instigated during the time course, rather, priority was 
focussed on the tapping test in order to obtain a more comprehensive record of drug 
response. From eighty-six minutes post-dose onwards the patient became progressively 
tired and slept periodically for the remaining sampling period. There were no observations 
of adverse effects resulting from apomorphine administration. The patient admitted to 
disliking the tapping test throughout the entire pharmacodynamic monitoring period. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
anti-parkinsonian effect plot (Figure 5-2B) suggested that there was a direct relationship 
between plasma concentration and effect. 
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Figure 5-2 Panel A: Plasma apomorphine concentration/clinical status profile 
foDowing apomorphine bolus administration (5mg) to Patient 02. 
Panel 8: Relationship between plasma apomorphine concentration and 
anti-parkinsonian effect. 
Arrows indicate chronological ()rder of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine-induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "oft" phase. 
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Patient 03. 
Whilst patient 03 displayed an absence of action and resting tremor at baseline, other 
parkinsonian symptoms were present in a severe form, ie. marked impairment of speech, 
hypomimia, moderate rigidity of major joints, extreme abnormality of posture, and an 
inability to stand or walk even with assistance. There was also severe impairment in the 
performance of the tests of rapid, alternating hand movements, and the patient was unable 
to perform the tapping test at baseline. 
At twelve minutes post-dose the patient remained unable to depress the counter on the 
tapping tester. The anti-parkinsonian response amounted to a minimal improvement in leg 
mobility (which was noted by the clinician at twenty-two minutes post-dose) and a tapping 
test score of four taps per 30s at thirty-seven minutes post-dose (compared to a mean 
baseline _score in the other patients of 55 taps per 30s, range = 36 to 96 taps per 30s, n=7). 
Yawning occurred at forty-four minutes post-dose. Due to the degree of discomfort and 
anxiety expressed by the patient, the study was terminated at sixty-six minutes post-dose. 
See Figure 5-3 for plasma concentration-time profile. 
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Patient04 .. 
At baseline patient 04 exhibited moderately impaired speech and: moderate hypomimia. 
Tremor was present at rest and on action (to a slight to moderate degree). Rigidity was 
present in the major joints, ranging from a slight affiiction in·the lower extremities to a 
severe form at the neck. Moderate to severe impairment in ability to perform tests of rapid, 
alternating hand movements was demonstrated. Moderately abnormal posture, impaired 
postural stability and a severe. disturbance of gait were additionally observed. 
The time course of apomorphine administration is illustrated in Figure 5-4 A. Within two 
minutes of subcutaneous apomorphine injection the patient stated that he was "confused". 
Biaphoresis, yawning; micturition, dyskinesia, a feeling.of"giddiness"and drowsiness 
occurred variously in the twenty-three minutes that followed apomorphine administration, 
during ~hich time the tapping test scores were sub-baseline level. Whilst there was a 
general amelioration of parkinsonian symptoms, e.g. tremor, the episodes.of drowsiness 
and sleeping continued up to and beyond the point at which the patient stated that he was 
'just going off'' (at 129 minutes post-dose). 
This was not a typical response to apomorphine compared to the patient's usual experience 
with sweating and loss of bladder control in particular being novel occurrences. Clearly the 
patient exhibited a number of the common adverse effects attributed to apomorphine and 
for this reason the response was deemed a ''toxic" response. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
effect plot (Figure 5-4 B) suggested that there was no clear relationship existed between 
effect and plasma concentration. 
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Figure 5-4 Panel A: Plasma apomorphine concentration/clinical status profile 
following apomorphine bolus administration (lOmg) to Patient 04. 
A 
B 
Panel B: Relationship between plasma apomorphine concentration and 
anti-parkinsonian effect. 
Arrows indicate chronological order of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine-induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "off" phase. 
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Patient OS; 
At baseline,this patient exhibited moderately impaired speech and hypomimia. Resting 
tremor, action tremor, and rigidity of the major joints were considered' to be mild to 
moderate in.nature. Posture and gait were more severely affected and consequently the 
patient was·not able to rise from a chair or stand without assistance, and could not walk 
even with assistance. Repetitive, alternating tasks involving the hands were moderately to 
extremely severely impaired, to the degree.at which the task could barely be performed. 
The time course of plasma apomorphine concentration and clinical status following 
apomorphine bolus administration is illustrated in Figure 5-SA 
Within ten minutes of apomorphine bolus administration, an intense period of yawning 
occurred, and the patient stated that she felt "droopy" during this time. There began a 
period of improvement in.parkinsonian bradykinesia, as evidenced by the improvement in 
tapping test performance. At thirty-one minutes post-dose muscle cramp developed in· the 
lower left extremity. Muscle cramp returned intermittently over the following eleven 
minutes, and was more·severe than typically experienced by this patient. Shortly after this 
period the patient complained offeeling ''weak" and at sixty-two minutes post-dose, she 
requestedthe administration of further anti-parkinsonian medication, since she felt that the 
effects of apomorphine were beginning to wane. The tapping test score post-sixty minutes 
was at sub-baseline levels, but improved dramatically when assessed.two holD's later as a 
result of the administration of the further anti-parkinsonian medication. 'The apomorphine-
induced response was deemed to be sub-optimal compared to the typical response in terms 
of magnitude and quality of effect. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
anti-parkinsonian effect plot (Figure 5-SB) suggested that there was a direct relationship 
between plasma concentration and effect. 
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Figure 5-5 Panel A: Plasma apomorphine concentration/clinical status profile 
following apomorphine bolus administration (5mg) to Patient 05. 
A 
B 
Panel B: Relationship between plasma apomorphine concentration and 
anti·parkinsonian effect. 
Arrows indicate chronological order of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine.induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "oft" phase. 
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Patient 07 
The time course of plasma apomorphine concentration and clinical status following 
cessation of (24h) apomorphine infusion is illustrated in Figure 5-6. The last anti-
parkinsonian medication taken prior stopping the infusion was Sinemet CR; this was 
administered 3.5 hours prior stopping the infusion. Nine minutes after the infusion was 
stopped, the patient commented on ''feeling .. high". At this time abnormal involuntary 
movements were present; a symptom that was absent at baseline. At twenty-nine minutes 
after the infusion was stopped, the patient commented that he was "definitely going "off"'. 
At forty-five minutes after stopping the infusion, the patient experienced dystonia in the 
left foot (which persisted for approximately thirty minutes), and was unable to walk even 
with assistance, whereas at baseline unassisted walking was demonstrated. Despite 
resuming other anti-parkinsonian medication, the tapping test scores did not return to 
baseline level At 247 minutes after stopping the infusion, dystonia had returned and the 
patient commented that he felt "off'. 
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Figure S-6 Plasma apomorphine level and clinical status profile: Patient 07. 
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Patient:os~ 
The time course of plasma apomorphine concentration and clinical status following 
cessation of(24h) apomorphine infusion is illustrated in Figure 5-7. The last anti-
parkinsonian medication taken prior stopping the.infusion was Sinemet CR; this was 
administered approximately three hours prior stopping the infusion. 
Postural stability, gait, body bradykinesia and the ability to rise from a chair deteriorated 
from being minimally to mildly affected during the apomorphine infusion to being 
markedly or severely affected in the absence of apomorphine. There was only minimal 
deterioration in rigidity of the neck and of the lower extremities on cessation of the 
apomorphine infusion, and also in tasks involving rapid, repetitive hand movements such 
as pronation-supination motion, but not in tapping test performance, which actually 
improve~ on cessation of the apomorphine infusion. Potential factors which may have 
contributed to this unusual outcome include: inaccuracy in the baseline tapping test score, 
practice (or learning). effects, changes in the motivation of the individual, or the continued 
benefrt from controlled release levodopa medication (see page 6-31 for a discussion on the 
limitations of the tapping test). 
At 138 minutes after the infusion was stopped, the patient commented that she was "a bit 
dopey ... feel like I want a bit more strength". Approximately 60 minutes after this, anti-
parkinsonian medication was re-established. 
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Patient 09. 
The time course ofpJasma,apomorphine:concentration and clinical status following 
apomorphine bolus administration is illustrated in Figure 5~8 and a detailed patient 
commentary given by patient 09 is represented in Figure 5-14. 
The onset of apomorphine~ induced effect, at five minutes post-dose, was defined by the 
patient's comment that she was "loosening up". Cessation of effect was,defined 
subjectively by the clinician, who noted the recurrence of tremor. Some mild adverse 
effects were observed, e.g. yawning, which occurred intermittently during the ''on" phase. 
The effect of apomorphine on individual parkinsonian symptoms is documented below, 
whereby the assessment of effect was made forty-one·minutes post-dose. 
Speech 
Speech was impaired to a minimal degree both prior to and following apomorphine dosing. 
Facial expression. 
At baseline moderate hypomimia was observed; this was reduced to a minimal impairment 
following apomorphine administration. 
Tremor. 
Resting tremor, whilst mild to moderate in the "off'' state, was absent following the 
apomorphine-induced "on" state. Similarly, action tremor was improved from a slight 
impairment to·being absent. 
Rapid, repetitive hand movements. 
Performance was rated as being moderately to severely impaired at baseline. Improvement 
was observed in certain aspects of the set oftests, whereas in other aspects, apomorphine 
administration did not effect a change in performance. 
5-14 
Posture 
The,effectof apomorphine was to .improve the mild postural instability observed at 
baseline to nonnal postoral status. 
Gait 
Patient-09 displayed some.difficulty in walking,,however did not require,assistance in 
doing so. Following apomorphine administration walking ability was improved, but not to 
the point at which gait could be considered normal. 
Body bradykinesia 
The patient exhibited mild body bradykinesia and hypokinesia at baseline; symptoms 
which were improved· to following apomorphine administration, although a minimal 
impairm!,:nt was considered to .persist in'the "on" state. 
The patient rated the response to the apomorphine bolus as typical of that experienced 
under nonnal circumstances. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
anti-parkinsonian effect plot (Figure 5-88) revealed the existence of counter-clockwise 
hysteresis. This was indicative of an.indirect, i.e. time-dependant, relationship between 
plasma concentration and effect. 
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Figure 5-8 Panel A: Plasma apomorphine concentration/clinical status profile 
following apomorphine bolus administration (2mg) to Patient 09. 
A 
B 
Panel B: Relationship between plasma apomorphine concentration and 
anti-parkinsonian effect. 
Arrows indicate chronological order of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine-induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "off" phase. 
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Patient 10. 
At baseline the patient was affected by sciatica independently of parkinsonian symptoms. 
The patient identified leg stretching as a characteristic sign that he was switching "on". 
This sign occurred at four minutes post-apomorphine. A period of improvement in 
parkinsonian symptoms .then ensued until 23 minutes,post dose, when parkinsonian 
symptoms, e.g. bradykinesia, returned. The return to a parkinsonian "off' state was short-
lived, 'lasting only 3 minutes. The second period of improvement in parkinsonian 
symptoms ended at 82 minutes post dose; cessation of effect wa5 defmed by the by 
patient's increasing difficuhy moving, as evidenced by the tapping test score. Thetime 
course of plasma apomorphine concentration and clinical status following apomorphine 
bolus administration is illustrated in Figure 5,9, 
The effect ofapomorphine on individual parkinsonian symptoms is documented below, 
whereby the assessment of effect was made in the second period of improvement in 
parkinsonian symptoms. 
Speech and facial expression. 
Both were considered to be moderately impaired at baseline, and were improved following 
apomorphine administration,.although minimal impairments in both persisted. 
Tremor. 
Resting and postural tremor was absent both prior to and following apomorphine 
administration. 
Rigidity. 
At baseline rigidity was judged to be slightly affecting the right lower extremity, was mild 
to moderate in the neck and the left extremities, and was marked in the right upper 
extremity. Apomorphine did not effect a change in these parameters. 
5-17 
Rapid, repetitive hand·movements. 
Performance at baseline ranged :from being mild to severely impaired, depending on the 
exact test and hand used. Following apomorphine administration, performance was 
predominantly only mildly impaired. 
Posture 
Slight improvements in posture were observed following apomorphine administration, 
however there was no improvement in postural stability; this remained slightly abnormal. 
Gait 
Patient 1 0 displayed some difficulty in walking at baseline, but did not require assistance 
in doing so. Following apomorphine administration walking ability was improved, but not 
to the po.int at which gait could be considered normal. 
Body bradykinesia 
The effect of apomorphine was to improve the moderate bradykinesia and hypokinesia that 
was evident at baseline to a mild, but definitely abnormal, state. 
The patient rated the response to the apomorphine bolus as sub-optimal compared to 
typical experience. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
effect plot (Figure 5-9B) revealed that no clear relationship existed between effect and 
plasma concentration. 
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Figure 5-9 Panel A: Plasma apomorphine concentration/clinical status profile 
following apomorphine bolus administration (Smg) to Patient 12. 
A 
B 
Panel B: Relationship between plasma apomorphine concentration and 
anti-parkinsonian effect. 
Arrows indicate chronological order of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine-induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "off" phase. 
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Patient 12. 
The time course of plasma apomorphine concentration and: clinical' status following 
apomorphine bolus administration is illustrated in Figure 5-l 0. Onset of effect occurred!at 
nine minutes post,dose according to the patient's commentary. The period ofimprovement 
in parkinsonian symptoms lasted for sixty minutes, the cessation cif effect being defined by 
a reductionrintapping test scores to below baseline leveL 
The effect.ofapomorphine on individual parkinsonian symptoms is documented below, 
whereby the assessment of effect was made thirty-three minutes post-dose. 
Speech. 
Apomorphine had no effect on speech, which remained moderately impaired. 
Facial expression. 
There was moderate hypomimia at baseline, which was improved by apomorphine to what 
was considered a slight diminution of facial expression. 
Tremor. 
At baseline a slight resting tremor affected the face, lips, chin, hands and right foot. 
Additionally a slight postural tremor affected the right hand. The effect of apomorphine 
was to abolish tremor from the aforementioned regions. 
Rigidity. 
Apomorphine had no effect oil rigidity of the neck (which was markedly affected) or the 
lower left extremity (which was slightly affected). However, the mild to moderate rigidity 
in the upper extremities was reduced to a very slight level following apomorphine 
administration. 
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Rapill, repetitive hand. movements. 
Performance at baseline in,tests~ofrepetitive hand movements ranged from being mild to 
severely impaired; depending on the exact test and:hand used, Following apomorphine 
administration, improvement was seen m the majority of parameters, such that the 
performance was mild to moderately impaired. 
Posture 
It was demonstrated that postural reflexes were normal at baseline and that posture was 
only slightly impaired. These features·did not change.upon apomorphine administration. 
Gait 
Patient lO displayed a normal gait at both baseline and post apomorphine dosing. 
Body bradykinesia 
The effect of apomorphine was to improve the mild bradykinesia that was evident at 
baseline to a minimal movement impairment that could be considered normal for some 
persons. 
The patient rated the response to the apomorphine bolus as typical of that experienced 
under normal circumstances. 
Visual inspection of the (observed) plasma apomorphine concentration verses (observed) 
anti-parkinsonian effect plot (Figure 5-l OB) revealed the existence of counter-clockwise 
hysteresis. This was indicative of an indirect, i.e. time-dependent, relationship between 
plasma concentration and effect. 
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Figure 5-10 Panel A: Plasma apomorphine concentration/clinical status profile 
following apomorphine bolus administration (5mg) to Patient 12. 
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B 
Panel B: Relationship between plasma apomorphine concentration and 
anti-parkinsonian effect. 
Arrows indicate chronological order of occurrence. 
Filled squares indicate that, at the time of sampling, the patient 
was in an apomorphine-induced "on" phase. Open squares 
indicate that, at the time of sampling, the patient was in a 
parkinsonian "off" phase. 
5-22 
UPDRSPartiD Tapping Test 
T 
Patient Change in score: Time of"on" Change in score: Time of Onset of effect Duration , Quality of 
ID "off'' to "on"b phase rating baseline to peak maximum score of effect "on"• 
"on" scorec 
(% improvement) (mins post-dose) (% improvement) (mins post-dose) (mins post-dose) (mins) 
01 NA NA 11 17 and 57 12 44 Sub-optimal 
02 NA NA 11 49 29 96 Sub-optimal 
04 NA NA 21 47 8 121 Toxic 
05 NA NA 25 42 10 54 Sub-optimal 
09 31 41 50 51 5 70 Optimal 
10 10 43 22 39 4 78 Sub-optimal 
12 18 33 26 32 9 60 Optimal 
Table 5-l Anti-parkinsonian effect of subcutaneous bolus administration of apomorphine. Abbreviation: NA = not applicable 
• Relative to patients' usual experience. 
b Calculated using (("off" score- "on" score) I 108) x 100. 
• Calculated as ((peak "on" score - baseline score) I baseline score) x 100. 
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5.2. Preliminary Study Of Needle-Free Subcutaneous Injections 
Of Apomorphine In Parlcinson.'s Disease. 
The time courses of apomorphine concentration and pharmacodynamic response following 
needle-free administration are given in Figure 5-11 to Figure 5-13. 
The improvements in tap score and inHPDRS score in each case reflected the patients' 
rating of the "on" phase (Table 5-2, raw data is,given in Appendix 8.14 ). 
Some mild adverse effects were observed in or reported by patient 09, Le. ,the patient 
reported being "hot" and "light-headed", and was observed to be restless and flushed in the 
face. 'Rlese occurred following both apomorphine doses, but to a slightly greater extent 
following needle-free administration, see Figure 5-14. Yawning was observed in two 
patients following each treatment, and in the third patient as a result of needle-free 
apomorphine only (patient 12). 
Needle-free delivery was rated as the same or more painful than conventional delivery 
(Table 5-3). Administration of apomorphine resulted in slight bleeding at the site on two 
occasions, each following needle-free delivery (patient 10 trial2 and patient 12- see Table 
5-3). 
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conventional (panel A) and needle-free (panel B) delivery: patient 09. 
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UPDRS Part Ill TanPinl! Test 
Patient ID Change in score: Time of"on" Hand Change in score: Time of Onset of effect Duration Quality of 
"off' to "on" phase rating used baseline to peak maxiinum score of effect "on"• 11 on 11 score 
(% improvement) (mins post-dose) (%) (mins post-dose) (mins post-dose) (mins) ' 
09 CON 31 41 Right 50 51 5b 70c Optimal 
NF 29 26 29 48 3b 74c Optimal 
CON 10 43 11 39 4d 78e Sub-optimal 
10 NF 1 14 33 Right 33 30 4d 85f Optimal 
NF2 20 36 38 31 15d 1058 Optimal 
12 CON 18 33 Left 26 32 ~ 
I 
60i 
I 
Optimal 
NF 9 38 17 31 13j 45i Sub-optimal 
Table 5-2 Anti-parkinsonian effect of subcutaneous apomorphine administered by conventional (needle) and novel (needle-free) devices. 
• Relative to patients' typical experience. 
b Onset of effect was defined by patient's comment: "loosening up now''. 
c Cessation of effect was defined subjectively by clinician: "slowing down now'', tremor reCtnTing. 
d Onset of effect was defined by leg stretching - identified as a qualitative marker of apomorphine effect in this patient. 
e Cessation of effect was defined by patient's increasing difficulty moving, supporting evidence from tapping test score. 
f Cessation of effect was defined by patient's comment: "going "off"'. 
g cessation of effect was defined by patient's comment: "gone "off"'. 
h Onset of effect was defined by patient's comment: ''taken away dead feeling''. 
i Cessation of effect was defined subjectively by clinician, supporting evidence from tapping test score. 
j Onset of effect was defined by observation that body movement became more fluid, especially evident in right upper limb. 
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Local tissue reaction 
Patient Pain score Bleeding at Significant adverse 
No. 
9 
10 
12 
Table 5-3 
ID puncture site? 
Treatment (O=min, lO=max) 
CON 1 No 
NF 3 No 
CON I No 
NF I 1 No 
NF2 3 Yes 
CON 1 No 
NF 1 Yes 
Tolerability of apomorphine administration. 
Abbreviations: CON = conventional, NF = needle-free. 
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event? 
No 
No 
No 
Yes 
No 
No 
Yes 
0n each•occasion followmg·conventional delivery of apomorphine, there was no evidence 
of abnormal local tissue reaction on the study day. Follow-up on the .injection site was 
possible for patients 09,and 10 on day seven and day four, respectively. At this time, there 
had 'been no abnormal reaction at the site of injection. There was,no follow-up.on patient 
I2. 
Administration via the needle-free jet injection system produced a "bull's-eye" marking on 
the epidermis, the outer ring having been imprinted by the syringe and the inner dot, a 
pinprick-sized· spot of blood, at the actual puncture site (as described by Florentine et 
a/[2]). 
On two 9ccasions (patient 09 and patient I 0 trial 2) there was no abnormal local reaction 
following needle-free delivery of apomorphine during the study day. Confirmation was 
received from patient I 0 four weeks after the study day (needle-free trial2) that there had 
been no subsequent adverse reaction at the injection region. There was no follow-up. on 
patient 09. 
However an adverse local tissue reaction did occur as a result of needle-free delivery on 
the other two occasions (patient I 0 trial I and patient 12). In fact it was due to this 
development that patient I 0 volunteered to return for a second trial of needle-free delivery 
of apomorphine. 
In the case of patient IO (trial I) it was noted that at approximately four hours post-dose a 
region of approximately 15rnm in diameter around the injection site had become hardened. 
The indurated tissue was surrounded by a bruise which extended to approximately 25rnm 
from the injection point. The hardened area persisted for five weeks post-dose and the 
bruise, which was described as being vivid in colour (purple and pink),. remained present 
for a further week. This local tissue reaction was described as being distinct from the 
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bruising which1occasionally had been experienced as. a resuh of apomorphine 
administration via a needle. The latter was reported'to be very dark blue in colour, and 
present.only for ten to fourteen days post dose. 
In the case ofpatient 12, a very slightlyraised.and indurated region of approximately 
15mm in diameter around the injection,point was·noted:at 183 minutes post-dose and, 
whilst no further changes were recorded on the study day, bruising was present at follow-
up (ten days post-dose). The·bruising, which was purple/brown in colour at this time, 
affected an area of approximately 70mm in diameter around the injection site. A region of 
approximately 1 Ommin diameter directly surrounding the injection site, and corresponding 
to the cross sectional area of the J-TIP® syringe,.appeared entirely unaffected. 
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5.3. Pharmacokinetic Study of Single-Dose Intra-Nasal 
Apomorphine Powder (Three Doses) in Healthy Volunteers. 
Analysis ofthe residual apomorphine contained in the used capsules (and insuffiators) 
revealed that the mean amount of apomorphine released was 77.8% ofthe initial amount, 
with a range of8.0 to 97.0% (Penn Pharmaceuticals, UK, reproduced with permission), see 
Figure 5-15. 
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Figure S-15 Release of apomorphine from intranasal delivery system. Reproduced 
witb permission (Britannia Pbarmaceuticals Ltd, Redhill, UK). 
The apomorphine concentration in two series of plasma samples, i.e. the low dose 
intranasal dose for volunteers I and 2, was found to be below the assay detection limits. 
Plasma apomorphine concentration-time profiles for the remaining series are given in 
Figure 5-16 to Figure 5-21. 
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Figure 5-20 Plasma apomorphine concentration following subcutaneous and 
-
.. intranasal administration to volunteer 6. Initial potency of intranasal 
capsule is given in parentheses. 
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Figure 5-21 Plasma apomorphine concentration following subcutaneous and 
intranasal administration to volunteer 7. Initial potency of intranasal 
capsule is given in parentheses. 
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There were no serious adverse effects,observed as a result of apomorphine adlninistration. 
The adverse effects that did occur were those which are'commonly associated with 
apomorphine therapy in Parkinson's,disease. 'The highest incidence of adverse effects 
occurred afte~ the,high(5mg) intranasal dose (unpleasant or bitter taste, tingling·in1nostril, 
lethargy, difficulty in maintaining concentration), although the number ofreported'adverse 
events was not dissimilar to that reported for the mid (3mg) intranasal dose or the 
subcutaneous dose. The incidence ofadverse.effects following the low (lmg) intranasal 
dose was extremely small, probably as a result ofthe very low administered doses of 
apomorphine. Nasa1 examination revealed that there were limited cases:of mild, transient 
inflammation and crusting[3]. 
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5.4. Pharmacokinetic Study of Single-Dose Buccal Apomorphine 
(Three Doses) in Healthy Volunteers. 
Analysis of the residual apomorphine contained in the used inserts revealed that the release 
of apomorphine from the inserts was low and variable: the mean amount of apomorphine 
released was 9.6% of the initial potency, with a range ofO.l to 35.1% (Controlled 
Therapeutics (Scotland) Ltd, reproduced with permission, see Figure 5-22). This 
corresponded to a range of apomorphine doses ofO.Ol to 7.37mg over 120 minutes. It was 
evident that at each dosage level the greatest release of apomorphine occurred in the same 
individual, i.e. volunteer 1. 
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Figure 5-22 Release of apomorphine from buccal hydrogel inserts (Controlled 
Therapeutics (Scotland) Ltd, reproduced with permission. 
5-38 
In eleven of the eighteen buccal series apomorphine could not be detected in any plasma 
samples. Plasma apomorphine concentration-time profiles are given for the subcutaneous 
infusion series in Figure 5-23, and the remaining seven buccal series in Figure 5-24. 
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Figure 5-24 Plasma apomorphine concentration following buccal administration to 
healthy volunteers. Initial potency of buccal insert is given in 
parentheses. Detail shown in panel B. 
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· ln•accordance with the.in vivo swelling characteristics.ofthe hydrogel, there was a lag in 
the·timetaken for apomorphine to reach a detectable•concentration in the plasma, with·the 
exception· of volunteer I (all three doses). Volunteer I was also exceptional in that this·was 
the only indiv_idual for whom reasonable,delivery of buccal apomorphine, based on 
analysis of residual apomorphine in the used buCcal inserts (see Figure 5-22, page 5-38), 
was demonstrated. T<hese.two features indicate that there was superior hydration of the 
insert and/or desorption of apomorphine from the insert in this individuai compared•to the 
other volunteers in the study. Factors which might be.considered conducive to the superior 
buccal apomorphine release observed for volunteer I are.high salivary flow and/or low 
salivary pH, neither of which were monitored in this study. 
In contrast.to the predicted performance ofthe buccal insert in vivo (based on the.in vitro 
and in vivo buccal swelling tests, see Figure 4-4 and 4-5 on page 4-29), there was no 
evidence of a slowing down in the rate of absorption of apomorphine into plasma in most, 
i.e. five out of seven, cases. This suggested that drug release rate had not (yet) plateaued in 
the latter stages of in situ exposure to the insert. In the remaining two cases, T max occurred 
one hour after the removal of the insert, i.e. at 180 minutes post-commencement of 
apomorphine administration. 
The incidence oflocal adverse effects reported by the volunteers was minimal, and where 
such an event did occur, the effect was mild and transient[4]. 
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SECTION 6: 
][)ISCUSSION 
6. DiscUJission. 
6.1. Pharmacokinetic-Pharmacodynamic Study of Subcutaneous 
Apomorphine Administration in Patients withParkinson's 
Disease. 
It is acknowledged that, as a result of difficulties experienced in the recruitment of patients 
in sufficient numbers for this study, the findings of this investigation are limited by a lack of 
information regarding intra-patient and inter-variation in pharrnacokinetic parameters·and 
pharmacodynamic response following apomorphine administration. 
6.1.1. Pharmacoklnetic Analysis. 
Using the strategy given in Section4.6, pharmacokinetic modelling was perfonned on nine 
plasma concentration-time series. In the majority ofseries,a two-compartment model best 
described apomorphine pharmacokinetics, whereas a one-compartment model was superior 
in the remaining series; a finding entirely consistent with published data[l-3] (Table 6-1 ). In 
all but one case a lag-time (between drug administration and the onset of absorption) was 
required to adequately describe the plasma concentration-time profile following bolus 
dosing (see Appendix 8.15). 
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Figure 6-1 Predicted plasma apomorphine concentration following subcutaneous 
administration. 
Panel A: Bolus doses were 2mg: patients 01 and 09, 3.5mg: patient 10, 
Smg: patients 02, OS and 12, 10mg: patient 04. 
Panel B: Doses were 87J.Lg/kglh: patient 07, 26J.Lglkg/h: patient 08. 
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Table 6-1 
Pharmacokinetic Model: 
Patient ID first order input and output. 
Compartments La~-time? 
01 2 Yes 
02 1 Yes 
04 2 Yes 
05 1 No 
09 2 Yes 
10 2 Yes 
12 2 Yes 
(post-infusion) 
first-order output. 
07 2 NA 
08 1 NA 
Structure of models required in the modelling of apomorphine 
pharmacokinetics following subcutaneous administration. 
Where parameter estimates are given in the following discussion, these are expressed as 
mean (range, number of observations) of values (individual patient parameter estimates can 
be found in Appendix 8.16). 
As documented by previous authors (see Table 6-2), it was demonstrated that apomorphine 
undergoes rapid absorption, evidenced by the very brieflag-time, i.e. 3.8 minutes (1.8 to 
5.9, n=6), short Tmax, Le. 17.5 (10 to 27, YF7), and short absorption half-live, i.e. 4.1 
minutes (1.4 to 7.3, n=7). A large volume ofdistnbution, i.e. 1.9 L/kg (1.0 to 3.4, n=7) 
and rapid clearance from plasma, i.e. 2.21/kg/h (1.5 to 3.3, n=7), was demonstrated, also in 
accordance with available literature (see Table 6-3). Such properties have been attnbuted 
to the relatively high lipophilicity of apomorphine (log P = 2.15)[1, 4, 5]. 
6-3 
Publication Apomorphine Dose 
20f.lg/kg as standard 
Gancher£5] 1989 :::::1.4mg' 
30uglkg as standard 
::=2.1mg' 
Gancher(6] 1991 20f.lg/kg as standard 
1.45mg (1.4 and 1.5) 
Montastruc[7] 1991 3mg as standard 
Grandas[8] 1992 2.3mg (2 to 3) 
Nicolle[l] 1993 40uglkg as standard 
::=2.8mg' 
Hofstee[9] 1994 4mg (3 and 5) 
Ostergaard[ 1 0] 1995 3.4mg (0.8 to 6.0) 
Przedborski[ll] 19951, 50uglkg as standard 
:::::3.5mg' 
Sam[l2] 1995 2.9mg (0.9 to 5.1) 
36~g/kg (10 to 58) 
• assuming a body weight of70kg. 
b units were converted, e.g. from pmoVmL. 
c estimated using approximate dose (in mg). 
d AUC range was not presented in publication. 
e median value. 
~.of 
patients 
4 5.5 
12 9.2 
2 6.5 
9 20 
3 (2 doses 12S 
each) 
8 14 
2 15 
16 NP 
6 20 
6 18.2 
r non-parkinsonian subjects with suspected normal pressure hydrocephalus. 
8 AUC range was 0 to 2h. 
T, ... 
minute 
(CV=49%) 
(CV=47%) 
(5 and 8) 
(CV=20%) 
(10 to 25) 
(4 to 30) 
(10 and20) 
(5 to 45) 
(NP) 
(6 to30) 
Crux AUC (0 to infinity, unless stated) 
nglmL normalised to ng/mL.min nonnalisedto , 
lmgdose lmgdose 
14.6b (CV= 8%) 10 • ./'•C NA 503b (C.V. = 17%) 359b,c NA 
19.0b (CV= 48%) 9.rf·C NA 818b (C. V.= 32%) 39rf·0 NA 
22b (16 and 28) JS.rf (11 & 19) 656b (474 to 875) 461b (338 to 583) 
26 (CV= 19%) 9 NA 837" (C.V. = 18%) 27fJ1 NA 
25.9b (16 to 39) 10.8b (8 to 13) NP (NP) NP (NP) 
15 (7 to 36) 5.~ NA 802 (585 to 982) 28~ NA 
34.7 (22 and48) 8.4 (7and 10) NP (NP) NP (NP) 
NP (NP) NP (7to 32) NP (NP) NP 
nmoi/L 
25 (CV= 19%) 7.JC NA NP (NP) NP (NP) 
10.5 (5 to 23) 4.1 (1.3 to 6.4) 576 (222 to 1190) 21'? (80to 274) 
continued .. . 
Publication Apomorphine Dose N". of Tmu Cmu AUC (0 to infinity, unless stated) 
patients 
,. 
minute nglmL normalised to nglmL.min normalised to 
lmgdose lmgdose 
van Larr[l3] 1996 2.2 (1.0 to 4.0) 13 14.5 (5 to 30) 19.2 (6 to 53) 8.7 NA NP (NP) NP (NP) 
0.5mg as standard 3 45e (15 to 45) 2.9 (CV= 73%) 5.8 NA 1498 (C. V.= 28%) 2998 NA 
1mg as standard 10 30e (15 to 90) 4.0 (CV = 43%) 4.0 NA 3668 (C.V. =74%) 36()8 NA 
Harder[3] 1998 2mg as standard 10 30e (15 to 120) 12.8 (CV= 42%) 6.4 NA 9828 (C.V. =53%) 4918 NA 
4mg as standard 8 30e (15 to 90) 14.1 (CV=47%) 3.5 NA 12978 (C. V. = 52%) 32-iB NA 
This study 1996- 4.6mg (2 to 10) 7 17.5 (10 to 27) 27.8 (11 to 61) 6.6 (2.2 to 10.7) 2020 (754 to 4861) 430 (257to 628) 
1999 67ug/kg (35 to 167) n=7 
c.v. =33% C. V. =42% C. V. =30% 
Table 6-2 Mean (range) pharmacokinetic parameters following single-dose apomorphine administration by subcutaneous bolus to patients with 
Parkinson's disease. 
Where the ranges ofpharmacokinetic parameter estimates were not available, the C. V. has been calculated using the mean and S.D. 
given in the publication. 
Abbreviations: NA = not applicable, NP =data not present in publication. 
8 AUC range was 0 to 2h. 
Publication Apomorphine dose ~.of Clearance (Apparent) t Y2 absorption• t Y2 distributionb t Y2 eliminatione 
patients Volume of 
distribution I 
l1k2/h Llk2 minute minute minute 
I 
Gancber[5] 1989 4 -2.5 -1.5 NP 4.8 (CV=23%) 33.6 (CV=12%) 
n=ll n=15 
Nicolle[l] 1993 40ug/kg as standard 8 3.1 (2.5 to 4.0) 3.5 (CV=17%) NP 15 (7 to 25) 72 {61 to 93) 
::q,8mgd n=4 
Hofstee[9] 1994 4mg (3 and 5) 2 NP ::::1.1a 6.4 (5.5 and 7.6) 7.2e 56.0" 
Sam[l2] 1995 2.9mg (0.9 to 5.1) 6 4.2 (3.1 to 7.1) 2.7 (1.2 to 4.1) 5.8 (0.2 to 15.2) NP 27.4 (CV=14%) 
36J..tg/kg (10 to 58) 
Ostergaard [ 1 0] 1995 3.4mg (0.8 to 6.0) 16 NP NP NP NP -30.0 (14.6 to 68.4) 
van Larr[l3] 1996 2.2mg {1.0 to 4.0) 13 ::q.4d NP NP NP NP 
van Laar[4] 1998 10 to 1001-lg /kglh 10 ::::3 .9d NP NP NP NP 
intravenous 
van dGeest[2] 1998 30~-Lg/kg x 1 5min 10 2.4 (1.4 to 4.1) 1.6 (0. 7 to 2.2) NP NP 41.0 (20.2 to 62.5) 
intravenous 
[Neef[14] 1999 Population PK analysis: several ::q,} 1.4 (CV =16%) 5.1 (CV=24%) NP 27.2 (CV=17%) 
studies,23 patients, various doses 
This study 1996- 4.6mg (2 tolO) 7 2.2 (1.5 to 3.3) 1.9 (1.0 to 3.4) 4.1 (1.4 to 7.3) 13.5 (7.1 to 23.5) 69.5 (36.3 to 98.6) 
1999 67ug/kg (35 to 167) c.v. =24% C.V.=44% C.V. =55% C. V.= 52%,n=5 C.V.= 30% 
Table 6-3 Mean (range) phannacokinetic parameters following single-dose apomorphine administration by subcutaneous bolus to patients with 
Parkinson's disease. Abbreviations: NA =not applicable, NP =data not present in publication. 
• quoted in publication as "absorption half life", or calculated using (In 2)/.KO 1. 
b quoted in publication as "distribution half life", or calculated using (In 2)/alpha. 
c quoted in publication as "elimination half life", or calculated using (ln 2)/K10 or (In 2)/beta for one- or two-compartment pharmacokinetics respectively. 
d assuming a body weight of70kg. 
e estimated using micro-constants given in publication. 
A linear relationship between C....,. and bolus dose was demonstrated (If= 0.8869, p<O.OOl 
over the•dose range (2 to 10 mg, 35 to 1667J.Lg/kg,,n=8)". Similarly, a linear relationship 
between ANC and'bolus·dose was demonstrated' (If = 0.9265, p<O:OOl•) over the,dose 
range (2 to 10 mg, Le. 35 to 1667J.Lg/kg, n=7). 
6.1.1.1. Inter-Patient Variation ;In. Apomorphine Phannacokinetics. 
'Ihere was considerable inter-patient variation~in Trmx. dose-normalised AUCo.inrmi~y and 
dose-normalised'Cm.x. i:e, 33, 30 and 42%,respectively. Inter"patient variation~in 
apomorphine absorption following subctitaneous administration is widely descn"bed [1, 2, 5, 
15]. It has been shown that factors which alter local blood flow, i.e. temperature of skin in 
the. region of administration, alter apomorphine absorption[5]. Also, local adverse reactions 
(infla~tion) which are induced by chronic apomorphine administration have been known 
to affect absorption[ ]. 
On the basis of visual inspection of the AUCo-infinity, and C"'""' versus dose plots it was 
considered that apomorphine absorption was not affected by administration site (Figure 
6-2). This finding is in contrast to the report by Nicolle eta/, in which a trend towards 
more complete absorption following injection in the abdominal wall compared to the thigh 
was observed[ I]. T max was not dose-related (If= 0.0046,p=0.8730, n=8)·and was also not 
influenced by administration site. 
Dose-normalised AUCo-iniinity was not correlated with age, weight, duration of disease, 
duration ofL-dopa therapy, duration of apomorphine therapy, disease severity (in terms of 
Hoehn and Yahr score), or related to gender (n=7 except HandY score where n=6). 
Dose-normalised Cmax was not correlated with age, duration of disease, duration ofL-
dopa therapy, duration of apomorphine therapy, disease severity (in terms ofHoehn and 
Yahr score), or related to gender (n=7 except H&Y score where n=6). 
• This correlation was based on predicted C...., with the exception of data from. patient 03, which was the 
observed C....,.. Data from.patienl 03 was included in the correlation in order to Jessen,the leverage that may 
be exerted by the outlying data at 1667J.lgfkg dose (adjusted fur body weight). 
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Figure 6-2 Correlation between dose (adjusted for body weight) and 
pharmacokinetic absorption parameten following subcutaneous bolus 
administration of apomorphine to patients with Parkinson's disease. 
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6.1.2~ Key Pharmacodynamic Events. 
Where response data is given in the following discussion, these are expressed as mean 
(range, number of observations):ofvalues. Individual data is given in Table 5-1, page 5-
23). 
&: 1.1.2. l:.atency to Onset of Anti-Parkinsonian Effect 
The ,latency to onset of effect following apomorphine bolus administration was short, i.e. 12 
minutes ( 4 to 29, n=7) and the duration of effect was brief: i.e. 72 minutes ( 44 to 144, n=7). 
(see Table 5.1, page 5-23). These data compare well with published data on apomorphine-
induced anti-parkinsonian effect[ 17-21 ], and correspond with the rapid absorption and 
elimination processes observed for apomorphine. 
T max occuired after the onset of effect in the ~rity (517) of cases; i.e. between 3 and 14 
minutes after the time of onset of effect in individual patients (Figure 6-4). In the remaining 
two cases, T max preceded the onset of effect, by 2 minutes on both occasions. The short 
latency to onset of effect, especially given the relation to T max. is indicative of a rapid 
equilibration of apomorphine between blood and the site of action in the brain[2, 3]]. 
Again, the high lipid solubility of apomorphine is considered to be an important factor in 
this[1, 4, 22]. 
The time of onset of effect was not correlated to T max (R2=0.0474, p=0.6045, n=7)or to 
dose adjusted for body weight (R2 =0.0206,p=0.7591, n=7. Additionally, neither AUCo. 
infinity (absolute or dose-normalised) nor Cn..x (absolute or dose-normalised) were correlated 
to the latency to onset (R2 =03253,p= 0.1813, n=7, and K =03327,p= 0.1344, n=8, 
respectively). 
6-12 
10 .-------------------------------------------------~ 
', 
I ' I ' 
I ', 1-------..::_,--___ __, 
----
• Onset of effect 
• Cmax 
• Maximum tap score 
x Cessation of effect 
--Trend 
I 
I 
I 
I 
----- I 
I r --------
0+-~l~+-~~+-~~1-~~~~~~~~-r~~~~~~ 
0 15 30 45 60 75 90 105 120 
Time (mins post-dose) 
Figure 6-4 Mean (dose-normalised) plasma apomorphine concentration at key 
pharmacodynamic events following subcutaneous bolus administration. 
,. Error bars show +/- 1 S.D. (n=7). 
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6.1.1.3. Duration of Anti-Parkinsonian Effect 
The duration of effect was not related to dose. Neither AUCo-inlinity (absolute;or dose-
normalised} nor Cm.x (absolute or dose-normalised) were correlated to the duration·of effect 
(R2 =0:0049,p= 0.8818, n=7, and R2 =Oi0798,p= 0:5394; n=n Some investigators have 
reported that duration of effect was.correlated to dose[5, 23]. 
In accordance with the observations ofSamet a/, the mean residence time, i.e. 77 minutes 
( 49 to I 03, n=7) was similar to the mean duration of effect, Le. 74 minutes ( 44 to 121, 
n=7), suggesting that the onset and termination of effect is determined by the parent drug, 
and not by a metabolite or second messenger[12]. However if the dirta is considered for 
individual patients, it can be shown that the mean residence.time was equivalent to the 
duration of effect in four cases and dissimilar in the remaining three, and therefore this 
aspect remains inconclusive for this group of patients. 
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6.1.1.4. Magnitude of Effect 
The magnitude of apomorphine-induced anti-parkinsonian effect (in terms of maximwn 
improvement in tapping test score from baseline) was not dose-related. Additionally, 
neither AUCo-intinity (absolute or dose-nonnalised) nor Cmax (absolute or dose-normalised) 
were correlated to the magnitude of effect (if =0.3334,p= 0.1746, n=7, and R2=0.1408,p= 
0.4069, n=8, respectively). 
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Figure 6-5 Mean dose-normalised AUCO-idlllty (Panel A) and Cmu (Panel B) 
following subcutaneous apomorphine bolus administration, grouped by 
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The maximum improvement in tapping test score from baseline was 24% (11 to 50, n=1) 
(raw data is given in Appendix 8.14 ). The threshold for positive apomorphine-induced 
anti-parkinsonian response is given as 15 % (e.g. in the apomorphine titration protocol[24 ]), 
20% (e.g. O'Sullivan and Lees[19]) or 25% (e.g. Danhof et a/[15]) improvement in 
tapping test score from baseline. It can be seen from Figure 6-6 (and Table 5.1, page 5-23) 
that, for this group of patients, a threshold of(at least) 25% improvement in tap score best 
reflects the threshold for positive response in terms of the patients' rating of the response. 
The finding that routine (previously optimised) apomorphine doses elicited sub-optimal or 
toxic responses was attributed to the effect of wash-out of other anti-parkinsonian drugs. 
Hutchinson et al observed that anti-parkinsonian drug withdrawal for longer than 12 h 
prolonged the onset of effect of an apomorphine bolus and increased the likelihood of a sub-
optimal clinical response to a previously effective dose[25]. 
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6.1.1.5. Adverse Effects. 
Apomorphine-related adverse events, e.g. diaphoresis and dyskinesia, occurred within two 
minutes of administration ofbolus apomorphine to patient 04 and continued until 
approximately T max (Figure 6-7). Additionally, drowsiness continued throughout the whole 
period of effect. Given that only a single dose was administered, the threshold for adverse 
effects could not be determined. 
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Figure 6-7 Plasma apomorphine concentration at key pharmacodynamic events 
following subcutaneous bolus administration (lOmg) to patient 04. 
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6.1.1.6. Evaluation of Beta-Phase Intercept in Relation to Anti-Parkinsonian 
Response. 
Values for the beta-phase intercept ranged from 0.4 to 11.3 ng/mL (n=6) (Table 6-4). 
There was a lack of correlation between the beta-phase intercept and response, in terms of 
magnitude of effect (R2=0.2187, p= 0.4270, n=5), and also in the terms of the patients' 
rating of the response compared to their typical experience (Table 6-4); the lack of a 
distinction between beta-phase intercept values associated with sub-optimal and optimal 
apomorphine-induced anti-parkinsonian responses is illustrated in Figure 6-8. It was 
therefore demonstrated that the beta-phase intercept did not represent a threshold 
concentration for effect, and as such was shown to be of no predictive value. Thus it is 
likely that the consistency in this parameter observed in the historical data (Tables 2-1 and 
2-2, page 2-3) was coincidental. 
Patient ID Apomorphine dose Beta-phase Improvement Quality of 
mode mg Jlg/kg 
intercept in Tap Score "on" phase 
(nwmL) (%) 
01 bolus 2 41.7 11.3 11 Sub-optimal 
04 bolus 10 166.7 0.4 21 Toxic 
07 infusion 87 .2J.Lg/kg/h 10.5 (-55) Optimal 
09 bolus 2 35.1 3.5 50 Optimal 
10 bolus 3.5 47.3 5.8 22 Sub-optimal 
12 bolus 5 55.6 7.7 26 Optimal 
Table 6-4 Beta-phase intercept values and apomorphine-induced response. 
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6.1.3, Phannacokinetic-Pharmacodynamic Analysis. 
Havingrexplored the.relationsliiprbetween post-distributional apomorphine pharmacokinetics 
and·anti-parkinsonian effect, another approach was emplOyed in the investigation of 
apomorphine pbarmacokinetic-pbarmacodynamic relationships. This approach was based 
on the findings,ofthe initial exploration of the relatlonship.between observed plasma 
apomorphine concentration and:observed effect (see Section 6.1). To summarise these 
findings. in the case of patients 01, 04 and 10 it was found that no clear relationship existed 
between effect and plasma concentration. Two of these patients (patients 01 and 1 0) 
experienced a bi-phasic "on" phase which could not be descn'bed using standard 
pharmacodynamic models. In the case of patients 09 and 12, there was evidence of 
counterclockwise hysteresis, indicating the existence ofan,indirect relationship~between 
plasma apomorphine concentration and effect. In contrast to this there was little or no 
hysteresis in the case of patients 02 and 05, the implication here being that a direct 
relationship between plasma apomorphine concentration and effect was involved. 
Given the variation in the plasma concentration-effect relationship of apomorphine in this 
group of patients. it was considered necessary to investigate both direct (i:e. time-
independent) and indirect (i.e. time-dependent) pbarmacokinetic-phannacodynamic models. 
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6.1.1. 7. Direct Phannacokinetic-Phannacodynamic Models. 
Initially basic pharmacodynamic models, Le. logarithmic and hyperbolic effect models, were 
fitted to the concentration-effect data, and discrimination between competing models was 
undertaken using the criteria given in Section 4.6, page 4-103). The sigmoid Emax model 
was identified as the appropriate model by these criteria. The predicted change in tapping 
test score following apomorphine administration according to this model is illustrated for 
patients 02, 05, 09 and 12 in Figure 6-9. 
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Figure 6-9 Predicted apomorphine-induced effect following subcutaneous bolus 
administration according to the sigmoid Emu model•. 
Whilst satisfactory fit (based on the criteria given m Section 4.6) was achieved in the cases 
of patients 02, 05 and 12, model mis-speci:fiation was apparent in the case of patient 09, 
based on the magnitude of the residuals and the large C. V. associated with the final 
parameter estimates (C. V. < 20000%). The use of a direct pharmacokinetic-
pharmacodynamic model may appear to be in conflict with the observation that the 
maximum effect occurred after T max (approxnnately 20 minutes later), however the lack of 
hysteresis observed for patents 02 and 05 can be explained by the existence of a (very) rapid 
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equilibrium of apomorphine with the effect site[3, 26]. The pharmacokinetic-
pharmacodynamic parameters of apomorphine according to the sigmoid Emax modela are 
summarised in Table 6-5. 
Publication/ Emu ECso Hill eo- KEo 
Patient I.D. (change in efficient (y) 
tap score, %) (nglmL) (min-1) 
Harder NA 6.0 9 0.10 
_{n=12)[3] (2.3 to 11.2) (3 to 25) (0.05 to 0.14) 
This study 
01 No relationship detected. 
02 7.4 7.7 6.6 
04 No relationship detected. 
05 25.2 20.3 10.0 
09 58.8 12.6 0.2 
10 No relationship detected. 
,. 12 15.1 5.8 4.9 
Table 6-5 Pharmacokinetic-pharmacodynamic parameters of apomorphine 
according to the sigmoid Emu modeL 
Parameter estimates reproduced from Harder[3] are expressed as the 
median (range) according to sigmoid Emu modeL 
Abbreviation: NA = not applicable. 
Values for the Hill co-efficient were large (excluding patient 09), thus indicating that the 
relationship between plasma apomorphine concentration and effect was an "all or nothing" 
(dichotomous) phenomenon[27]. 
Where a steep sigmoidal concentration-effect relationship exists, ECso is considered to be a 
threshold concentration for effect[3]. In the cases of patients 02 and 05, ECso was a 
reasonable approximation of the plasma apomorphine concentration at onset of effect, ie. 
11 and 26 ng/mL respectively. In contrast, there was little agreement between ECso and the 
plasma apomorphine concentration at onset of effect for patient 12, i.e. 34 ng/mL. Due to 
the small number of patients involved it was not possible to make a judgement on this issue. 
a E = (Emax . C') I (C1 + ECso'). 
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6.1.1.8. Indirect Phannacokinetic-Pharmacodynamic Models. 
Sigmoid Emax Phannacodynamic Model. 
This model was comprised of the previously identified pharmacokinetic model which best 
described the time course of apomorphine concentration in plasma for a given patient, 
linked via an effect compartment to the sigmoid Eu.x pharmacodynamic modeL An example 
is given in Figure 6-10. 
subcutaneous 
bolus dose 
Ce 
Figure 6-10 Schematic representation of the effect compartment model used for 
patient 09 and 12: two-compartment, first order input (lagtime) 
phannacokinetic model with an effect compartment, whereby effect is 
described according to the sigmoid Emu modeL 
Abbreviations: 1 = central compartment , 2 = peripheral compartment, 
Ce = drug concentration in effect compartment, E = effect 
compartment, K01, K10, K12, K21 =compartment rate constants. 
However this particular solution was rejected for each patient dataset on the basis that 
predicted data did not reflect trends in observed data, i.e. estimates ofEmax were up to 100 
times the observed maximwn effect, and model parameters estimates were associated with 
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unacceptably large C.V.s. 1lhis otitcome:indicated that model mis-specification'has 
occurred, ie. the Emax model had been,applied to effect data which did not exhibit 
saturable behaviour (in the observed concentratiomrange). 
The effect compartment( sigmoid E.n.xpharrilacodynamic) modelhas previously been 
applied to subcutaneous bolus administration of apomOrphine in patients with Parkinson's 
disease by Harder et a/[3] and consequently information on Emax has in fact been 
successfully· derived. The contrast in outcome, between the study by Harder et a/ and the 
study presented in this thesis, following application of the effect compartment (sigmoid E.n.x 
pharmacodynamic) model might be expected due to differences in the(mean) apomorphine 
phannacokinetics of the patients in each ofthe.two studies; whilst the mean1Cmax was 
similar for each, it appeared that there was a difference in clearance between the two, ie, 
r, 
. the mean concentration of apomorphine at 120 minutes,post-dose was approximately 74% 
of that at Cmax in the case of Harder et a/, and only 17% for the patients presented in this 
thesis. 
The absence of a clearly defined E.n.x is likely to be the result of a deficiency in the 
experimental design, i.e. the non-steady state design. The study of apomorphine under non-
steady state conditions (and in the absence of continuous pharmacodynamic monitoring), 
was problematic in that, as a consequence of the short absorption and elimination half-lives 
and the brief period of effect, the observed plasma apomorphine concentration range was 
not sufficiently large enough nor sustained for long enough to efficiently sample the 
pharmacodynamic response. For these reasons it would be more appropriate to conduct the 
pharmacokinetic and pharmacodynamic sampling under multiple plasma pseudo-steady state 
. conditions since this strategy allows more time, compared to the administration of a single 
bolus dose, for multiple measurements of response to be performed[28). Consequently a 
more reliable definition,ofthe concentration-effect relationship is likely to result. If applied 
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correctly this approach· is considered to be the "gold standard" in the elucidation of 
concentration-effect relationships in vivo[29.]. This· approach was used' by van Laar et al in 
the characterisation of the therapeutic window of apomorphine in Parkinson's disease[ 4]. 
A further contnbutory factorto the absence of a clearly definable Emax may be one of 
insufficient pharmacodynamic sampling during the response. Ahhough, generally, 
pharmacokinetic and pharmacodynamic sampling is performed simultaneously, the 
pharmacodynamic sampling scheme could have been optimised mdependently of the plasma 
sapling scheme in an attempt to·cbaracterise peak effect[30]. It should, however, be taken 
into· consideration that the use of a more intensive pharmacodynamic sampling scheme 
might induce fatigue and/or loss of motivation on the part of the· patient which in turn may 
increase pharmacodynamic variability[31 ]. 
The choice of pharmacodynamic tool may also have contnbuted to the inability to model 
Emax in that the tapping test lacks a definitive maximum score, in·contrast to the gradation of 
response that a rating scale e;g. Webster rating scale, offers. In the light of this, attempts 
were made to re-define the range of effect, Le. (i) the maxirnum·tapping test score for each 
patient was assigned as 1 00% improvement from baseline, and other tapping test scores 
were redefined accordingly, and (ii) a simple scoring system was constructed whereby 0 = 
"otr, 1 =between 0 and 20% improvement in score, and 2 =greater than 20% 
improvement in tap score. However, there remained an absence of a plateau in response 
with increasing plasma concentration and so such data transformations were proved not to 
be useful 
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Exponential Pharmacodynamic Model. 
In the light of the mis-speci:fication of the Elll8X model, an exponential pharmacodynamic 
model was substituted for the sigmoid Emax model (Box 6-1 and Appendix 8.17 .1 ). This 
was based on.the observation that, according to the effect compartment (sigmoid Emax 
pharmacodynamic) model, an approximately linear relationship existed between lo~ (effect) 
and apomorphine concentration in the effect compartment (Figure 6-11). 
E = Eo . ell·ee 
where 
• Eo is the baseline effect, 
• TJ js the slope factor for the relationship between the concentration of drug in the 
effect compartment and lo~(effect), 
• Ce is the drug concentration in the effect compartment. 
Box 6-1 '" Exponential pharmacodynamic model. 
5 ~------------------------------------------------. 
4 
• 
• 
• Patient09 
:c Patient 12 
- Linear (Patient 09) 
- Linear (Patient 12) 
0 +---~--~--~--~--~---+--~--~----~--+---~~ 
0 4 8 12 16 20 24 
[Apomorphine]biopb.ase (nglmL) 
Figure 6-11 Relationship between loge-transformed pharmacodynamic data and 
predicted apomorphine concentration in the effect compartment, 
according to the effect compartment (sigmoid Emu) model 
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The application ofaneffect compartment.model which incorporated exponential 
pharmacodynamics allowed a satisfactory fit ofthe:concentration-effect relationship 
observed for patients 09 and 12 (only). The'predicted apomorphine concentration-effect 
relationship·aGCOrding to this model is illustrated using data from patient 09 in Figure 6-12 
and Figure,6-13, 
The inherent limitation of this approach wasthe absence of information relating to maximal 
apomorphine-induced anti-parkinsonian effect. An,additionalconstraint was that the 
exponential pharmacodynamjc model did not allow a meaningful. definition oH~0• Using 
patient 09 as an example in order to elaborate on this issue; the final'estimate for Eo was 
given as 6% improvement from baseline according to the exponential dylliunic modeL There 
was an obvious disparity between the estimate of baseline effect and,actual baseline 
response, the latter having been defined as zero improvement from baseline. Since this 
model did not allow a value of zero for Eo this parameter was fixed at a value of I%, as an 
approximation of baseline effect. 
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In the cases of patients 02 and 05, the predicted time course of effect compartment 
apomorphine concentration and plasma apomorphine concentration were essentially 
superimposed, indicating that a direct pharmacokinetic-pbarmacodynamic model was indeed 
the appropriate solution. 
The pharmacokinetic-pharmacodynamic parameters of apomorphine according to the effect 
compartment model are summarised in Table 6-6. 
Table 6-6 
Publication/ Keo t%Keo Slope 
PatientLD. (Teq} factor 
(min-1) (min) (11) 
Harder 0.10 7 
(n=12)[3] (0.05 to 0.14) (5 to 13) n=7 NA 
This study 
01 No relationshi__g detected. 
02 NA NA NA 
04 No relationship detected. 
05 NA NA NA 
09 0.042 16.5 0.38 
10 No relationship detected. 
12 0.084 8.3 0.13 
Pharmacokinetic-pharmacodynamic parameters of apomorphine 
according to the (exponential pharmacodynamic) effect compartment 
model 
Parameter estimates reproduced from Harder[3] are expressed as the 
median (range) according to the sigmoid Emu modeL 
Abbreviation: NA =not applicable, Teq = equilibration half-time. 
The short equilibration half-time (Teq), i.e. 16.5 and 8.3 minutes in patients 09 and 12 
respectively, accounts for the rapid onset of anti-parkinsonian effect and reflects the rapid 
passage of apomorphine across the blood-brain-barrier[3]. This feature of the 
concentration-effect relationship of apomorphine has been attnbuted to the high lipophilicity 
of apomorphine[3]. 
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6.1.4. Considerations in·the Use of· the Tapping Tester. 
The strategy taken for the study of apomorphine pharmacokinetic-pharmacodynamic 
relationships presented in• this thesis wouldi likely have benefited from·the incorporation of 
more rigorous· pharmacodynamic monitoring. Whilst the ·tapping .test·reflected well the 
global clinical response (evidenced, for example, by the agreement between maximum 
improvement in' tap score and the•patients' rating of response), the tool is lacking in a 
. number of the features that are eonsidered to be desirable in a pharmacodynamic monitoring 
system[28, 30, 12, 33]. These limitations of the tapping test include:-
(i) The range of outcome values. 
• The tapping test does not possess an explicit miniinum and maximum value. This 
potenlially introduced problems in pharmacokinetic-pharmacodynamic modelling, 
especially since the·number of observations was low. (The lack of a pre-defined range 
does, however, allow flexibility in the application of the tapping test as a 
pharmacodynamic tool, i.e. the task can be applied to patients with different baseline 
and/or peak motor function, since each patient acts as their own control.) 
• The absence of a direct relationship between tapping test performance and anti-
parkinsonian response, i.e. adverse effects that occur at supra-threshold levels of 
dopaminergic stimulation (e.g. dyskinesia, postural hypotension, neuropsychological 
effects such as confusion, somnolence,.nausea- the latter being specific to 
apomorphine) have the potential to impair performance in the tapping test. In this 
respect, the tapping rate at ''toxic" apomorphine levels may not be distinguishable from 
that at baseline or "sub-optimal" levels. 
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(ii) The invalidity oftbe test. 
Tapping'test perfonnance has, been shown to,correlate well with other measures of 
parkinsonism[34], e;g. the rigidity rating ofthe,ColumbiaUniversity Rating Scale[3'1 ], and 
change in score for the modified Webster scale[35]. That having'been said, the(restored) 
ability to execute repetitive precise movements of the upper extremity due to administration 
of apomorphine may not necessarily translate to an improvement in other, perhaps more 
troublesome, parkinsonian symptoms, e.g. painful dystonia of the lower extremity, in 
individual cases. In this respect the tapping test may be considered to be lacking in clinical 
relevance. 
(iii) The influence of psychological status. 
Motor function at any given time is clearly dependent on the physiological and biochemical 
status of the motor centre ofthe CNS, however tapping test perfonnance is potentially 
influenced by changing psychological status during the sampling time course. As with other 
performance tasks, the tapping test relies heavily on the active co-operation of the subject. 
It is likely that the patients' motivation varied during the sampling time course, as that 
phannacodynamic variability was introduced as a direct consequence ofthis. It is 
noteworthy that the baseline tapping test performance was assessed at the point where 
patients were undergoing a protracted parkinsonian "off" state as a result of the prolonged 
drug wash-out period. It was at this point that a lack of motivation, and feelings of 
depression and anxiety were likely to be at their'highest level (resuhing in the case of one 
patient in the withdrawal from the study). Clearly it might be expected that a general 
improvement in psychological status may result from the amelioration of parkinsonian 
symptoms following administration,ofapomorphine, and with that, a different approach to 
the tapping task. 
6-31 
(iv) Learning effects. 
There is evidence to,show that (at least) two attempts'at the task are required to establish a 
stable baseline motor performance[31; 34, 3sr It must, however, be taken into 
consideration that substantial repetitionofthe task at baseline may be difficuh for some 
patients in the "off' state[31, 34]. 
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6; 1.5. Summary of outcomes in the:study:of the pharmacokinetic-
pharmacodynamics of subcutaneous apomorphine,in patients with 
Parkinson~s disease. 
The investigation of apomorphine pbarmacokirietics andipbarmacodynamics·in,patients with 
Parkinson's disease was designed primarily as an exploration of the relationship between the 
beta-phase intercept and clinical·response. This was a nove}approach in. the study of 
apomorphine pharmacokinetic-pharmacodynamic relationships and was based on 
observations of an apparent correlation between this particular pharmacokinetic parameter 
and the anti-parkinsonian effect in general terms. 
However it was demonstrated that the beta-phase intercept was unrelated to apomorphine 
pharmacodynamics (in terms of improvement in tapping test score from baseline) and 
f: 
therefore was of no predictive value in the patients studied (n--6). The correlation between 
the beta-phase intercept and response initially observed in the literature was therefore 
interpreted as co-incidental. 
According to the traditional two-stage approach to data analysis, there was a short 
absorption half~ life, i.e. mean (S.D.) of 4.1 (2.1). minutes, short elimination half life, i.e. 69.5 
(21.1).minutes, rapid clearance from plasma, i.e. 2.2 (0.5) Llkglh, and the volume of 
distnbution was 1.9 ( 0.8) Llkg . The typical features of apomorphine-induced anti-
parkinsonian effect following subcutaneous bolus were observed, e.g. the short latency to 
onset of effect, i.e. 12 (8)minutes, and.the brief duration of effect, ie. 72 (25) minutes. 
Simultaneous pharmacokinetic-pharmacodynamic modelling was perfonned, using an effect 
compartment (exponential pharmacodynamics) model to account for counterclockwise 
hysteresis in a sub-group of patients (n=2). The equilibration half-life was short, i.e. 8.3 and 
16.5 minutes. The limitations of this approach were that neither baseline nor maximal 
apomorphine-induced anti-parkinsonian response could be predicted. 
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A direct pharmacodynamic (sigmoid E.n.xJ model was applied to series where hysteresis in 
the plasma concentration-effect plot was not evident (n=2). 11he absence of 
counterclockwise,hysteresis in these ,patients was attributed to a ~very}rapid equih'brium of 
apomorphine with the effect site. 'fhe drug concentration which produced 50% of 
maximum effect (ECso) was 7.7 and 20.lng/mL. Valuesfor the Hill co-effiCient were large, 
i.e. 7 and 10, indicating that the relationship between plasma apomorphine concentration 
and effect was an "all or nothing" (dichotomous) phenomenon. 
Whilst the experimental design, i.e. single (bolus) dose of apomorphine (at the patients' 
routine dose), was appropriate for·the investigation of the beta-phase intercept in individual 
patients, the design was not entirely compatible with the application ofthe,aforementioned 
pharmacOdynamic modelling techniques, i.e. the observed plasma apomorphine 
concentration range was not sufficiently large enough nor sustained for long enough to 
efficiently sample the pharmacodynamic response. This was a direct consequence of 
performing the study under non-steady state conditions, confounded by the short absorption 
and elimination half-lives of apomorphine, the brief period of anti-parkinsonian effect, and 
the absence of continuous pharmacodynamic monitoring. 
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6.2. Preliminary Study of Needle-Free Subcutaneous Injections of 
Apomorphine in Parlcinson's Disease. 
It must be state<Hbat the :fiitdings.of this investigation are limited by a Jack of information 
regarding intra-patient variation in phannacokinetic parameters and pharmacodynamic 
response following either conventional or needle-free delivery ofapomorphine, and by the 
small number of patients involved. Therefore, whilst trends in the data arecreported here, 
the statistical significance of any differences in the pharmacokinetics, pharmacodynamics or . 
tolerability between the two treatments could not be established. 
In the interpretation of the comparison of the two treatments, it is important to note the 
following issues:-
(i) The target time period for administration of apomorphine was between 08:00 and I 0:00, 
however due to various practical and logistical difficulties, e.g. resistant "on" phase (patient 
lO, needle-free trial I) and additional procedure required in the manipulation of the pallidal 
stimulator (patient 12), the time of administration did in fuct fall outside the stated range in 
these patients (see Table 4-5, page 4-20). Nevertheless, consistency in the times of 
administration of apomorphine was maintained for both trials of the needle-free device in 
patient 10. 
(ii) The site of subcutaneous administration was, in each case, the anterior aspect ofthe 
thigh. The posture of the patients during apomorphine administration varied, i.e. standing 
up versus sitting on a chair, depending on the patients' usual routines, however a 
consistency in posture was maintained within each patient for both treatments (see Table 
Table 4-5, page 4-20) 
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(iii~ Blood sampling times for each patient were well matched across the two treatments, 
with particular attention given to initialtsamples. There wasimore variation in.the timing of 
later samples collected' from patient 12 due to time constraints (see Appendix 8.18). 
Pharmacokinetics were best described by a first order input, two compartment model' which 
included:a Iag~time. See Figure 6-14 to Figure 6-16, and Table 6-8. 
There was one exception to this.outcome in that a lag-time was not required'in~the case of 
patient 10 needle-free trial'2. In this particular case the lag-time model was rejected in 
favour of a non-lag-time function on the basis that the lag-time was estimated' (as 0.013 
minutes) with great imprecision·(C.V. > 80000%), in addition to the fact that the predicted 
apomorphine.concentration-time profile using this model did not miinic the trend in the 
observed data, i.e. the predicted T rmx occurred after the observed T rmx· This was attributed 
to the fact that from the first sampling point the concentration was in·decline, thus there was 
an absence of data descnbing the increase in concentration directly following dosing. 
The repeat subcutaneous administration of apomorphine to patients 09, 10 and 12 in the 
investigation of needle-free delivery of apomorphine allowed an intra-patient comparison of 
beta-intercept values to be made. In accordance with the previous findings (Section 6.1.1.6, 
page 6-18), the beta-phase intercept was not predictive of anti-parkinsonian response, and 
furthermore it was found that the beta-phase intercept was of no predictive value even 
within a given patient (Table 6-7). 
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No. 
9 -
10 
12 
Table 6-7 
Patient ID Beta-phase intenept Quality of "on" phase. 
Treatment (nglmL) 
CON 3.5 Optimal 
NF 0.4 Optimal 
CON 5.84 Sub-optimal 
NF 1 NA Optimal 
NF2 12.4 Optimal 
CON 7.7 Optimal 
NF 10.2 Sub-optimal 
Beta-phase intercept values following administration of subcutaneous 
apomorphine. 
Abbreviations: CON = conventional, NF = needle-free. 
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Figure 6-14 Predicted plasma apomorphine concentration: Patient 09 (dose= 2mg). 
30~---------------------------------------------, 
o Conventional device: Cp obs 
- Cp predicted 
o Needle-free device trial l: Cp obs 
- Cp predicted 
tJ. Needle-free device trial 2: Cp obs 
- Cp predicted 
0 30 60 90 120 150 180 210 240 270 300 330 360 
Time Post Dose (mia) 
Figure 6-15 Predicted plasma apomorphine concentration: Patient 10 (dose= 
3.5mg). 
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Figure 6-16 Predicted plasma apomorphine concentration: Patient 12 (dose= 5mg). 
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Patient CIDU. CIDI:t Dose- TIDU. Tmax A U Co-mflnlty Dose- Bioequivalence• 
ID observed predicted normalised observed predicted normalised 
Cmax predicted 
, 
A U Co.lnflnlty 
No. Treatment (nglmL) (ng/mL) (J.L2fmL) (minute) (minute) (ng.min/mL) (J.L2.minlmL) (%) 
CON 18.9 18.5 9.3 16 16.2 1083 542 100 
9 
NF 25.4 25.9 12.9 11 10.0 1031 516 95 
CON 19.3 18.5 5.3 21 17.6 1350 386 100 
10 NF 1 12.6 12.2 3.5 13 13.0 977 279 72 
NF2 25.5 26.3 7.5 5 2.3 1263 361 94 
CON 35.2 35.7 7.2 10 11.5 1667 333 100 
12 
NF 17.2 17.3 3.5 23 18.1 1102 220 66 
Table 6-8 Pharmacokinetics of apomorphine injection by conventional (needle) and novel (needle-free) devices. 
Abbreviations: CON = conventional, NF = needle-free. 
a Estimated using intra-patient AUCO-infiniiY relative to conventional delivery. 
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When the·dose was delivered efficiently by needle-free injection,i.e. where there was an 
J 
absence of a significant local tissue reaction (n = 2: patient 09'and patient I O·trial'2), then 
C...... was greater than that estimated for conventionalidelivery in those patients (by a mean 
of 41 %), T max was shorter (mean of 63%) and AhlCo.in!inity was·essentially equivalent, being 
on average 95% of that observed for conventional delivery. 
Conversely, when.an adverse "local tissue reaction occurred in response to needle-free 
administration ofapomorphine (n = 2: patient 10 trial I and patient 12), there was a 
reduction in Cmax (mean of 43%) and AUCo.infinity (mean of3l%) as compared to 
conventional delivery in those patients. T max varied, being quicker than conventional 
delivery on one occasion and slower on the other occasioiL 
These findings indicate an association between absorption and local tissue effects in this 
study, whereby damage to the subcutaneous tissue compromised absorption of drug into the 
bloodstream. However there remains the possibility that absorption was reduced (relative 
to conventional delivery) in the two cases described independently oflocal tissue effects. 
An alternative explanation for the comparatively low C...... and AUCo.umm1y that occurred on 
two occasions following needle-free injection is that there was incomplete drug delivery as a 
result of poor technique or a design failure. 
It is possible that a proportion of the apomorphine solution may have flowed back through 
the epidermis immediately after injection in the case of patient I 0, since it was reported that 
the skin surface at the administration site was wet following the first trial of the needle-free 
device. Indeed the experience of Cooper et a/[36] with needle-free injection of lidocaine to 
the human forearm showed that it was important to press the J-TIP® both firmly and 
perpendicularly against the skin and to maintain the applied pressure for a few seconds after 
discharging the device to limit back-flow of the drug solution through the skin. 
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However in the case of patient 12, in which relatively incomplete absorption was:also 
demonstrated,the skin surfuce was absolutely dry. Therefore in this case it may 1be that a 
proportion ofthe:apomorphine solution was ejected into the air, and'not across the 
epidermis. 
A further variable which may theoretically be relevant to both absorption and bruising 
following needle-free injection is the posture adopted by the patient at the time of injection. 
However, given that the two trials of needle-free apomorphine delivery in patient lO 
resulted in opposing outcomes with respect to absorption and.bruising (and pain) despite 
the fact that the two trials were carried out under the same conditions regarding posture, it 
is unlikely that posture contn'buted greatly to the results. 
In fact the posture that is thought to give an optimum absorption/pain profile is one 
whereby the·availability of subcutaneous tissue is maximised, but where muscle contraction 
is minimised. For subcutaneous injection to the thigh this would entail the patient lying 
down with the leg outstretched but relaxed[37]. 1!his information.became available after the 
completion of the clinical study. 
The development of an adverse local tissue reaction was independent of bleeding on 
administration of apomorphine. 
Reports oflocal side effects resulting from jet injection of drug solutions are given in the 
literature. Approximately 500/o of patients experienced mild local reaction (redness and 
swelling) following fine-needle aspiration biopsy of breast lesions, which was performed 
following application oflocal anaesthetic via a jet injector[38]. It was stated that such 
complications could have been related to the anaesthetic method, biopsy, or indeed to both. 
Local side effects, including bruising[39], have been reported as a result of using needle-free 
technology for insulin administration[ 40]. Verrips et a/ compared the use of a jet-injector 
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with· a multi-dose injection.pen in·human.growth hormone therapy, the incidence of bruising 
occurring as a• consequence of using the jet injector was higher that that for the pen 
system[41]' 
There;are, however, reports to the!contrary: Hardison.eta/ states that the use of a needle-
free device for induction ofiOcal anaesthesia was significantly free ofside effects[42], and in 
a separate investigation of the application of local anaesthetic using a jet injector there were 
no adverse local effects in the 206 patients studied[43]. 
Considering the high incidence of local tissue complications in subcutaneous·apomorphine 
therapy, it was not surprising that local,tissue complications did occur, however the severity 
of the bruising following needle-free delivery was somewhat unexpected. It appeared that, 
when rup1ure of capillaries did occur, the process occurred extensively. It could be 
suggested that this was a direct result of the relatively wide dispersal of solution into the 
subcutaneous tissue as.compared to a needle·injection. Bruising occurred in combination 
with local induration, the latter being a characteristic complication of apomorphine therapy. 
Thus it is likely that the manifestation oflocal tissue complications was a result of a 
Britaject®-specific reaction and the properties.ofthe needle-free device. Whilst both 
factors were implicated, it was not poSStble in this study to establish the relative 
contributions of each. The inclusion of needle-free subcutaneous injections of saline and 
sodium metabisulphite (the latter being the additive used in the Britaject® preparation) in 
the study protocol as controls for needle-free injection and apomorphine-induced effects, 
respectively, might have served to resolve this issue. 
The needle-free treatment compared unfavourably with the conventional treatment in 
respect of the pain experienced on administration. Familiarisation with the use of needles 
for injection is potentially a factor here since both of the patients currently receiving 
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apomorphine by subcutaneous bolus injectioO'rated the needle-free device as·relativety·more 
painful In a study of,lidocaine administration to the foreann'in which 72 patients were 
randomised'to receive the locahnaesthetic either by the J-TIP® or from a standard needle 
· and syringe, the authors reported that the needle free group had experienced significantly 
less pain on injection than the conventional1treatment group[36). There are other examples 
in the literature which state that the pain or discomfort of needle-free injection was less 
than[38, 41, 44, 45] or equal to[40] that experienced due to drug delivery through a needle. 
The quality of the "on" phase as reported by the patients, and also in terms of magnitude of 
effect (maximum improvement in tapping test score from baseline) and onset and duration 
of effect, was independent ofpharmacokinetic parameters (Cmax. Tmax and AUC) and 
independent of locaJ tissue reaction. 
It was not possible to establish any trends relating to differences in pharmacodynamic 
response, e.g. onset or magnitude of effi:ct, between the treatments. This was due to (i) a 
lack of information regarding intra-patient variation in the quality of the apomorphine-
induced "on" phase, and (h) the inter-patient variation in response following the contro~ i.e. 
conventional, administration of apomorphine. 
It was considered that the differences in the pharmacodynarilic response between the two 
treatments were probably within normal intra-patient variation under the study conditions. 
In future similar investigations, intra-patient variation must be determined in order to 
interpret the differences in response between the treatments. 
The patient commentary was useful in the comparison of anti-parkinsonian responses in a 
given patient. However it was recognised that the extent to which details regarding changes 
in clinicaJ symptoms were volunteered by the patients was somewhat dependent on the 
individuals' motivation at the time. 
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Factors which had the potential to influence phannacokinetic and pharmacodynamic 
outcome,but were independent of delivery device included the temperature of.the skin at the 
administration site[ I] and the effect of changes in circulation to the subcutaneous tissue, 
e.g. reduction-in blood flow as a result of feeding. Such factors were not. controlled in this 
investigation. 
To summarise, it was demonstrated that a potentially desirable.phannacokinetic.profile (in 
terms of a quicker T max and greater Cm.x) could be achieved, but that this did not necessarily 
translate to an improved pharmacodynamic response. Whilst this represents an advantage 
for those who are adverse to needle injection, the unfuvourable outcome· in terms of adverse 
local tissue effects and/or pain of administration may actually preclude the use of the device. 
It was not possible in this preliminary study to identify the cause of the unacceptable tissue 
reaction, only to predict that both the delivery mechanism and the drug solution 
(Britaject®) were implicated, and that poor technique may have contnbuted to the 
outcome. If the risk oflocal tissue damage could be reduced then the needle-free device 
has the potential to be developed as a viable alternative to the existing needle system for 
intermittent apomorphine therapy. 
The study was designed as a preliminary investigation of the utility of a needle-free injector 
system as a delivery device for apomorphine in Parkinson's disease, combined with an 
investigation of pharmacokinetic-phannacodynamic relationships which included the beta 
phase intercept as an outcome measure. Given these objectives, a sampling protocol over 
(approximately) 300minutes post-dose was employed. However, since the novel feature of 
needle-free delivery is based on the potential for rapid absorption (as a consequence of the 
increased surface area of drug solution made available to subcutaneous vasculature), it 
would be a requirement that in a future investigation of this technique, a more intensive 
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sampling,strategy in the immediate periodiafter dosing~should be employed;in1order to 
characterise Cm.x with greater accuracy. 
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6.3. Pharmacokinetic Study of Single-Dose Intranasal 
Apomorphine (Three Doses) in Healthy Volunteers. 
The observed concentration-time series were best descnbed by a first-order input, one-
compartment pharmacokinetic model, with the exception of five out of the twenty-two 
series for which a two compartment model was superior. In the majority of cases, i.e. 
sixteen out of twenty-two series, a Jag-time was required to adequately reflect trends in the 
observed data Predicted plasma apomorphine concentration-time profiles are given in 
Figures 6-17 to 6-22. A comparison of the salient pharmacokinetic parameters for the two 
routes is presented in Table 6-10 (page 6-59). 
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Figure 6-17 Predicted plasma apomorphine concentration following subcutaneous 
and intranasal administration to volunteer 1 (doses are given in 
parentheses). 
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Figure 6-18 Predicted plasma apomorphine concentration following subcutaneous 
and intranasal administration to volunteer 2 (doses are given in 
parentheses). 
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Figure 6-19 Predicted plasma apomorphine concentration following subcutaneous 
and intranasal administration to volunteer 4 (doses are given in 
parentheses). 
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Figure 6-20 Predicted plasma apomorphine concentration following subcutaneous 
and intranasal administration to volunteer 5 (doses are given in 
parentheses). 
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Figure 6-21 Predicted plasma apomorphine concentration following subcutaneous 
and intranasal administration to volunteer 6 (doses are given in 
parenthesis). 
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Figure 6-22 Predicted plasma apomorphine concentration following subcutaneous 
and intranasal administration to volunteer 7 (doses are given in 
parentheses). 
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Subcutaneous Intranasal, initial potency:-
lmg 3mg Smg 
n=6 n=4 n=6 n=6 
Dose 3.00 0.75 2.68 4.52 
(mg) (3.00 to 3.00) (0.54 to 0.84) (2.56 to 2.84) (4.02 to 4.85) 
Lag-time 3.3 4.2 4.2 2.8 
(minute) (0.0 to 9.6) (0.0 to 9.6) (0.0 to 14.4) (0.0 to 7.9) 
KOl~ 7.7 3.3 5.2 4.2 
(minute) (3 .9 to 15.8) (0.6 to 6.7) (1.35 to 14.4) (0.5 to 10.5) 
Tmaxpredicted 21.8 13.3 15.8 16.6 
(minute) (13.3 to 32.6) (11.2 to 18.0) (1 0.2 to 22.3) (6.8 to 27.3) 
Dose-normalised Cmu 3.0 3.2 1.6 1.1 
predicted (nglmLa) (2.6 to 4.8) (2.2 to 3.9) (0.8 to 2.5) (0.9 to 1.8) 
C.V.=25% C.V.= 23% C.V.= 38% C.V.= 25% 
Dose-normalised AUC 269 133 96 84 
(ng.min/mL) (178 to 372) (94 to 182) (49 to 174) (37 to 123) 
C.V.=21% C.V.= 33% C.V.= 51 % C.V.= 30% 
Relative Bioavailabilityb 100 57 38 34 
(Ofo) (100 to 100) (49 to 70) (19 to 65) 10 to 56) 
Elimination tY.i c 46.1 19.5 41.1 50.5 
(minute) (35.6 to 54.5) (13.5 to 27.0) (13.4 to 99.3) (24.2 to 102) 
Table 6-9 Mean (range) pharmacokinetic parameters for the subcutaneous and 
intranasal administration of apomorphine to healthy volunteers. 
• Per lmg dose. 
b Estimated using intra-patient AU4-in1inity relative to subcutaneous delivery. 
c Calculated using (In 2)/K l 0 or (In 2)/beta for one-or two-compartment models respectively. 
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As·demonstrated in previous investigations; apomorphine is as.mpidly absorbed•via the 
intranasal i:oute as:the subcutaneous route[l2, 23, 46], and substantial inter-individual 
variation in phaimacokinetic parameters.exists. 
The pharmacokinetic parameters derived1 for volunteers 1 and 2, i.e. for subcutaneous mid-
and high-dose nasal·treatments, were excluded from:the ANOVA due to the absence of 
pharmacokinetic parameters for the low intmnasal dose. 
There was a short absorption half life following intranasal dosing, the means of which were 
less than that for subcutaneous administration, but were•not statistically different (p=O.l63). 
The time-lag was brief for both administration routes and, with a C. V. of approximately 
100% for eacb.ofthe treatment groups, was not statistically different acrossthetreatments 
(p=0.736). In contmst to Sarn et a/[12], the means forT""" following intmnasal 
administmtion were shorter than that estimated for the subcutaneous route, indicating that 
satisfactory deposition of apomorphine powder into the nasal cavity was achieved, but as 
with the published comparative Trmx data(l2], the difference in Tmax between the treatments 
was not statistically significant (p=O.l78). 
Crmx and AUCo.iniinity were correlated to administered intranasal dose (p<O.Ol in each case, 
dose mnge = 0.54 to 4.85mg, n=16), see Figure 6-23. 
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Figure 6-23 Correlation between dose and AUCo.lnfinity(panel A), and dose and Cmu 
(panel B), following intranasal administration of apomorphine (three 
doses) to six healthy volunteers. 
Both the dose-normalised Cmax and AUCo-infinity obtained for the intranasal route were 
reduced relative to those obtained for subcutaneous administration in the same volunteer. 
This was represented in the mean relative bioavailability of the intranasal route, which was 
41% (range was 10 to 70%, n=16) ofthe control subcutaneous route (defined as 1000/o), in 
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terms.of intra" individual AUCo:.umnity normalised•for dose. "f.he mean relative bioavailabilliy 
of the intranasal system used in this preliminary study compares closely with thatreported 
by Sam et a/[12]. There was a significant difference in:mean relative·bioavailability between 
the subcutaneous treatment and each of the three intranasal treatments, but no·significant 
differences between the three intranasal treatments themselves (p=O.OOI). That•having been 
said, there was an apparent decrease in mean·relative bioavailability with increasing 
intranasal dose. This can be explained by a consideration ofthe rates of apomorphine 
dissolution and mucociliary clearance in situ, whereby the percentage of an administered 
dose that was unavailable for intranasal absorption, i.e. cleared to the nasopharynx and 
swallowed, would increase with increasing dose. Evidence for this was in the form of the 
reporting of a bitter taste in the mouth following intranasal administration, and the short 
T""" following intranasal administration relative to subcutaneous administration. 
Factors which are likely to have contnouted to the poor relative bioavailabilliy of intranasal 
apomorphine administration include the limited solubility of apomorphine in nasal mucus, 
the incompatibility of local pH and pKb of apomorphine with regard to the predominance of 
the ionised, i.e. non-absorbable, form of apomorphine, and the residence time of 
apomorphine powder at the nasal mucosa, which is limited by the mucociliary clearance 
rate[47]. 
Having taken account of the variation in amount of apomorphine released from the 
insufilator, it was possible that an inter- or intra-individual variation in the volume of nasal 
secretions contributed to the large variation in relative bioavailability (since this would alter 
the proportion of the administrated dose that was allowed to dissolve). Other proposed 
contributory factors are: (i) a variation in the pH of nasal mucus, which affects the 
percentage of ionised form of apomorphine present (pH of nasal secretion was not 
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measured), and (ii) a variation in sniff effort, which in,turn has the:potential'to result in 
variation in·the rate of clearance ofparticulates to the nasophurynx[47]. 
'Fhe local'environment at the administration site cati be modified in order to enhance the 
partitioning of the drug into the mucosal tissue. One strategy is to.reduce the mucosal 
barrier function, by the incorporation a.penetration enhancer into the,drug delivery process. 
Examples o£penetration enhancers are surfactants, which act to perturb membrane integrity 
and thus facilitate drug diffusion[48, 49], and inclusion complexes with cyclodextrins, which 
enable the transient opening of tight junctions between epithelial cells[ 48, 49] and can 
improve the solubility and stability and tolerability of the drug[50][51'). In addition, 
alteration of the pH of the local environment in· order to favour the non-ionised form 
potentially allows for more comprehensive absorption of drug[ 52]. In the case of intranasal 
and absorption of apomorphine, a lowering of the pH in vivo would increase the percentage 
of the non-ionised form. 
It may be desirable to increase the residence time of intranasal formulations. This can be 
achieved by the use of a mucoadhesive intranasal formulation, whereby mucociliary 
clearance is impeded[48]. 
Local tissue adverse reactions to intranasal apomorphine dosing have the potential to 
compromise absorption[23]. The incidence of adverse local effects reported by volunteers 
was minimal and those that were reported were mild and transient[53]. This is very much in 
agreement with the findings of other acute studies of intranasal administration of 
apomorphine[54, 55]. Chronic use of the dosage form was not the subject of this 
investigation. This remains an important issue to be addressed in the future, given that there 
is considerable evidence in the literature associating significant local tissue damage with the 
chronic use of intranasal apomorphine[23, 46, 54, 55]. 
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See Section 6.4J for a'general summary of outcomes in'the study of intranasal and buccal 
delivery of apomorphine compared to.conventional (subcutaneous) apomorphine delivery. 
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6.4. Pharmacokinetic Study of Single-Dose Buccal Apomorphine 
(Three Doses) in Healthy Volunteers. 
The pharmacokinetics of the subcutaneous infusions of apomorphlne were best described by 
a one compartment model with constant input and first-order output (Figure 6-24). 
Apomorphlne pharmacokinetics following buccal administration were descn"bed using the 
same mode~ but with a lag time (between drug administration and the onset of drug 
absorption) incorporated into the pharmacokinetic model to account for the time lag in 
swelling of the insert (see Figure 6-25 and Appendix 8.17.2). 
It is acknowledged that this is a basic representation of the pharmacokinetics of the buccal 
formulation of apomorphine, in that the model does not fully describe drug input, the latter 
being a complex function of the swelling ofthe hydroge~ dissolution of apomorphine and 
release of drug from the insert. The buccal drug input function might be better descnOed by 
a Weibull function [56-58]. A comparison of salient phannacokinetic parameters is given in 
Table 6-10 (page 6-59). 
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Figure 6-24 Predicted plasma concentration following subcutaneous infusion to 
healthy volunteers (dose = 2mglh x 2h). 
Abbreviations: Cp = concentration in the plasma, obs = obsenred. 
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Figure 6-25 Predicted plasma apomorphine concentration following buccal 
administration to healthy volunteers. Detail shown in panel B. Doses 
are given in parentheses. 
Abbreviations: Cp = concentration in the plasma, obs = observed,v = 
volunteer ID. 
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Subcutaneous Buccal, initial potency:-
Smg lOmg 20mg 
n=6 n=1 n=1 n=4 
Dose{mg) 4.00 0.79 2.30 2.94 
(4.00 to 4.00) NA NA (1.59 to 7.37) 
Lag-time (minute) NA 30.0 16.5 45.6 
NA NA NA (6.6 to 80.0) 
T mu observetfl 120 120 120 120 
(minute) (60 to 120) NA NA (120 to 180) 
Dose-normalised Cmu 1.7 0.3 0.3 0.3 
predicted (nglmL ~ (1.3 to 2.2) NA NA (0.1 to 0.5) 
Dose-normalised AUC 224 95 61 53 
(ng.minlmL ~ (154 to 306) NA NA (32 to 93) 
Relative Bioavailabilitye 100 30 20 21 
(%) (100 to 100) NA NA (14 to 30) 
t~KlO 33.6 150.6 84.5 112.4 
(minute) (19.8 to 49.9) NA NA (69.2 to 170.0) 
Table 6-10 Mean (range) pharmacokinetic parameters for the subcutaneous and 
buccal administration of apomorphine to healthy volunteers. 
The relationship between dose and both Cmax and AUC4intinity is illustrated in Figure 6-26. 
Estimates ofCmax and AUC4intinity for the buccal apomorphine treatment appear to be dose-
related, however, since the outlying data point exerted considerable leverage on the linear 
relationship between said phannacokinetic parameters and apomorphine dose, it was 
considered inappropriate to present such correlation statistics. 
• Median (range). 
b Per 1 mg dose. 
~Estimated using intra-patient AUCo..infinity relative to subcutaneous delivery. 
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Figure 6-26 Relationship between dose and AUCO-ialilliay(panel A), and dose and C._ 
(panel B), following buccal administration of apomorphine to healthy 
volunteers. 
In comparing the means of pharmacokinetic parameter estimates between subcutaneous and 
buccal administration of apomorphine, it was considered appropriate to treat all six buccal 
series as a single group. This approach was used due to the limited observations of such 
parameters in the case of the low and mid-dosage buccal apomorphine insert. Thus single 
factor ANOV A was performed. 
6-60 
Both the dose-nonnalised c,;,. and AU€o-u.rlllity obtained for the buccal apomorphine 
formulation were very much reduced compared, to those obtained for subcutaneous 
administration in the same volunteer. There was a significant difference between,the two 
treatments in both mean C.,... and ANCo.intinity (p<OlOOl in each case). 
In accordance with this the relative bioavailability of the buccal route was low (mean of 
22%, range 14 to 30%, n=6), although improved from published sublingual studies( means 
of 10 to 18%[6, 7, 13, 59]). 
The factors which may have contributed to the poor relative bioavailability ofbuccally 
administered apomorphine are of a similar nature to those identified with regard to the poor 
relative bioavailability following intranasal apomorphine administration{See Section 6.3). 
Thus the likely fuctors include the limited solubility of apomorphine in saliva, i.e. 
approximately 0.8 mg/mL (Controlled Therapeutics (Scotland), East Kilbride, UK) 
compared to 20mg/mL in water[60], and the ionization state of apomorphine under in vivo 
conditions. 
The variation in relative bioavailability oould have resulted from an inter- or intra-individual 
variation in rate of salivation, thereby influencing such factors as the desorption of 
apomorphine from the insert and the proportion of the administered dose that was 
swallowed. Additionally, a variation in salivary pH might have affected the percentage of 
· ionised form of apomorphine present. The pH of the volunteers' saliva was not measured. 
The variation in relative bioavailability may be related to the absorption of apomorphine at 
oral mucosa other than buccal mucosa, i.e. gingival and/or sublingual mucosae. It was 
reported that, on some occasions, the insert had detached from the surface of the gingiva 
prior to the end of the 120 minute duration of apomorphine administration. On these 
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occasions the•insert was retained in the mouth until the l20 minute period'had elapsed. 
Details ofvolunteer(s)/buccalapomorphine dose(s)that were·implicated>were not recorded. 
General,strategies to improve the absorption of apomorphine at buccal mucosa are similar 
to those given in Section 6.3 for intranasa1 apomorphine, e.g. incorporation of a penetration 
enhancer. 
Strategies to increase the solubility of the drug in vivo with regard more specifically to 
buccal administration include: (i) the positioning, of the insert in relation to salivary flow, i.e. 
at rest the salivary flow in the lower buccal region is greatest (the submandibular and 
sublingual glands produce 75%ofthe total amount of saliva produced), however upon 
stimulation, the parotid glands in the upper oral cavity produce double the amount of saliva 
1":. 
than do the submandibular and sublingual glands[49], (it) the modification of the 
composition of the hydrogel in order to optimise the mechanisms which control the release· 
of water soluble drugs from the hydrogel[61) (or, by the incorporation of a laminated 
surface on the insert, in·order to ensure uni-directional release from the hydrogel[49]), and 
(ill) attention to teeth cleaning, since this procedure could have the effect of raising the pH 
of the local environment to the extent that apomorphine solubility is reduced. 
The incidence oflocal adverse effects reported by the volunteers was minimal, and where 
such an event did occur, the effect was mild and transient[62). Chronic use of the dosage 
form was not the subject of this investigation, and thus remains an issue to be addressed in 
the future. 
As. an exploration of the pharmacokinetics of multiple buccal insert usage, repeated buccal 
administration every three hours was simulated (WinNonlin version 1.5, Pharsight, USA) 
using the user-defined pharrnacokinetic model described previously in this Section (see 
Appendix 8.17.2. The pharrnacokinetic parameter estimates used in the simulation were the 
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mean values for the six buccal apomorphine pbarmacokinetic series descnbed previously, 
ie. volume = 3402L, klO = 0.0074 minute, lag-time = 39.7 minute. The dose used was the 
mean dose of the six buccal apomorphine pbarmacokinetic series, i.e. 3.2mg (Figure 6-27). 
This particular schedule was investigated as it represented a practical schedule for buccal 
usage, i.e. after two hours in situ the insert tends to detach from the mucosa and since the 
insert cannot be in place whilst eating, intermissions are required. Apomorphine 
administration was simulated for an eleven hour period, a duration which represented the 
use of buccal inserts during waking hours, since buccal delivery of apomorphine during 
sleep is precluded due to the risk of swallowing the insert. 
~ 1.0 
~ 
! 0.8 
.s 
u 
~0.6 
e-
0 
a 
8,0.4 
~ 
• a 
= 0.2 s:; 
0.0 
: 
• . 
0 
... 
' \ 
. 
, 
' 
' 
' 
120 
1', i \ 
' \ 
,' \ 
, 
' , 
. 
. ' 
. ' 
. ' 
\. 
.. 
.... 
I \ 
I \ 
I \ 
' ' 
' 
' 
\ 
\ I 
.. 
..J 
-Buocal insert in situ 
.... 
I ', 
I \ 
I \ 
' ' ' 
' 
' 
' I 
. . 
· ..: 
• • Predic1ed apomorphine concentration 
240 360 4SO 600 720 
nme (miaute) 
. 
• 
840 960 
Figure 6-27 Predicted plasma apomorphine concentration on repeated dosing: 
buccal administration (for lh duration) every 3 hou..S. 
A plateau effect was observed after application of the second buccal insert. The steady 
state plasma apomorphine concentration range was 0.5 to 0.9 ng/mL. 
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6.4.1. General summary of outcomes in the study of intranasal and buccal 
delivery ofapomorphine·compared•to conventional (subcutaneous) 
apomorphine delivery. 
Apomorphine release from the buccal hydrogel rand, to a lesser extent, the nasalinsufHator 
was low and variable, indicatirig the need to optimise the delivery mechanisms of the 
devices used in order to proceed with the development of these novel systems. When drug 
release did occur, dose-related plasma concentrations wererobserved, but the bioavailability 
was low in comparison with the subcutaneous controhpomorphine administration, 
suggesting that formulation issues must be·addressed in order to achieve thempeutic plasma 
concentmtions ofapomorphine. 
It is likely that the two delivery systems would achieve high patient acceptability in 
compariSon to the conventional subcutaneous system. Patient acceptability, and therapeutic 
outcome, will depend on the local· adverse effects profile resulting from chronic use of the 
novel apomorphine formulations. 
It was considered by the investigators (Section 4.2.2.1 and Section 4.2.3 .1) that the open 
labe~ non-randomised, ascending dose protocol was an efficient approach in the exploration 
of new formulations of apomorphine. However it must be stated that apomorphine 
pharmacokinetics following subcutaneous administration are subject to conSiderable inter-
subject variation and, to a lesser degree, intm-subject variation[1]. Thus the inclusion of 
repeated dosing of the intranasal and buccal formulations with a matched number of 
subcutaneous control doses may have afforded· a more robust investigation of the novel 
apomorphine formulationS. Nevertheless, the objective of deriving information on the 
pharmacokinetics and relative bioavailability of the novel formulations/delivery modes was 
met. Such information allowed the investigators to proceed with development of the novel 
apomorphine delivery modalities. 
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SECTION 7: 
FINAL SUMMARY AND FUTURE WORK. 
7. Final Summary and Futurre Wo~k. 
There were two aspects to the study of apomorphine inthe treatment ofParkinson's disease 
presented in this thesis. These were: (i) a clinical pharmacokinetic-pharmacodynamic study 
which was undertaken in view of the challenges of apomorphine dose-titration in 
Parkinson's disease, and in response to the scarcity of available literature on the 
pharmacokinetic-phannacodynamic relationships of apomorphine in Parkinson's disease, 
and (ii) exploratory pharmacokinetic (and tolerability) studies of apomorphine 
administration·using novel delivery/formulation combinations, which were undertaken in 
view of the inherent limitations associated with the conventional (subcutaneous) route of 
administration of apomorphine (e.g. cutaneous nodule formation, needle-phobia). 
An HPLC assay was developed which allowed the detection of apomorphine in .plasma at 
suitably low levels of the analyte (LOQ was 0.05ng/mL), could distinguish apomorphine 
(forced) degradation products and potential apomorphine metabolites(apomorphine 
orthoquinone and isoapocodeine), and was not compromised by the concomitant 
administration of the commonly prescnbed anti-parkinsonian drugs. The success of 
apomorphine quantification in clinical samples depended heavily on the use of anti-oxidants 
in the collection, storage and extraction procedures. 
It was noted that the analytical method could be further developed to include the 
quantification of other (proposed) apomorphine metabolites, such as apomorphine 
glucuronide and N-demethylated apomorphine. 
With regards to the first aspect of the research, focus was given to investigating the 
relevance of a potential,correlation between the beta-phase intercept of a two-compartment 
pharmacokinetic model and apomorphine-induced· anti-parkinsonian response in patients 
7-1 
with Parkinson's disease. It was'hypothesised that this particular correlation, which was 
based on a review of plasma apomorphine concentration-time profiles in the literature, 
may be of use in a dose-optimisation scheme. However it was demonstrated that the beta-
phase intercept was unrelated to apomorphine pharmacodynamics (in tenns of improvement 
in tapping test score from baseline) and therefore was:of no predictive value in the patients 
studied (n--6). The correlation between the beta-phase intercept and response initially 
observed in the literature was therefore interpreted as being co-incidental. 
The characteristic features of apomorphine pharmacokinetics were clearly demonstrated in 
the seven patients treated with subcutaneous bolus apomorphine; according to the 
traditional two-stage approach to data analysis, there was a short absorption half-live, i.e. 
mean (S.D.) of4.1 (2.1) minutes, short elimination half live, i.e. 69.5 (21.1) minutes, rapid 
clearan~ from plasma, i.e. 2.2 (0.5) L/kg!h, and the volume of distribution was 1.9 ( 0.8) 
L/kg. Similarly, the typical features of apomorphine-induced anti-parkinsonian effect 
following subcutaneous bolus were observed, e.g. the short latency to onset of effect, i.e. 12 
(8) minutes, and the. brief duration of effect, i.e. 72 (25) minutes. 
Simultaneous PK-PD modelling was performed, using an effect compartment (exponential 
pharmacodynamics) model to account for counterclockwise hysteresis in a sub-group of 
patients(n=2). The equilibration half-life was short, i.e. 8.3 and 16.5 minutes. The 
limitations of this approach were that neither baseline nor maximal apomorphine-induced 
anti-parkinsonian response could be predicted. 
A direct pharmacodynamic (sigmoid Em.x) model was applied to series where hysteresis in 
the plasma concentration-effect plot was not evident (n=2). The absence of 
counterclockwise hysteresis in these patients was attributed to a (very) rapid equilibrium of 
apomorphine with the effect site. The drug concentration which produced 50% of 
maximum effect (EC50) was 7.7 and 20.3 ng/mL. Values for the Hill co-efficient were large, 
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i.e. 7 and 10; indicating that the relationship between plasma apomorphine concentration 
and effect was'an "all or nothing" (dichotomous) phenomenon. 
Whilst the experimental:design, i.e. single (bolus),dose of apomorphine (at the patients' 
routine dose), was appropriate for the investigation,ofthe beta~ phase intercept in individual 
patients, the design was not entirely compatible with the application of the aforementioned 
pharmacodynamic modelling techniques in that the observed plasma apomorphine 
concentration range was not sufficiently large enough nor sustained for long enough to 
efficiently sample the pharmacodynamic response. This was a. direct consequence of 
performing the study under non-steady state conditions (and in the absence of continuous 
pharmacodynamic monitoring), given that apomorphine has short absorption and 
elimination. half-lives and a brief period of effect. 
The research highlighted the difficulties involved with the study of pharmacokinetic-
pharmacodynamic relationships of a drug which is associated with high inter- and intrac 
patient variability in pharmacokinetics, pharmacodynamics and narrow therapeutic window. 
In particular the importance of appropriate experimental design on the success of modelling 
concentration-effect relationships was demonstrated, i.e. the disadvantages ofthe.non-
steady state approach, the detrimental effect of drug withdrawal (wash-out):on anti-
parkinsonian response, and the requirement for a pharmacodynamic tool which is capable of 
continuously monitoring apomorphine-induced anti-parkinsonian effects, 
In order to further elaborate on the relationship between apomorphine pharmacokinetic and 
pharmacodynamics, a departure from standard two stage modelling techniques to a more 
direct population modelling approach, i.e. mixed effects·modelling, is warranted. 
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The novel delivery systems under scrutiny were: {i)Britaject® (Britannia Pharmaceuticals 
Ltd.) apomorphine formulation. administered subcutaneously using a needle-free Get) 
injector (J-TIP®, National Medical Products Inc.), (ii) an intranasal apomorphine powder 
formulation delivered using a turbospin insufilator (CDFS), and (iii) an apomorphine 
hydrogel co-polymer produced as a dosage-form for buccal delivery {Controlled 
Therapeutics (Scotland) Ltd.). 
llte pharmacokinetics, pharmacodynamics and tolerability of subcutaneous needle-free 
delivery of apomorphine {Britaject®, Britannia Pharmaceuticals Ltd) in comparison with the 
conventional apparatus, i.e. needle and syringe or Penject® (Britannia Pharmaceuticals Ltd) 
were determined in three patients with Parkinson's disease. It was demonstrated that the 
p~kinetics of needle-free administration using the J-TIP® injector {National Medical 
Products Inc.) depended on the "efficiency'' of dosing. 
On two occasions, a local adverse tissue reaction, i.e. bruising and induration, occurred in 
response to administration of apomorphine by needle-free injection. On these occasions, 
Crrmx and AUCo-infiruty were reduced {by means of 43% and 31% respectively, n=2) as 
compared to conventional delivery in those patients. T max varied, being quicker than 
conventional,delivery on one occasion and slower on the other occasion. 
Conversely, in the absence of adverse reaction at the injection site, Crrmx was greater than 
that estimated for conventional delivery in those patients (by a mean of 41%, n=2), T max was 
shorter (mean of63%, n=2) and AUCo.infinity was essentially equivalent, being on average 
95% of that observed for conventional delivery. 
It was not possible to establish any trends relating to differences in pharmacodynamic 
response, e.g. onset or magnitude of effect, between the treatments. This was due to (i) a 
lack of information regarding intra-patient variation in the quality of the apomorphine-
induced "on" phase, and (ii) the inter-patient variation in response following the control, i.e. 
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conventional. administration of apomorphine. It was considered that the,differences in the 
pharmacodynamic response between the two treatments were probably within nonnal intra-
patient variation under the study conditions. In future similar investigations, intra,patient 
variation must be determined in order to interpret the differences in response between the 
treatments. 
The implication of these findings was that, whilst it was demonstrated that a desirable 
pharmacokinetic profile could be achieved (in terms of an equivalent AUC, shorter T max and 
greater Cmax), the unfavourable outcome in terms of adverse local tissue effects and/or pain 
of administration, which was not patient-specific, negates the use of the device, despite the 
obvious advantage of the novel system for those who are adverse to needle injection. It was 
proposed that the manifestation oflocal tissue complications was a result of a Britaject®-
specific reaction and the actual delivery mechanism, Le. pressurised jet injection. Whilst 
both factors were implicated, it was not possible in this study to establish the relative 
contributions of each due to the absence of administration of apomorphine-free solutions as 
a control in the experimental design. 
A comparison of apomorphine pharmacokinetics following conventional subcutaneous 
administration and either intranasal dosing with a powder formulation (CDFS), or buccal 
administration using a hydrogel formulation (Controlled Therapeutics Scotland Ltd), was 
performed in heahhy volunteers. 
Apomorphine release from the buccal'hydrogel and, to a lesser extent, the nasal insufflator 
was low and variable, indicating the need to optimise the delivery mechanisms of the 
devices used in order to proceed with the development of these novel systems. When drug 
release did occur, dose-related plasma concentrations were observed, but the bioavailability 
was low in comparison with subcutaneous control apomorphine administration, i.e. mean 
(S.D, number of observations) was 41% (18, n=l6) for the intranasal system and 22% (7, 
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n=6)for the buccal,system This suggests that formulation issues must be addressed in order 
to achieve therapeutic plasma concentrations of apomorphine; 
It is likely that the two delivery systems would achieve high patient acceptability in 
comparison to the conventionalsubcutaneous·system. Both patient acceptability and 
therapeutic outcome will depend on.the local adverse effects profile resulting from chronic 
use of the novel apomorphine delivery systems. Development of the intra-nasal and buccal 
systems has proceeded based on the pharmacokinetic (and tolerability) data generated in 
these studies, with the intranasal route proving the more promising ofthe,two. 
A recurring issue ·in the (chronic) administration of apomorphine (Britaject®, Britannia 
Pharmaceuticals Ltd) is the occurrence oflocal adverse reactions, i.e. inflammatory events, 
at the site of administration, be that the subdermis and epidermis, nasal mucosa, or 
sublingual mucosa. 'The cause.ofthe adverse reaction, in terms of the contribution of 
apomorphine and/or the Britaject® excipient, remains .to be established. It is·suggested in 
the literature that diluting the apomorphine solution with normal saline prior to 
subcutaneous adminiStration reduces the risk of nodule formation, however, in the absence 
of apomorphine stability data and storage guidelines in such solutions, there may be some 
difficulties in supplying patients with such. In this respect, a study on the stability of 
apomorphine in saline, with a combined assessment of the effect of on cutaneous nodule 
formation is warranted. 
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SECTIONS: 
APPENDICES 
8. Appendices. 
8.1. Unified Parkinson's Disease Rating Scale (IJPDRS). 
Part 1: MENTA11ION, BEHAVIOUR AND MOOD 
Rate items 1-4 by interview. 
1. InteUectual impairment: 
0 = None 
1 = Mild: consistent forgetfulness with partial rec()Ilection of events 
and no other difficulties 
2 = Moderate memory loss, with disorientation and moderate 
difficulty handling complex problems; mild but definite 
impairment of function at home, with need,of occasional 
prompting 
3 = Severe memory loss with disorientation for time and often for 
place, severe impairment in handling problems 
4 = Severe memory loss with orientation preserved to person only; 
~ unable to make judgements or solve problems; requires much 
help with personal care; cannot be left alone at all 
2. Thought disorder (due to·dementia or dmg intoxication): 
0 = 
1 =· 
2 = 
3 = 
4 = 
None 
Vivid dreaming 
'Benign' hallucinations with insight retained 
Occasional to frequent hallucinations or delusions without 
insight; could interfere with daily activities 
Persistent hallucinations, delusions, or florid psychosis; not able 
to care for self 
3. Depression: 
0 = 
1 = 
2 = 
3 = 
4 = 
Not present 
Periods of sadness or guilt greater than normal but never 
sustained for days or weeks 
Sustained depression( I week or more) 
Sustained depression with vegetative symptoms (insomnia, 
anorexia, weight loss, loss of interest) 
Sustained depression with vegetative symptoms and suicidal 
thoughts or intent 
4. Motivation I initiative: 
0 = Normal 
1 = Less assertive than usual; more passive 
2 = Loss of initiative or interest in elective (non-routine) activities 
3 = Loss of initiative or interest in day-to-day (routine) activities 
4 = Withdrawn, complete loss of motivation 
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D 
D 
Part D: ACI'MTIES OF DAILY LIVING (in the past week) 
Rate items 5-17 by interview. 
5. Speeeh: 
0 
1 
2 
3 
4 
= 
= 
= 
= 
= 
Normal 
Mildly affected, no difficulty in being understood 
Moderately affected, sometimes asked to repeat statements 
Severely affected, frequently asked to repeat statements 
Unintelligible most of the time 
6. Salivation: 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal 
Slight but definite excess of saliva in the mouth; may have 
night-time drooling 
Moderately excessive saliva; may have minimal drooling 
Marked excess of saliva; some drooling 
Marked drooling; requires constant use of tissue or handkerchief 
7. SwaUowing: 
0 = Normal 
1 = Rare choking 
2 = Occasional choking 
3 = Requires soft food 
4 = Requires nasogastric tube or gastrostomy feeding 
8. Handwriting: 
0 = Normal 
1 = Slightly slow or small 
2 = Moderately slow or small; all words are legible 
3 = Severely affected; not all words are legible 
4 = 'Jhe majority of words are not legible 
9. Cutting food.and handling utensil'!: 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal 
Somewhat slow and clumsy, but no help needed 
Can cut most foods, although clumsy and slow; some help 
needed 
Food must be cut by someone but can still feed slowly 
Needs to be fed 
10. Dressing: 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal 
Somewhat slow, but no help needed 
Occasional assistance needed with buttoning, getting arms into 
sleeves 
Considerable help required, but can do some things alone 
Helpless 
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N. Hygiene: 
0 = Normal 
1 = Somewhat slow, but no help.needed 
2 = Needs help to shower or•bathe; very slow in hygiene care 
3 = Requires assistance for washing, brushing teeth, combing hair, 
going to bathroom (toilet) 
4 = Needs Foley (bladder) catheter or other aids 
12. Turning in bed and adjusting bedclothes: 
0 = Normal 
1 = Somewhat slow and clumsy, but no help needed 
2 = Can turn alone or adjust sheets, but with great difficulty 
3 = Can initiate attempt but cannot turn or adjust sheets alone 
4 = Helpless 
13. Falling (unrelated to freezing): 
0 = None 
1 = Rare falling 
2 = Occasional falls, less than once daily 
3 Falls an·average of once daily 
4 = Falls more than once daily 
14. Freezing when walking: 
0 = None 
1 = Rare freezing when walking; may have start hesitation 
2 = Occasional freezing when walking 
3 = Frequent freezing; occasionally falls because of freezing 
4 = Frequently falls because of freezing 
15. Walking: 
0 = Normal 
1 
2 
3 
= 
= 
= 
Mild difficuhy; may not swing arms or may tend to drag leg 
Moderate difficulty, but requires little or no assistance 
Severe disturbance of walking; requires assistance 
4 = Cannot walk at all, even with assistance 
16. Tremor: 
0 = Absent 
1 = Slight and infrequently present 
2 = Moderate; bothersome to patient 
3 = Severe; interferes with many activities 
4 = Marked; interferes with most activities 
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17. Sensory complaints related to parkinsonism: 
0 = None 
1 = Occasionally has.numbness 
2 
3 
= 
= 
Frequently has numbness, tingling, or aching; not distressing 
Frequent painful sensations 
4 = Excruciating pain 
Part ID: MOTOR EXAMINATION 
18. Spe«b: 
0 = Nonnal 
1 = Slight loss of expression, diction and/or volume 
2 = Monotone, slurred but understandable; moderately impaired 
3 = Marked impairment, difficult to understand 
4 = Unintelligible 
19. Facialexpression: 
0 = Nonnal 
1 = Minimal hypomimia; could be nonnal'poker face' 
2 
3 = 
'" Slight but definitely abnormal diminution of facial expression 
Modemte hypomimia; lips parted some of the time 
4 = Masked or fixed facies, with severe or complete loss of facial 
expression; lips parted Y4 inch (6 mm)·or more 
20. 'Fremor at rest: 
0 = Absent 
1 = Slight, and infrequently present 
2 = Mild in amplitude and persistent, or modemte in amplitude but 
only intermittently present 
3 = Moderate in amplitude and present most of the time 
4 = Marked in amplitude and present most of the time 
21. Action or postural tremor of bands: 
0 = Absent 
1 = Slight; present with action 
2 = Moderate in amplitude; present with action 
3 = Moderate in amplitude; present with posture-holding as well as 
with action 
4 = Marked in amplitude; interferes with feeding 
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D 
D 
Face, lips, 
chin 
R hand 
L band 
R root 
L foot 
22. Rigidity: 
Judged on.passive movement with patientrelaxed in sitting position; 'cogwb ee I!' lin to 
k bet ignored; 
0 = Absent 
1 = Slight or detectable only when activated by mirror or other 
movements 
2 = Mild to moderate 
3 = Marked, but full range of motion easily achieved 
4 = Severe, range of motion achieved with difficulty 
23. Finger taps: 
Nee 
Ru pper 
emity exlr• 
Lu pper 
emity extr 
R lo wer 
emity extr 
L I ower 
extremity 
Patient taps thumb witb index finger in rapid succession with widest amplitude 
possible, 
each band separately. 
0 = 
1 = 
2 = 
3 c 
4 = 
Normal 
Mild slowing and/or reduction in amplitude 
Moderately impaired; definite and early fatiguing; may have 
occasional arrests in movement 
Severely impaired; frequent hesitation in initiating movements 
or arrests in ongoing movement 
Can barely perform task 
24. Hand movements: 
DRight 
DLeft 
Patient opens and closes bands in rapid succession with widest amplitude possible, 
each band separately. D . 
Roght 
0 = Normal 
2
·1 = Mild slowing and/or reduction in movement DLeft 
= Moderately impaired; definite and eal'ly fatiguing; may have 
occasional arrests in movement 
3 = Severely impaired; frequent hesitation in initiating movements 
or arrests in ongoing movement 
4 = Can barely perform task 
25. Rapid alternating movements of the band: 
Pronation-supination movements of bands, vertically or·borizontally, witb as large an 
amplitude as possible, both bands simultaneously. 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal 
Mild slowing and/or reduction in movement 
Moderately impaired; definite and early fatiguing; may have 
occasional arrests in movement 
Severely impaired; frequent hesitation in initiating movements 
or arrests in·ongoing movement 
Can barely perform task 
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DRight 
D Left 
26. ·Leg agility: 
Patienttaps,heel.on ground in rapid succession, picking up entire leg; amplitude 
should be1about 3 inches (75 mm). 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal 
Mild; slowing and/or reduction in movement 
Moderately impaired; definite and early fatiguing; may have 
occasional arrests in movement 
Severely impaired; frequent hesitation in initiating movements 
or arrests in ongoing movement 
Can barely perform task 
27. Arising from chair: 
D Right D Left 
Patient attempts to arise from a straight-backed wood or metal chair, with arms 
folded across chest. · · 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal 
Slow, or may need more than one attempt 
Pushes selfup from arms of seat 
Tends to fall back and may have to try several times but can get 
up without help 
Unable to arise without help 
28. Posture: 
0 = 
1 = 
2 = 
3 = 
4 = 
29. Gait: 
0 = 
1 = 
2 = 
3 = 
4 = 
Normal erect 
Not quite erect, slightly stooped posture; could be normal for 
older person 
Moderately stooped posture, definitely abnormal; can be slightly 
leaning to one side 
Severely stooped posture with kyphosis; can be moderately 
leaning to one side 
Marked flexion, with extreme abnormality of posture 
Normal 
Walks slowly, may shuffie with short steps but no festination or 
propulsion 
Walks with difficulty, but requires little or no assistance; may 
have some festination, short steps, or propulsion 
Severe disturbance of gait; requires assistance 
Cannot walk at all even with assistance 
30. Postoral stability: 
D 
D 
D 
Response to sudden posterior displacement produced by a puU on shoulders while 
patient is erect, with eyes open· and feet slightly apart; patient is prepared. 
0 = Normal 
1 = 
2 = 
Retropulsion but recovers unaided 
Absence of postural response, would fall if not caught by 
examiner 
3 = Very unstable, tends to lose balance spontaneously 
4 = Unable to stand without assistance 
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31. Body bntdyldnesia and hypokinesia: 
Combining slowness, hesitancy, decreased ann swing, smaU amplitude and poverty of 
movement•in generaL 
0 = None 
1 = Minimal slowness giving movement a deliberate character, 
could be normal for some persons; possibly reduced amplitude 
2 = Mildidegree of slowness and poverty of movement that is 
definitely abnormal; alternatively some reduced·amplitude 
3 == Moderate slowness; poverty or small amplitude of movement 
4 = Marked slowness; poverty or smalhmplitude of movement 
Part IV: COMPLICATIONS OF THERAPY (in the past week) 
A. Dyskinesias 
32. Duration: 
D 
What proportion of the waking day are dyskinesias present? (Historical information) 
0 = None 
1 =,. l-25%ofday 
2 = 26-50% of day 
3 = 51-75% of day 
4 = 76-100%.ofday 
33, Disability: 
D 
How disabling are the dyskinesias? (Historical information, may be modified by office 
examination) 
0 = Not disabling 
1 = Mildly disabling 
2 = Moderately disabling 
3 = Severely disabling 
4 = Completely disabling 
34. Painful·dyskinesias: 
How painful are the dyskinesias? 
0 = No painful dyskinesia 
1 = Slightly 
2 = Moderately 
3 = Severely 
4 = Markedly 
35. Presence of early morning dystonia. (Historical information): 
0 = No 
1 = Yes 
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B. CUnicaliFiuctuations 
36. Are there any 'oft' periods predictable as to timing after a dose of 
medication? 
0 = No 
l = Yes 
D 
37. Are there any 'oft' periods unpredictable as to timing after a dose of D 
medication? 
0 = No 
l = Yes 
38. Do any 'off' periods come on suddenly (Le. within a few seconds)? 
0 = No 
l = Yes 
39. What proportion ofthe waking day is the patient 'oft' on average? 
0 = None 
l = ~. 1-25% of day 
2 = 26-50%-of day 
3 = 51-75%ofday 
4 = 76-1000/o of day 
C. Other Complications 
40. Does the patient have anorexia, nausea, or vomiting? 
0 = No 
l = Yes 
.D 
D 
41. Does the patient have any sleep disturbances (for example, insomnia or D 
hypersomnolence)? 
0 = No 
l = Yes 
42. Does the patient have symptomatic orthostasis? 
0 = No 
l = Yes 
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Part V: MODIFIED HGEHN AND YABR STAGING 
StageO = No signs of disease 
Stage 1 = Unilateral disease 
Stage 1.5 = Unilateral plus axial involvement 
Stage 2 = Bilateral disease without impairment of balance 
Stage 2.5 = Mild bilateral disease with recovery on pull test 
Stage 3 = Mild to moderate bilateral disease; some postural instability; 
physically independent 
Stage4 = Severe disability; still able to walk or stand unassisted 
Stage 5 = Wheelchair-bound or bedridden unless aided 
Part Vh SCHW AB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE 
Ask patient and relative to score patient's ability over the preceding week to the nearest 5 
per cent using the following guidelines. 
100% = Completely independent; able to do all chores without slowness, 
difficulty, or impairment; essentially normal; unaware of any 
difficulty 
90% = Completely independent; able to do all chores with some degree of 
slowness, difficulty, or impairment; may take twice as long as usual; 
beginning to be aware of difficulty 
80% = Completely independent in most chores; takes twice as long as 
normal; conscious of difficulty and slowness 
70% = Not completely independent; more difficulty with some chores; 
60% = 
SO% = 
40% = 
30% = 
20% = 
10% = 
0% = 
takes three to four times as long as normal in some; must spend a 
large part ofthe day with some chores 
Some dependency; can do most chores, but exceedingly slowly and 
with considerable effort and errors; some chores impossible 
More dependent; needs help with half the chores, slower, etc.; 
difficulty with everything 
Very dependent; can assist with all chores but does few alone 
With effort, now and then does·a few chores alone or begins alone; 
much help needed 
Does nothing alone; can be a slight help with some chores; severe 
invalid 
Totally dependent and helpless; complete invalid 
Vegetative functions such as swallowing, bladder and bowels are 
not functioning; bedridden 
Source: Wade [I].· 
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8.2. Current Threshold Dose-Finding Protocol. 
Provoking and Assessing an "Off'' State: After at least three days of hospitalisation all 
anti-parkinsonian therapy is withheld overnight to provoke an "off' state in motor 
performance and to undertake a baseline motor assessment as follows: 
a) Ahemate, unilaterathand tapping for 30,seconds on, mounted digital counters 
(preferably 20cm apart)[2] 
b) Time,taken to walk 12 metres. 
c) Clinical, assessment of tremor and dyskinesia according to a four point scale (O=nil, 
l=mild, 2=moderate, 3=severe). 
d) Scoring on a modified Webster disability scale to assess 12 features of parkinsonism 
(maximum disability score of36)[3] 
Determination of the Threshold Dose: Following baseline motor assessment the patient is 
challenged for apomorphine responsiveness according to the following schedule; 
- 1.5mg apomorphine HCI is injected subcutaneously and the patient is observed over 30 
minutes for motor responsiveness. 
If no or poor response is obtained, a second dose of 3mg apomorphine HCI is given 40 
minutes after the first dose, and the patient observed for a further 30 minutes. 
The dosage is increased in an incremental fashion every 40 minutes and the patient 
observed carefully for an unequivocal motor response. The third dose is 5mg 
subcutaneously, and the forth dose is 7mg subcutaneously. If the patient shows no 
response to the 7mg dose then the patient must be classified as a non-responder to 
apomorphine HCI and no further attempts to provoke a motor response should be made. 
If the patient shows only a mild response to the 7rng dose, a maximum dose oflOmg 
can be used to see if an unequivocal motor response is possible. 
The lowest dose producing an unequivocal motor response is called the ''threshold 
dose". For the majority of patients the threshold dose is less than 7mg apomorphine 
HC~ although very occasionally it can be made up to 1 Omg apomorphine HCI. 
Motor response is judged to be positive if2 or more of the following are seen: 
a) More than 15% increase in tapping.score. 
b) More than 25% improvement in walking time. 
c) An improvement of at least 2 points of tremor score. 
d) An improvement ofWebster's score of3 or more. 
Initiation a/Treatment: Following establishment of an acceptable threshold dose of 
apomorphine HCl injection, the patient should be restarted on conventional anti-
parkinsonian therapy. A subcutaneous injection of the established threshold dose may then 
be given into the lower abdomen or outer thigh at the first signs of an "off' episode. The 
patient should then be observed over the following hour and the quality of the "on'; period 
noted. It may be appropriate to modify the dose of apomorphine HCI according to the 
patient's response. 
Close monitoring of therapeutic benefits and side effects under specialist supervision is 
required after initiation of treatment. The daily dose can vary between patients and will 
typically be in the range of3mg upto 30mg per day in divided doses. The frequency of 
injection will also vary between patients and may be between I to 10 per day but in rare 
cases may be up to 12 times per day. 
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:Patientsrwho have shown a good "on" ;period response during the initiation stage, but 
whose.overall control remains unsatisfactory using intermittent injections, or who require 
many and ,frequent injections (more·than 10 per day), may be commenced on or transferred 
to continuous subcutaneous infusion by rninipump as follows; 
Continuoils· infusion is started at a, rate of lmg;apomorphine:HCI per hour then increased 
according to the. individual response. Increases'intthe infusion rate should not exceed 
05mg per hour at intervaJs,ofnotless than 4·hours,. Hourly infusion rates may change 
between 1mg-and·4mg, equivalent to 0.015-0:06 mg/kg/hour. 
Source: Britaject® Data Sheet[4] 
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8.3. UK Parkinson's Disease Society Brain Bank Clinical 
Diagnostic Criteria 
STEP 1 Diagnosis of parkinsonian syndrome 
• Bradykinesia and at least one of the following: 
• m1,1Scular rigidity 
• 4-6Hz resHremor 
• postural instability not caused by primary visual, vestibular, cerebellar or 
proprioceptive dysfunction 
STEP 2 Exclusion criteria for Parkinson's disease 
• History of repeated strokes with stepwise progression of parkinsonian features 
• History of repeated head injury 
• History of definite encephalitis 
• Oculogyric crises 
• Neuroleptic treatment at onset of symptoms 
• More than one affected relative 
• Sustained remission 
• Strictly unilateral featmes after three years 
• Supranuclear gaze palsy 
• Cerebellar signs 
• Early severe autonomic involvement 
• Early severe dementia with disturbances of memory, language and praxis 
• Babinski sign 
• Presence of cerebral' tumour or communicating hydrocephalus on CT scan 
• Negative response to large doses oflevodopa (if malabsorption excluded) 
• MPTP exposure 
STEP 3 Supporting prospective positive criteria for Parkinson's disease. 
Three or more required for diagnosis of definite Parkinson's disease. 
11 Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting the side of onset most 
• Excellent response (70-100%)to levodopa 
• Severe levodopa-induced· chorea 
11 Levodopa·response for 5 years or more 
• Clinical course for 10 years or more 
Source: Gibb and Lees[5] 
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8.4. Patient Demographics. 
Patient ~ Gender Age · ~ Body weight 
' 
Height Body Mass Index 
ID 
- I (yearsf 1 (q) (m) (kg/m2) I 
01 female 51 ' 48.2 1.5 20.5 
~ 
02 male 74 105.4 1.8 33.2 
03 ; male 55 69.9 1.8 2L6 
04 male 73 60.1 1.7 19.8 
' 
05 female 73 65.1 1.6 26.5 
' 
I 
06 NA 
' 
' 
' 
07 male 49 85.8 L8 26.5 
c 
08 female 76 I 72.5 1.6 28.5 
09 female 55 57.1 1.6 21.5 
10 male 70 74.3 1.7 24.7 
ll male 69 65.3 1.7 
12 male 57 90.4 1.8 28.47 
Table 8-l Patient demographics. Abbreviation: NA = not applicable. 
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Patient Disease Duration of Duration of Current UPDRS Hoehnand 
ID duration L-dopa apomorphine apomor()hine total score Yahr score 
therapy therapy regimen ("on") ("on'') 
(years) (years) (years) 
-
OI I7 I7 5 bolus: 2mg x5 I week 35 NR 
02 11 11 I bolus: 5mg x5 I day NR 4 
03 11 9 5 (infusion: 50mg/24h) 68 4 
04 13 I2 I infusion: 30mg/I5h 7I 4 
05 I4 I2 2 bolus: 5mg x2 I day 74 4 
07 I3 12 <I infusion: I80mg/24h 36 4 
08 10 9 <I infusion: 45mg/24h 40 3 
09 28 20 3 bolus: 2mg x 5 I day 36 2 
IO IO IO 3 bolus: intermittent 42 2 
I2 I6 5 9 not currently taking 48 2 
Table 8-2 Parkinson's disease status of study population. Abbreviation: NR = not recorded 
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8.5. Effect of Dantron-Based Laxatives on Apomorphine Assay. 
Introduction. 
Quantification,ofapomorphine in plasma· sampled from patient 11, using the analytical 
method given in Section 4A (page 4-60), was precluded' by the presence of two 
components in the plasma extract which eo-eluted with apomorphine (Figme 8-1 A and B). 
Case History: Patient 11. 
A 69 year old male with Parkinson's disease had onset of right arm tremor 22 years 
previously and 15 years previously he underwent left thalamotomy complicated by 
hemorrhagic stroke with residual dysarthria, right hemiparesis and right hemidystonia His 
parkinsonian symptoms responded to levodopa/carbidopa but were complicated by motor 
fluctuations. He did not tolerate benzhexol or pergolide and was.commenced on 
subcutaneous apomorphine injections 4 years previously. Continuous infusion of 
apomorphine was commenced I year later, but significant abdominal nodules and erratic 
control lead to its discontinuation after I year and ropinirole was commenced. He 
continued to obtain significant benefrt from intermittent subcutaneous injections of 
apomorphine however. His condition was complicated by long-standing constipation for 
which he had been.taking regular co-danthramer and co-danthrusate for more than 5 years. 
Experimental 1. 
Concomitant drugs administered to patient 11 (listed on the study day as current 
medication) were investigated as potential sources of the interferences. Of these, 
levodopa/carbidopa, ropinirole and domperidone had previously been investigated during 
assay validation and found not to compromise apomorphine determination using the 
described HPLC assay (see Section 4.5.1.4, page 4-78). Hence solutions of the remaining 
drugs in the current drug regimen were prepared in water and assayed according to the 
method described. The drug solutions were: amitriptyline tablet (0.3% w/v ), co-
danthramer (0.0 l% w/v ), co-danthrusate (0.6% w/v ), diazepam emulsion I. V. injection 
(0.1% w/v), vitamin and mineral supplement (Ketovite® tablet, substituted for Forceval® 
which was not available locally, l tablet dissolved in 8mL water), senna tablet (substituted 
for Manevac®, which was not available locally, 0.1% w/v). 
Results 1. 
On the basis of chromatographic retention time alone, co-danthrusate and co-danthramer 
emerged as potential sources of the interference (Figure 8-1 C and D). 
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Figure 8-1 Determination of eo-eluting analytes observed in plasma of patient 11. 
Panel A: Apomorphine (20nglmL) extracted from pooled control plasma. 
Panel B: Baseline (pre-apomorphine) plasma extract from patient 11. 
Panel C: Co-danthrusate powder (0.6% wlv) in water. 
Panel D: Co-danthramer suspension (0.01% wlv) in water. 
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Experimental 2. 
A spectral library search was performed whereby·the peak spectra of components A and B 
were compared.to reference peak spectra contained in a· user-defined library (see Appendix 
8.12), The spectral library contained, apomorphine and NP A standards; ,products of the 
forced 1 degradation of apomorphine and'NP A in water under acidic, alkaline and oxidative 
conditions, and on>heating to,60°C (see SeCtion 4.5. L3, page 4-69); and .co-danthrusate and 
co-danthramer standards .. For each comparison a spectral similarity index (SS I) was 
obtained, where SSI = 1 represented a complete match. 
Results 2. 
Comparison of peak spectra of components A and B with reference drug spectra for co-
danthrusate and co-danthrarner resuhed in high {>0.98) SSI (Table 8-3). 
Interference in baseline Reference spectrum SSI 
plasma extract 
Peak Origin 
Peak A c co-danthrusate powder 0.991 
D co-danthramer suspension 0.983 
PeakB B co-danthramer suspension 0.993 
c co-danthrusate powder 0.990 
Table8-3 Outcome following peak spectra library sean:b routine. 
Abbreviation: SSI = spectral similarity index. 
Discussion. 
On the basis ofspectral·analysis it was concluded that peaks A and B were derived from 
co-danthrusate and co-danthrarner, medication which had been administered (as indicated) 
up to and including the study day. 
Co-danthrarner and co-danthrusate are stimulant laxatives based on dantron (i.e. 1,8-
dihydroxyanthraquinone, see Figure 8·2). Dantron is formulated with a surfactant laxative, 
i.e. docusate sodium and poloxamer "188" in co-danthrusate·and co-danthramer, 
respectively. 
A B 
KO 
Figure 8-2 Chemical structures of apomorphine (Panel A) and dantron (Panel B). 
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Whilst the definitive identification of peaks A and B has not been attempted ·in this 
investigation,.peak retention times suggest that peak A·is due to co-danthrusate·and peak.B 
is due:to,co-dahthramer. 'Ibe difference in'retention,times:obser.ved for the,two dantron 
preparations might be attributable to the different surfactant!laxatives in·the fOrmulations. 
co~administration of co-danthramer and•co,.danthrusate prevented· the quantification of 
apomorphine by theHPLC method described; 'Ibis has implications for the determination 
of plasma apomorphine concentration, using the described assay (or similar), in subjects 
whose drug regimen includes these, or other, anthraquinone~ based preparations, especially 
given that such laxatives are commonly prescribed for (elderly) Parkinson's,disease 
patients[ 6l 
Preliminary work whichaimed to remove the interferences from the plasma.extract was 
performed. It was demonstrated that increasing the 500/o (v/v}methanol:water washes 
from I x I mL to 3 x lmL had the effect of removing the interfering compounds from the 
solid phase extraction column (to waste), without detriment to the isolation and subsequent 
elution of apomorphine. It was therefore recommended that , for future work, the HPLC 
assay be validated incorporating the additional 50% (v/v) methanol:water washes. 
Acknowledgement. . 
Dr. J. O'Sullivan provided the case history. 
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8.6. Tapping Test Instructions to Patient 
Investigator: Your task is to tap as fast as you can between the two counters using your 
leftlright8 'hand on1y (give brief demonstration). You should start with your tapping band 
on the table m line with,the middle of the tapping tester. I will ask if you are ready to 
begin. When you are, I will say ''Start", and you will begin tapping. You should keep 
tapping until you hear the beep, which signals the end of the 30s test period. 
8. 7. Walking Test Instructions to Patient 
Investigator: Your task is to walk as quickly as you can up to the mark, turn, and walk back 
to the start point. I will ask if you are ready to begin. When you are, I will say "Start", and 
you will begin walking. 
• The side most· affected with parkinsonian symptoms. 
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8.8. Patient Information Leaflet (for Subcutaneous Bolus Study). 
University of Plymouth, De"iford Hospital 
We,are a research group who are interested in the use ofBritaject apomorphine in 
Parkinson's d,isease. We would like to find out more about the way the level'of 
apomorphine in the blood changes as you switch "on" and "oft". 
We hope that this information will help us to tailor apomorphine therapy to individual 
patients. If we could do this, it would mean that each individual would be getting the most 
from their apomorphine injections or infusion. 
As one ofDr ............. patients who is being treated with apomorphine, we would like to 
ask if you would be willing to participate in one of our studies 
What will happen on the study day? 
You will need to come to ..................... Hospital. We will ask you not to take your 
early morning anti-parkinsonian medication so that you will be "off" at the start of the 
study day. 
Between'8am and I Oam you will receive a single apomorphine injection at your normal 
dose so that you will switch "on". This will be the only apomorphine you will receive for 
the following six hours. We ask this because we want to look at the effects of a single 
apomorphine dose. All the other medication that you usually take will be available to you. 
We want to take blood samples over the six-hour period that follows the apomorphine 
injection. We will use a sampling needle known as a ''venflon" to do this. Once the venflon 
is inserted into a vein in the arm, blood can be taken without pricking the skin. 
Normally five samples will be taken in the first hour and another five will be taken over 
the following five hours. 
As well as taking blood samples, we will ask you questions about your symptoms. We will 
make notes on your answers and also on things like which medication you take during the 
study day and the times that you have something to eat. 
We will also ask you to complete some straightforward tests i.e. a tapping test (on seven 
occasions during the study) and a walking test (three times during the study). 
@] 0 0 
TAPPING lESTm 
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With your consent, you will~be videoed as you take some of these tests. The purpose of the 
video is to make sure that we have recorded' all your symptoms:correctly. The video will 
not be shown to anybody other than the members of the research team. 
Your blood pressure and pulse will be checked on occasions during the study. 
The study finishes when the last blood sample is collected (~ix hours after the apomorphine 
injection). 
General Information. 
• During the day you can eat, drink, rest or move around as you wish. 
• We are happy to pay your transport costs to and from the hospital on the study day. 
If you agree to take part we will let your GP know. 
Do you bave to take part? 
No, taking part is voluntary. 
You may decline to participate in this study without giving your reasons or incurring 
displeasUre. If you agree to participate you will need to sign a consent form. 
You are free to withdraw from the study at any stage without affecting your subsequent 
care or treatment in any way. You do not have to give a reason for your withdrawal from 
the study. 
Britannia Pharmaceuticals does not believe that you will suffer injury by participating in 
this study. You should know however that, in the event that you do suffer injury as a result 
of any procedure carried out in accordance with the study protoco~Britannia 
Pharmaceuticals will compensate you without you having to prove that they are at fuult. 
Britannia Pharmaceuticals will not compensate you where injury results from any 
procedure carried out not in accordance with the protocol for the study. 
Your right at law to claim compensation for injury where you can prove negligence is not 
affected. 
If you have any questions, please do not hesitate to contact: 
at. .......................................................................... . 
on ........................................................................ .. 
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8.9. Patient Consent Form. 
Please ask the patient to complete the foUowing:-
Have you rea3 the Patient Information Sheet? 
Have you had the chance to ask questions and to discuss the study? 
Have you received satisfactory answers to your questions? 
Have you received enough information about this study? 
Please cross out 
as necessary 
Yes/No 
Yes/No 
Yes/No 
Yes/No 
Who has spoken to you about what is involved in this study? ................................. . 
Do you understand that you are free to withdraw from the study: 
at any time? 
without having to give a reason for withdrawing? 
and without affecting your future medical care? 
Do you agree to take part in this study? 
Do you consent to be videoed during the study? 
Signed: ............................................................................ . 
Yes/No 
Yes/No 
Yes/No 
Date: ................... . 
Nante (in block letters) : .............. .................. ..... .. .............. ............................................. . 
Signed (investigator) : .................................................... . Date: ................... .. 
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8.10. Example of Variance Inflation Factor Analysis. 
Output generated for patient 09. 
Parameter Estimate VIF origiBII VIF restractll~d 
-
A(ng/mL) 24 373022 2899.17 
Alpha (min) 0.03 0.0042 0.0026 
B (ng/mL) 3.5 1147 203.2 
Beta (min) 0.009 0.000187 0.000161 
K01 (min-') 0.24 379 3.21 
Tlag (min) 6 606477 844.961 
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8.11. The Development of Apomorphine Extraction Methods. 
Year of Liquid-liquid extraction Solid-liquid Solid phase ,extraction 
puba. extraction 
I 
1980 I Smith [7] I 
l 
I Smith f8} I 
1985 I Bianchi [9] I 
~, I Lampen [10] I 
I Gancher [ 11] I 
1990 • I Durif[12] I I Essink [13] I 
(Montastruc [ 14]) J I Nicolle [15] I 
I Durif[16] I (Hofstee [ 1 7]) 
1995 I Sam [18] I (van Laar [19]) ,, 
.. {van Laar (:20?} I Ameyibor [21] I Priston [22] 
~, I Sam [23] I I v. Geest )4= I I Bolner [25] I + (Harder [26]) (van Laar [27] 
& v.Geest [28]) in-house 
2000 
Figure 8-3 Summary of the development, modification (and use) of assay methods for apomorphine. The extraction methods given in the 
highlighted articles were evaluated (refer to Section 4.3.5, page 4-52). 
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8.12. User-Defined Spectral Library. 
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8.13. Pharmacodynamic Response Following (Conventional) 
Subcutaneous Apomorphine Administration to Patients: 
Raw Data. 
Patient Mean baseline Maximum score Time of maximum Change in score: 
ID score (n=2) score baseline to peak 
"on" score• 
(no. taps/30s) (no. taps/30s) (mins post-dose) (% improvement) 
1 44 (n=l) 49 17 and 57 11.4 
2 47 (n=l) 52 49 10.6 
4 52 63 47 21.2 
5 36 45 42 25.0 
9 54 81 51 50.0 
-
10 54 65 39 21.5 
12 96 120 32 26.0 
Table 8-4 Pharmacodynamic effect of apomorphine: assessed using the 
tapping test. 
• Calculated as ((peak "on" score - baseline score) I baseline score) x 100. 
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Patient 
ID 
1 
2 
4 
5 
9 
10 
12 
Table 8-5 
Total score when "on" Part ID score when "on" 
Part m Time of "on" Change in pill 
baseline following Obtained prior to following Obtained prior to phase rating score: "off'' to 
score (off'') apomorphine study day apomorphine ., study day "on"• 
administration administration 
(mins post-dose) (% improvement) 
57 NR 35 NR 4 NA NA 
NR NR NR NR NR NA NA 
58 NR 71 NR 39 NA NA 
69 NR 74 NR 29 NA NA 
52 36 NR 19 NR 41 63 
39 42 NR 28 NR 43 28 
42 48b NR 23 NR 33 45 
UPDRS assessment: Total scores of zero (representing normal mobility) to 206 (representing maximum motor disability) 
are possible. Pharmacodynamic effect of apomorphine (assessed using the UPDRS part m motor evaluation): Scores of 
zero (representing normal mobility) to 108 (representing maximum motor disability) are possible. 
• Calculated as (("oft" score- "on" score) I 1 08) x 100. 
b Assessed following needle-free apomorphine dose. 
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8.14. Pharmacodynamic Response Following (Conventional and 
Needle-free) Subcutaneous Apomorphine Administration to 
Patients: Raw Data . 
.. 
Patient Baseline "On" phase Time of"on" Change in s~ore: 
ID ("ofl") s~ore s~ore phase rating "oft" to "on"1 
No. Treatment l(mins post-dose) (% improvemenft 
CON 52 19 41 31 
9 
NF 40 9 26 29 
CON 39 28 43 10 
10 NF I 43 28 33 14 
~ NF2 42 20 36 20 
CON 42 23 33 18 
12 
NF 33 23 38 9 
Table 8-6 Pharmarodynami~ effed of apomorphine: assessed using the UPDRS 
part m (motor evaluation). Scores of zero (representing normal 
mobility) to 108 (representing maximum motor disability) are possible. 
Abbreviations: CON = conventional, NF = needle-free. 
• Calculated as (("off'' score - "on" score) / I 08) x I 00. 
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Patient Hand used for Mean baseline Peak "on" score Time of Change in score: 
ID tapping test score (n=2) 
., 
peak "on" score baseline to peak 
"on" score• , 
No. Treatment (no. taps/30s) (no. taps/30s) (mins post-dose) (% improvement) 
CON 54 81 51 50 
9 Right 
NF 66 85 48 29 
CON 54 65 39 22 
10 NF 1 Right 50 69 30 38 
NF2 62 68 31 11 
CON 96 120 32 26 
12 Left 
NF 88 103 31 17 
Table 8-7 Pharmacodynamic effect of apomorphine: assessed using the tapping test. 
Abbreviations: CON = conventional, NF = needle-free. 
• Calculated as ((peak "on" score- baseline score) I baseline score) x 100. 
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8.15. Diagnostic Features Used in Pharmacokinetic Model 
Discrimination. 
Patient 01 
Diagnostics 1 Compartment 2 Compartments 
minus lag-time plus tag-time plus lag-time 
WSSR 4.61E-01 3.91E-OI 4.38E-02 
s 0.28 028 0.12 
Degrees of freedom 6 5 3 
Correlation (ohs Y vs preY) 0.9256 0.9491 0.9997 
Akaike Information Criteria -0.97 -0.46 -16.16 
Condition No. 45 12659 993 
Rank 3 4 6 
Number of sign changes 3 3 5 
in consecutive residuals 
Patient 02 
DJ agnostics 1 Compartment 2 Compartments 
minus lag-time plus lag-time plus lag-time 
WSSR 4.53E-01 6.15E-02 error (see below) 
s 0.30 0.12 
Degrees offreedom 5 4 
Correlation (obs Y vs preY) 0.9398 0.9816 
Akaike Information Criteria -0.33 - 14.31 
Condition No. 7 13 
Rank 3 4 
Number of sign changes 3 4 
in consecutive residuals 
** WARNING *** 
VARIANCE - COY ARIANCE MATRIX IS NOT OF FULL RANK OR iS ll..L-CONDITIONED. 
PARAMETER ESTIMATES AND THEIR ASSOCIATED STANDARD ERRORS SHOULD BE 
INTERPRETED WITH CAUTION. 
Patient 04 
Diagnostics I Compartment 2 Compartments 
minus lag-time plus Jag-time minus lag-time plus lag-time 
WSSR 5.01E-01 4.60E-01 9.63E-02 9.59E-02 
s 0.25 0.28 0.14 0.15 
Degrees of freedom 7 6 5 4 
Correlation (ohs Y vs preY) 0.9972 0.9984 
Akaike Information Criteria 0.92 0.23 - 13.40 - 11.44 
Condition No. 15 496 402 201 
Rank 3 4 5 6 
Number of sign changes 3 3 4 6 
in consecutive residuals 
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Patient 05 
Diagnostics 1 Compartment 2 Compartments 
minus tag-time plus Jag-time minus Jag-time 
WSSR J.05E-OJ l.03E-Ol error (see below) 
s 0.16 0.19 
,. 
Degrees of freedom 4 3 
Correlation ( obs Y vs pre Y) 0.9714 0.9717 
Akaike Information Criteria -9.77 -7.91 
Condition No. 12 7427 
Rank 3 4 
Number of sign changes 4 4 
in consecutive residuals 
ERROR 10203 ***AN ERROR OCCURRED DURJNG CURVE STRIPPING. 
ERROR 10201 ***INITIAL ESTIMATES CANNOT BE DETERMINED FOR TIIIS MODEL. 
***WARNING*** 
VARIANCE - COV ARIANCE MATRIX IS NOT OF FULL RANK OR IS ILL-CONDITIONED. 
PARAMETER ESTIMATES AND THEIR ASSOCIATED STANDARD ERRORS SHOULD BE 
INTERPRETED WITH CAUTION. 
Patient 07 r 
Diagnostics I Compartment 2 Compartments 3 Compartments 
WSSR 6.73E-Ol 6.25E-02 l.llE-01 
s 0.29 0.11 0.17 
Degrees of freedom 8 5 4 
Correlation (obs Y vs preY) 0.8742 0.9941 0.9890 
Akaike Information Criteria 0.43 -16.95 -7.81 
Condition No. 3 26 81927 
Rank 2 4 6 
Number of changes 2 4 3 
in sign of residuals 
Patient 08 
Diagnostics l Compartment 2 Compartments 
WSSR 1.71E-Ol 1.09E-Ol 
s 0.19 0.23 
Degrees of freedom 5 2 
Correlation (obs Y vs preY) 0.9894 0.9853 
Akaike Information Criteria -6.58 -5.31 
Condition No. 4 188 
Rank 4 4 
Number of changes 2 3 
in si~n of residuals 
8-31 
Patient 09 
Diagnostics 1 Compartment l Compartments 
minus Jag-time plus Jag-time plus Jag-time 
WSSR error (see below) l.l1E+OO 3.12E-02 
s 0.36 0.07 
-
Degrees of freedom 9 6 
!Correlation ( obs Y vs pre Y} 0.9554 0.9984 
Akaike Information Criteria 9.83 -29.60 
Condition No. 1920 27 
Rank 4 6 
Number of sign changes 3 7 
in consecutive residuals 
••• ERROR 10203 ••• AN ERROR OCCURRED DURING CURVE STRJPPING. 
••• ERROR 10201 ••• INITIAL ESTIMATES CANNOT BE DETERMINED FOR TillS MODEL. 
Patient tO 
Diagnostics 1 Compartment l Compartments 
minus Jag-time plus Jag-time plus Jag-time 
WSSR 5.74E-01 5.70E-01 1.33E+Ol 
s 0.27 0.29 1.63 
Degrees of freedom 8 7 5 
Correlation (obs Yvs preY) 0.9452 0.9876 
Akalke Information Criteria 0.45 2.40 37.88 
Condition No. 10 47 3348 
Rank 3 4 6 
Number of sign changes 4 4 5 
in consecutive residuals 
Notes Cmaxmissed Cmaxmissed Cmax fit 
Patientl2 
Diagnostics 1 Compartment l Compartments 
minus Jag-time plus Jag-time plus Jag-time 
WSSR 5.74E-Ol 5.70E-01 l.33E+Ol 
s 0.27 0.29 1.63 
Degrees of freedom 8 7 5 
Correlation ( obs Y vs pre Y) 0.9452 0.9876 
Akaike Information Criteria 0.45 2.40 37.88 
Condition No. 10 47 3348 
Rank 3 4 6 
Number of sign changes 4 4 5 
in consecutive residuals 
Notes Cmaxmissed Cmaxmissed Ctnax fit 
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8.16. Pharmacokinetic Parameter Estimates. 
Patient A(nglmL) Alpha (min-1) B (nglmL) 
Estimate CV(%) Estimate CV(%) Estimate CV(%) 
OL 22.4 416.8 0.0982 137.8 11.3 31.5 
02 NA NA NA NA NA NA 
04 118.1 38.3 0.0207 19.2 0.4 52.2 
05 NA NA NA NA NA NA 
09 23.9 9.4 0.0295 11.6 3.5 32.1 
10 136.2 2775.5 0.0597 451.2 5.8 256.2 
12 61.8 58.5 0.0576 30.3 7.7 23.2 
Patient Beta (min-1) K10 (min-1) Lag-time (min) 
Estimate CV(%) Estimate CV (o/o) Estimate CV(%) 
01 0.0191 5.2 0.5064 1485.8 5.3 185.7 
02 NA NA 0.1250 36.3 5.7 8.6 
04 0.0011 1287.3 0.0952 76.2 1.2 340.3 
~ 05 NA NA 0.1550 31.1 NA NA 
09 0.0089 11.6 0.2438 22.2 5.9 3.7 
10 0.0070 173.7 0.0807 388.7 1.8 85.8 
12 0.0086 10.4 0.2360 81.8 3.1 72.4 
Table 8-8 Primary pharmacokinetic parameter estimates. 
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Patient t % Alpha (min) AUC (nglmL.min) t ~Beta (min) CUF(mUmin) 
' 
Cmax (nglmL) t%K01 (min) 
Estimate CV% Estimate CV% Estimate CV% Estimate CVo/o Estimate CV% Estimate CV% 
01 7.1 137.7 754 50.4 36.3 5.2 2651 50.4 21.3 312.1 
, 
1.4 1484.3 
02 NA NA 1287 4.7 NA NA 3885 4.7 11.2 6.9 5.5 36.3 
04 33.4 19.2 4861 71.7 42.7 1286.0 2057 71.8 60.8 14.3 7.3 76.2 
05 NA NA 3143 6.8 NA NA 1591 6.8 28.7 8.0 4.5 31.1 
09 23.5 11.6 1083 2.6 77.5 11.6 1847 2.6 18.5 3.9 2.8 22.2 
10 11.6 450.7 1350 30.6 98.6 173.5 2592 30.8 18.5 5.8 8.6 388.3 
12 12.0 30.2 1667 5.0 80.2 10.4 3000 5.0 35.7 12.2 2.9 81.7 
Patient K10 (min-1) t%K10 (min) K12 (min-1) K21 (min;;y) Tmax(min) Volume (m.L) 
Estimate CV% Estimate CV% Estimate CV% Estimate cv•!o Estimate CV% Estimate CV% 
01 0.0384 59.6 18.1 59.5 0.0301 243.5 0.0489 83.7 10.0 354.4 69107 27.5 
02 o.ono• 6.8 63.0 6.8 NA NA NA NA 27.0 17.2 352977. 7.9 
04 0.0191 84.5 36.3 84.5 0.0015 834.5 0.0012 1220.7 21.7 22.6 107735 16.3 
os 0.0112• 11.4 61.7 11.4 NA NA NA NA 18.3 20.0 1416788 10.9 
09 0.0224 6.2 30.9 6.2 0.0042 27.8 0.0118 17.7 16.2 7.2 82339 6.7 
10 0.0301 363.2 23.0 362.8 0.0227 611.8 0.0139 252.0 17.6 12.2 86039 35.5 
12 0.0325 22.5 21.3 22.5 0.0185 47.4 0.0153 20.3 11.5 15.6 92384 23.6 
Table 8-9 Secondary pharmacokinetic parameter estimates. 
• Primary parameter. 
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8.17. User-Defined Models. 
8.17 .1. Subcutaneous Apomorphine Bolus Link Model (Exponential 
Pharmacodynamics). 
MODEL 9 
remark****************************************************** 
remark 
remark 
Developer : Ingram 
Model Version: 1.0 
remark****************************************************** 
remark 
remark 
remark 
remark 
rema 
rema 
rema 
rema 
rema 
rema 
rema 
rema 
rem a 
rem a 
rema 
rem a 
rema 
comm 
nparm 8 
nsec 11 
pnames 
snames 
nfun 2 
end 
temp 
E0=1 
vc=p (1) 
no . 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
filename : userlnk1 
WNL mode l 412 modifi ed to i nclude exponent i al PO 
(two compartment mode l, first order input and 
output, Tlag , de f i ned in ter ms of micro-constant s) 
parameter constant secondary parm . 
---------
--------
---------------
volume strippi ng dose auc 
k0 1 # doses k10 half l i f e 
k10 dose 1 k01 half life 
k12 t ime of dose 1 alpha 
k21 beta 
tla g alpha hal f life 
keo bet a ha l f lif e 
eta a 
b 
keo half life 
c l 
' vc ' , ' k01 ', ' k10 ' , ' k12 ', ' k2 1 ' , ' tlag ' & 
' keo ' , ' eta ' 
' auc ', 'k10_h l ' , ' k01_hl ', ' alpha' , ' beta ', 
I a l pha_ h l I f & I beta hl I f I a 1 f I b I f I ke0 _ hl I f I Cl I 
r1=dsqrt ( (k12+k21+k10 ) **2- (4*k21*kl0)) 
alpha= ( (k12+k21+k10) + r1)/2 
beta= ((k12+k21+k10) - r1)/2 
end 
func 1 
j=1 
ndose = con(1) 
do i =1 to ndose 
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j=j+2 
if x <= con(j) then goto red 
endif 
next 
red: 
ndose i-1 
sum=O 
j=l 
do i=l to ndose 
j=j+2 
t=x - con(j) - tlag 
d=con (j -1) 
al=(d/vc)*k0l*(k21-alpha)/(alpha-beta)/(alpha-k01) 
bl=-l*(d/vc)*k0l*(k21-beta)/(alpha-beta)/(beta-k01) 
cl=(d/vc)*k01*(k21-k01)/(beta-k01)/(alpha-k01) 
if t le 0 then 
amt = 0 
else 
amt=max(O,al*dexp(-alpha*t) + bl*dexp(-beta*t) + cl*dexp(-
kOl *t)) 
endif ~ 
sum=sum + amt 
next 
f=sum 
end 
func 2 
j=l 
ndose = con(l) 
do i=l to ndose 
j=j+2 
if x <= con(j) then goto blue 
endif 
next 
blue: 
ndose = i-1 
sum=O 
j=l 
do i=l to ndose 
j=j+2 
t =x - con(j) - tlag 
d=con(j-1) 
coef= keo*d*kOl/vc 
ce0= ((k21-k01)/((alpha-k01)*(beta-k0l)* (keo-k01 ))) *exp( -
k01*t) 
cel=((k21-alpha)/((k01-alpha)*(beta-alpha)*(keo-
alph a ))) *exp (-alpha*t ) 
ce2= ((k21-beta)/((k01-beta )*(alpha- beta ) * (keo-beta ))) *exp (-
beta*t) 
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ce3=((k21-keo)/((k01-keo)*(alpha-keo)*(beta-keo)))*exp(-
keo*t) 
if t <= 0 then 
arnt = 0 
else 
arnt=coef*(ce0+cel+ce2+ce3) 
end if 
sum=sum +- arnt 
next 
ce=sum 
if ce > 0 then 
f=EO*exp(eta*ce) 
else 
f = 0 
end if 
end 
se eo 
d=con(2) 
auc=d/vc/klO 
klO_hl=- dlog(.S)/klO 
k01_hl=-dlog(.5)/k01 
alpha~hl=-dlog(.5)/alpha 
beta_hl=-dlog(.S)/beta 
a= (d/vc)*k01*(k21-alpha)/(alpha-beta)/(alpha-k01) 
b=-l*(d/vc)*k0l*(k21-beta)/(alpha-beta)/(beta-k01) 
keo_hl=-dlog(.S)/keo 
cl=d/auc 
end 
EOM 
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8.17.2. Buccal Apomorphine Pharmacokinetic Model. 
MODEL 7 
remark****************************************************** 
remark Developer: Ingram 
remark Model Version: 1.0 
remark one compartment model - constant iv input , first order 
remark output, including lag-time . 
rema 
rema no . parameter constant secondary parm. 
rema 
---------
--------
---------------
rema 1 volume # doses auc 
rema 2 klO dose 1 k10 half life 
rema 3 Tlag start time cmax 
rema 4 end time , etc . cl 
rema 5 aumc 
rema 6 mrt 
rema 
rema********************************************************* 
7 vss 
comm 
nparm '3 
nsec 7 
pnames ' VOLUME ' , 'KlO', 1 Tlag 1 
snames ' AUC 1 , 1 Kl0HL 1 , 1 CMAX 1 , 
end 
func 1 
j = 0 
ndose = con(l) 
I Cl '' I AUMC I ' 1 MRT', 1 Vss 1 
rema Count up the number of doses administered up to time x 
do i = 1 to ndose 
j=j+3 
if x <= con(j) then goto red 
endif 
next 
rema Perform superposition 
red: 
ndose = i-1 
sum=O 
j=O 
do i = 1 to ndose 
j j + 3 
t = x - con(j) - Tlag 
d = con (j -1) 
ti = 120 - tlag 
del = t - ti 
tstar = max (O, del) 
coef = d I (ti * volume * klO) 
if t le 0 then 
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amt = 0 
else 
amt = coef * (exp(-klO * tstar) - exp(-klO * t)) 
end if 
sum = sum + amt 
next 
f = sum 
end 
se eo 
dose= con(2) 
ti = con(4) - con(3) 
auc = dose I (volume * klO) 
klOhl = -loge(.S)IklO 
coef = dose I (ti * volume * klO) 
cmax = coef * (1- exp(-klO * ti)) 
cl = dose I auc 
aumciv = dose I (volume * klO * klO) 
aumc = aumciv + (ti * auc I 2) 
mrt = {aumclauc) - ti I 2 
vss =dose* ((aumclauc) - ti I 2) I auc 
end ~ 
EOM 
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8.18. Needle-Free Study: Raw Concentration-Time Data. 
Blood Patient 09 Patient 10 Patient12 
Sample conventional needle-free conventional needle-free needle-free conventional needle-free 
trial#l trial#2 
no. mins time [apo] time [apo] time [apo] time [apo] time [apo] time [apo] time [apo] 
(mins) ng/mL (mins) ng{mL (mins) ng/mL _(mins) ng/mL {_mins} ng/mL (mins) ng/mL (mins) ng/mL 
1 pre ND ND -7 ND -57 ND -3 ND ND ND 
2 5 7 5.5 6 16.6 5 9.2 5 8.8 5 25.5 6 25.5 6 5.9 
3 10 11 15.7 11 25.4 9 14.4 10 11.8 9 20.2 10 35.2 10 13.8 
4 15 16 18.7 18 23 .6 13 17.6 13 12.6 13 23.0 16 33.3 16 17.1 
5 22 23 17.9 24 15.7 21 19.3 21 11.4 21 15.2 23 26.8 23 17.2 
6 30 32 13.7 32 13.2 29 17.6 29 9.1 29 15.6 30 18.4 30 14.7 
7 50 52 7.5 51 6.4 50 6.4 51 7.1 51 6.7 55 7.9 54 6.0 
8 80 85 4.3 81 3.5 80 5.3 80 5.8 81 5.0 83 4.5 82 5.3 
9 125 123 2.0 124 1.3 133 <3N 141 1.9 146 1.6 135 2.8 133 2.6 
10 180 182 0.8 181 0.4 198 2.3 198 0.7 214 0.4 200 1.4 183 1.3 
11 240 246 0.4 240 0.2 272 0.5 254 0.4 268 0.2 230 0.8 235 0.5 
12 310 314 0.2 NR1 287 ND 286 0.2 307 0.7 273 0.4 
13 360 344 0.2 351 l 0.2 354 ND 346 <3N 346 0.4 
Table 8-10 Needle-Free Study: Raw Concentration-Time Data 
Abbreviations: <3N = apomorphine peak area < three times the baseline noise, ND = no apomorphine detected, NRI = not recorded: problem with 
venflon. 
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8.19. Contribution to Publications. 
WM Ingram, TJL Malone, VR Pearce, MJ Priston & GJ Sewell, Phannacokinetic-
pharmacodynamic study of subcutaneous,apomorphine in Parkinson's disease. Age and 
Ageing 2001; 30Sl: 47. 
PreseiiledaJ the British Geriatrics Society Autumn Meeting 2001 (London). 
Introduction 
Subcutaneous apomorphine is a potent dopamine agonist and a useful agent in Parkinson's 
disease for patients experiencing unpredictable 'off periods. High interpatient variability 
in apomorphine pharmacokinetics and'pharmacodynamics indicates the need for dose 
optimisationto be based on individual handling of the drug. A pilot phannacokinetic study 
involving patients onoptimisedapomorphine therapy identified a consistency in post-
distributional pharmacokinetics. The significance of this relationship was explored. 
Methods 
Five patients optimised on intermittent subcutaneous apomorphine'had antiparkinsonian 
medication withheld overnight and were given a single subcutaneous apomorphine bolus, 
Two patients optimised on 24 hour subcutaneous apomorphine infusions were also 
recruited and their infusions stopped. During the following six hours blood samples were 
taken for. apomorphine assay from both groups. The tools used for pharmacodynamic 
monitoring were (1) the tapping test and (2) individualised qualitative markers of response. 
Results 
An apomorphine bolus following overnight wash-out produced atypical 'on' periods in 
four out of five patients, i.e. three exhibited a sub-optimal response, one experienced 
adverse effects. The pharmacodynamic effect was best described by the sigmoid Emax 
model. The quality of the "on" period was not related.to post-distributional 
pharmacokinetics or to EC50 (drug concentration required to produce 500/o of maximal 
effect). 
Conclusions 
Apomorphine post-distributional pharmacokinetics were not correlated to antiparkinsonian 
response. No other significant pharmacokinetic predictors of pharmacodynamic effects 
could be identified. 
8-41 
r 
WM lngram, MJ Priston & GJ Sewell; Pbarmacokinetic-pharmacodynamic study on 
apomorphine in patients with idiopathic Parkinson's disease. Journal of Pharmacy and 
Pharmacology 1999; 51S: 160. 
Presented at the 1 36/h British Pharmaceutical Conference (Cardiff). 
Idiopathic Parkinson's disease is common 
amongst the elderly population. 
Parkinsonism is caused by degeneration of 
the dopaminergic neurones·ofthe 
nigrostriatal system. Loss of function at 
this region•accounts for all the motor 
manifestations of the disease; these being 
akinesia, rigidity, postural instability and 
tremor. Levodopa preparations are the 
treatment of choice, being particularly 
effective in alleviating akinesia and 
rigidity. However, approximately 10% of 
patients per treatment year develop 
fluctuations in motor function. The 
response to levodopa becomes 
increasingly brittle. Ultimately some 
patients d.evelop the "on-off' response, in 
which cliiiical state fluctuates abruptly 
between periods of relative mobility 
("on") and severe parkinsonian disability 
("off') despite optimally timed doses of 
levodopa. 
of drug response. The quantitative 
measurement. employed is the ''tapping 
test''. See Fig. I for typical results. 
Blood~sample analysis incorporates 
propyl-norapomorphine as.an internal 
standard. 
Apomorphine is extracted from plasma 
under vacuum using Bond-Eiut C 18 
I mU I OOmg columns and subsequently 
analysed by reverse phase liquid 
chromatography. The column used is a 
Phenomenex Columbus (Cl8, SJ.I.IIl, 
150mm x 4.6mm ID). The 
mobile phase consists of (0.2SM 
NaH2P04, 0.25% heptane sulphonic acid 
(w/v), to pH 3.3 with orthophosphoric 
acid) containing 0.003% (w/v) ED'M and 
40% (v/v).methanol, and is run at 
lrnUmin. Apomorphine .is detected using 
a Jasco spectrofluorometer at A.ex 270nm. 
Aem 450nm. The assay is stability 
indicating and has proven linearity. Intra-
day precision is.8.2% and 2.1% at 0.5 and 
20ng/mL, respectively (n=7). Inter-day 
precision is 4.9% and 5. 7% at 0.5 and 
20ng/mL, respectively (n=7). TheU>Q is 
43pg/mL. ' 
Fig. I Plasma Apomorphine Concentration 
and Clinical Status Proflle (Subject 0 I) 
Apomorphine, a potent dopamine receptor 
agonist, is used in anti~parkinsonian drug 
regimes to reverse refractory motor 
fluctuations. The drug is administered 
subcutaneously by intermittent injections, 
usually in the role of a rescue therapy, or 
by prolonged continuous infusion. 
Peripheral PK studies have documented 
the large inter-patient variation. in drug 
absorption, indicating the need. for dose 
optimisation to be based on individual 
handling ofthe drug (Gancher 1989, 
Nicolle 1993). 
m,------------r"' 
A review of published PK profiles 
revealed a potential PK-PD relationship 
which is based on post-distribution 
elimination PK. It is envisaged that a rapid 
dose optimisation protocol.for 
apomorphine therapy can be developed 
around this relationship. 
A PK-PD study to determine the 
significance of this relationship is in 
progress. This study involves blood 
sampling over an extended period. PD 
monitoring is individualised by the 
identification of key symptom changes in 
each subject prior to the study day. These 
changes are used as "qualitative markers" 
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Findings will be discussed 
Nicolle E et a/ (1993) Fund Clin Phar 7 
(5): 245-52 
Gancher STet a/ (1989) Ann Neur 26 (2): 
232-38 
.. 
WMingram, MJ Priston & GJ Sewell; Dose optimisation scheme for apomorphine in 
Parkinson's disease: preliminary pharmacokinetic-pharmacodynamic studies. European 
Journal of Pharmaceutical Sciences 1999; 8 {2): x. 
Presented atthe 5th Congress of the European Federation of Pharmaceutical 
Sciences (Jerusalem). 
Apomorphine, a potent dopamine receptor agonist, is used in anti-
parkinsonian drug regimes to reverse refractory motor fluctuations. The 
drug is administered subcutaneously, by intermittent injections or 
prolonged continuous infusion. Peripheral PK studies have documented 
the large inter-patient variation in drug absorption', indicating the need 
for dose optimisation to be based on individual ''handling" of the drug. A 
review of published PK profiles revealed a potentialPK-PD relationship, 
based onpost-distribution elimination PKs. It is envisaged that a rapid 
dose-optimisation protocol for apomorphine therapy can be developed 
around this relationship. A PK-PD study to determine the significance of 
this relationship is in progress. This study involves blood sampling over 
an extended period and the use of the "tapping tester" as the primary PD 
tool. Plasma apomorphine is measured using a novel solid phase 
extraction procedure and highly sensitive LCassay employing 
flu d . P limin PK I . orescence etectton. re lary resu ts are gtven:-
i-. Patient Route & AUC t~ t~ B 
Dose ng.h/mL (min) (min) (ng/mL) 
1 bolus: 2rng 11.2 7.4 36.1 9.1 
2 bolus: 5mg 28.6 21.7 127.0 6.9 
3 bolus: 10rng 67.3 39.1 103.8 7.9 
4 infusion: 236.1 8.2 76.4 10.9 
35mgf.12h 
5 infusion: 405.2 46.6 166.5 10.8 
14lmg/12h 
Prelimmary fmdmgs will be discussed. 
1Essink A.W.G et al JournalofChromatography 1991; 570: 419-424 
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